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AN ANALYSIS OF THE INFLUENCE OF SAMPLING METHODS ON 
ESTIMATION OF DRUG USE PREVALENCE AND PATTERNS AMONG 
ARRESTEES IN THE UNITED STATES: IMPLICATIONS FOR RESEARCH 
AND POLICY 
 
JANINE KREMLING 
 
ABSTRACT 
 
Using data from the Drug Use Forecasting (DUF) and the Arrestee Drug Abuse 
Monitoring (ADAM) programs collected by the National Institute of Justice the question 
whether the drug estimates of DUF, using a non-probability sample, and the drug use 
estimates of ADAM, using a probability sample, yield substantially different results will 
be explored. The following main questions will be addressed using equivalence analysis: 
Are there substantial differences in the DUF and ADAM samples with regard to the drug 
use information obtained from arrestees at nine sites across the United States? The 
analysis suggests that the drug use information contained in DUF and ADAM is not 
substantially different for marijuana, cocaine, and opiates for all sites analyzed together. 
Additionally, there are no substantial differences for seven of the nine sites. The 
implications of these findings are discussed.
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CHAPTER ONE 
INTRODUCTION AND OVERVIEW OF THE STUDY 
Statement of the Problem 
In 1987, the National Institute of Justice (NIJ), in cooperation with the Bureau of 
Justice Assistance (BJA), implemented a national study tracking drug use prevalence and 
drug use patterns among arrestees. The program, called the Drug Use Forecasting (DUF) 
program, started in 12 cities. The DUF program was unique for three reasons: (1) it 
collected a urine specimen as a validation technique of self-reported drug use; (2) it 
collected data on drug use prevalence and patterns from arrestees, a population group at 
high risk for drug use that is not studied consistently across the United States; and (3) it 
provided local data on drug use prevalence and patterns with the explicit goal of 
providing policy makers with the necessary information to develop programs that 
effectively reduce drug use (National Institute of Justice, 1998).  
In 1993, the General Accounting Office (GAO) published a report on the 
strengths and limitations of the three national drug use studies funded by the Federal 
Government. One of these three studies was the DUF program.  The report stated that the 
major shortcomings of DUF were the use of a non-probability sample, more specifically a 
judgment-based sample, and a lack of standardization across sites. According to the GAO 
(1993) these two major shortcomings made it impossible for researchers to generalize 
findings to the population of arrestees in that specific geographic area. As a result, the 
DUF data was said to be useless for policy makers, who had as a major goal the 
development of programs aiming to reduce drug use.  
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After the evaluation by the GAO, NIJ decided to implement some major changes 
to the study design. The most important modification was the decision to change the 
judgment-based sample to a probability sample. In 1998, the name of the study changed 
from Drug Use Forecasting (DUF) to Arrestee Drug Abuse Monitoring (ADAM) 
program and the data collection was now standardized at all sites, but the study still used 
a judgment-based sample. The probability sample was not fully implemented until the 
latter half of 1999. Similar to DUF, the ADAM study collected data about drug use 
prevalence and patterns and used urine analysis as a validation technique for self-reported 
drug use. In addition, ADAM also collected data on drug market activity, drug treatment, 
and other drug-related issues (National Institute of Justice, 2000).  
Due to the implementation of a probability sample, the findings of the ADAM 
program were now said to be representative of the target population of booked arrestees, 
allowing researchers to generalize the findings to the general population of arrestees for 
the geographic area at which the study was implemented.  However, the ADAM program 
was only carried out for approximately three years. 
The federal government terminated the ADAM study in January 2003. The high 
costs of the program and significant budget cuts by Congress have been cited as the 
major reasons for the termination of ADAM by the National Institute of Justice 
(Yacoubian, 2004). Originally, Congress had allocated $20 million per year in 
discretionary money for social science research, but this research money was reduced to 
$6 million for the year 2004. Thus, the ADAM program became too expensive to 
continue. Whereas the DUF program costs about 1 million dollars per year, ADAM costs 
about 8.4 million dollars per year (National Institute of Justice, 2004). The much greater 
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costs of ADAM were due mainly to the greater number of sites where data were 
collected, the greater amount of time interviewers spent at the facility supervised by a 
correctional officer, continuous training of the interviewers, modifications to the 
questionnaire (more extensive and detailed than DUF), and changes in urine specimen 
processing. All of these changes in the program (from DUF to ADAM) will be described 
in detail in Chapter Three.   
Between 2003 and 2006 no drug use data was systematically collected for the 
population of arrestees. In 2007, the Office of National Drug Control Policy (ONDCP) 
revived the ADAM program with its probability sample. However, the ADAM II 
program was only implemented at 10 sites that were previously part of the ADAM 
program. These 10 sites represent individual counties in 10 separate states. This is 
significantly less than the original ADAM program (35 sites) and it is also significantly 
less than the National Household Survey (NHSDUH) and Monitoring the Future (MTF), 
both of which are national studies. These differences are important for two reasons: (1) 
drug use varies by geographic location and (2) arrestees have significantly higher rates of 
drug use as compared to the general population, which is being studied by the NSDUH 
and the MTF.  
Research has consistently shown that drug use prevalence and patterns vary 
significantly across geographic locations, and as a result studying only 10 counties in the 
entire country does not provide sufficient data for drug using behaviors among arrestees 
(Feucht and Kyle, 1996; Peters, Yacoubian, Baumler, Ross, and Johnson, 2002; Riley, 
1997; Yacoubian, 2002). For example, the ADAM data itself shows that the prevalence 
of certain illicit drugs depends on the geographic location of the site. In 2001, drug test 
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results demonstrated that the percent of arrestees who tested positive for cocaine use 
ranged from a low of 11.0% in Des Moines, Iowa, to a high of 48.8% in New York. 
Similarly, the percent of arrestees who tested positive for marijuana ranged from 28.5% 
in Laredo, Texas, to 54.2% in Minneapolis, Minnesota, and for opiates from 2.0% in 
Omaha, Nebraska, to 27% in Chicago, Illinois (NIJ, 2001).  
Additionally, illicit drug use also varies considerably within states. The percent of 
arrestees who tested positive for cocaine in Texas varied between 20.4% in San Antonio 
and 45.0% in Laredo. Also, marijuana use in Texas ranged from 28.5% in Laredo to 
40.7% in San Antonio (NIJ, 2001). This result demonstrated that Laredo had the lowest 
number of cocaine users, but the highest number of marijuana users. These within-state 
differences did not just apply for Texas, but were also apparent for other states including 
California, Washington, and Florida. These geographic differences in drug use 
prevalence and patterns demonstrate the importance of collecting data from arrestees 
nationwide. Collecting data for 10 sites (counties) is not sufficient to provide a 
comprehensive overview of drug use prevalence and patterns in the United States because 
these 10 sites are not representative of drug use for other cities and states. As a result, 
important changes in drug using behaviors may not be discovered at all or they may be 
discovered only once they have become epidemic.  
Second, research has consistently shown that arrestees have substantially higher 
rates of illicit drug use than the general population (NSDUH) and school children (MTF) 
(BJS, 2004). Brecht, et al. (2003) estimated that about 65% of arrestees use illicit drugs. 
By comparison, approximately 8.3% of the general population (as determined by the 
NSDUH) and about 9.5% of school children use illicit drugs (SAMHSA, 2003; 2008). 
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Thus, the NSDUH and the MTF track illicit drug use nationwide for population groups 
that use illicit drugs at much lower rates than arrestees. It might be more useful to put a 
greater focus on population groups who use drugs regularly because regular use of illicit 
drugs results in great costs for society.  
Illicit drug use is very costly for society for several reasons. First, drug use is 
related to criminal behavior in three ways: (a) users must obtain money for drugs, (b) 
drugs may have a detrimental effect on the individual’s behavior, and (c) as part of the 
lifestyle and business methods of drug dealers (NIDA, 1990). For instance, studies have 
found that the rise in crack cocaine was associated with a significant increase in the urban 
crime rate, especially violent crimes (Grogger and Willis, 2000, Inciardi, 1990).  
Additionally, violent behavior has been found to be related to the use of other 
psychoactive substances, such as amphetamines, cocaine, LSD, and PCP (Roth, 1994). 
Research has also demonstrated that drug users engage in criminal activities, such as 
burglary and drug sales to obtain monies for drugs (Dembo, Williams, Wish, Berry, 
Getreu, Washburn, and Schmeidler, 1990). Finally, the lifestyle and business practices of 
drug dealers include violence as part of the interaction between drug dealers, rival gangs 
dealing drugs, drug runners, and informants (Goldstein, 1987).  
Second, drug use contributes significantly to the costs of health care. Specifically, 
researchers have estimated that almost 50% of all health care costs are related to alcohol 
and drug use. French and Martin (1996) provide an overview of the cost of illicit drug use 
for society. According to the authors, these costs can be divided into nine categories. The 
categories are: “medical services costs; prenatal costs; drug abuse treatment costs; drug-
associated disease costs; cost of alcohol, illicit drug and mental health (ADM) 
  6
comorbidity; crime-related costs; foster care payments; special education and early 
intervention costs; and costs of Aid to Families with Dependent Children (AFDC) 
including food stamps” (French and Martin, 1996, p. 454). These costs can only be 
reduced if drug use decreases. Arrestees are a population group who use drugs at high 
rates. Therefore it is important to study their drug-using behaviors and implement 
programs that help decrease their drug use.  
Third, drug use has been shown to be associated with loss of employment, loss of 
housing, and family disintegration (NIDA, 1990). Each of these consequences constitutes 
and contributes to the costs of illicit drug use for society. For example, a loss of 
employment can lead to criminal behavior because individuals who use illicit drugs have 
to find another way to get money for drugs. They might engage in drug selling or other 
illegal activities that help them get more drugs. Thus, it is crucial to track drug-using 
behaviors among arrestees across the nation to be able to implement effective programs. 
In fact, the National Institute of Drug Abuse (NIDA) suggests that in order to reduce drug 
use, it is imperative to implement “community-based prevention and treatment programs" 
(Roth, 1994). If the goal is to decrease the costs of drug use for society and implement 
local prevention and treatment programs, as proposed by NIDA, then a reasonable 
approach would include arrestees because they have high rates of illicit drug use (65%), 
and who then, as a result, contribute greatly to the costs of drug use for society.  
Main Purpose of DUF and ADAM 
As stated previously, the main purpose of the DUF and ADAM program was and 
still is (with ADAM II) to guide policy and program implementation at the local level 
(GAO, 1993). In order to fulfill that purpose it is necessary to know which drugs are 
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being used, how they are being used, and what distinguishes drug users, that is, arrestees 
who use illicit drugs, at the different geographic areas within the United States. This 
information can then be used to develop programs and services targeting specific drug 
users, and programs can be designed and implemented that are tailored towards the needs 
of a certain community or geographic area. Tailoring the programs to the needs of the 
community is important in order to be effective in reducing illicit drug use.  
Customizing Programs to the Community 
Research on drug abuse treatment has shown that programs specifically 
customized for a certain individual are more effective in reducing future drug use and 
related issues, such as recidivism and infectious diseases (Hammett, Harmon, and 
Rhodes, 2002; Murphy, Collins, and Rush, 2007). Similarly, programs aiming to prevent 
the spread of infectious diseases, such as HIV, are also most effective when they meet the 
needs of the community (Kelly, et al., 1992). Accordingly, it could be expected that 
programs aiming to reduce illicit drug use among arrestees would be more successful if 
they would meet the specific requirements of drug users in a certain community. These 
customized programs might also be more cost effective because they don’t waste 
resources on combating drugs that are not widely used. For example, there is no great 
need to implement programs targeting methamphetamine users in Florida, because 
methamphetamine is used rarely in that area. There is, however, a need for such programs 
in San Diego and other west coast cities where up to 22% of arrestees use 
methamphetamine. Collecting data locally but expanding the collection sites to be 
representative of the nation will provide the necessary information to implement 
customized programs, as a result reducing illicit drug use, recidivism, and the spread of 
  8
infectious diseases.  
The major obstacle, it seems, are the costs associated with such a program. 
Considering that the total economic costs of illicit drug use are estimated to be 
approximately $143.4 billion each year (Office of National Drug Control Policy, 2001) 
and that $50 million is spent by the government via NSDUH to survey a population 
group that rarely uses drugs (8.2%), it would be reasonable to also implement a 
nationwide program monitoring illicit drug use among arrestees, 65% of whom use illicit 
drugs. It is, however, also important to recognize current budget cuts and the economic 
situation. Thus, this study will examine whether it is possible to implement a study 
similar to ADAM that is equally effective but less expensive.  
Purpose of the Study 
As described above, the main reason for the change from a non-probability 
sample (DUF) to a probability sample (ADAM), and eventually the termination of the 
study altogether, was the critique of DUF by the General Accounting Office (GAO). A 
detailed overview of the DUF program and the criticisms of the GAO will be discussed in 
Chapter Three, but the main conclusion of the GAO was that the sampling procedure of 
DUF did not allow for the generalization of results to arrestees in general because it is 
unclear whether the information contained in DUF is valid with regard to drug-using 
behaviors among arrestees within the geographic areas studied (GAO, 1993).  
To date, no one has systematically assessed this question. The purpose of the 
current study is to examine this issue by comparing the results of the probability sampling 
used in ADAM to the non-probability sampling of DUF. Specifically, the main research 
question is whether the non-probability sample of DUF contains drug use information 
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that could be said to be equivalent to the drug use information contained in the 
probability sample of ADAM. 
Significance of the Study 
The proposed research question is important for two main reasons. First, if the 
analysis indicates that the DUF and ADAM data do not provide substantially different 
information, this might help implement a drug abuse monitoring program that observes 
drug use among arrestees nationwide and provides local data on drug use prevalence and 
patterns among arrestees. As a result, the research can guide policy development and 
program implementation aiming to reduce drug use at the local level.  
Second, the current analysis is important because the DUF data (data between 
1987 and 1999) has only been used by a few researchers. The results of the current study 
might enable researchers to publish research findings from the DUF data and from both 
DUF and ADAM over time. This might be especially important for researchers 
monitoring (a) the relationship between drug use and crime over time; (b) the popularity 
of certain drugs over time; (c) the introduction of new drugs and how they spread around 
the country; and (d) the relationship between newly implemented drug laws, policies and 
drug use prevalence and patterns. 
Uniqueness of the Current Study 
The current study is also unique. To date, there is little research comparing the 
data from two different samples, using different sampling strategies, with the purpose of 
exploring whether these two samples contain substantially different information. 
Although there is no study assessing differences across the DUF and ADAM data 
systematically, there is some evidence that the information contained in DUF might not 
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be substantially different from ADAM.   
The National Institute of Justice (NIJ) conducted a study comparing drug use 
outcomes for one site for the DUF and ADAM data (NIJ, 1990). The study used data 
from the Uniform Crime Report (UCR) as a base rate to assess whether differences in the 
charge distribution of arrestees lead to biased drug estimates. The results demonstrated 
that drug use estimates did not appear to be biased. Although the demographic 
characteristics of the sample were different, the drug use information was similar.  
A second study was conducted in Anchorage, AK with the goal of determining 
whether the male and female arrestees interviewed were representative of the arrestee 
population at that site (Myrstol and Langworthy, 2005). For this purpose the authors 
compared the demographic information of the arrestee sample to the demographic 
information collected via face sheets from all arrestees, including nonrespondents. The 
authors found that although female arrestees were not sampled in accordance with the 
probability sampling plan for males, they were more representative of the population of 
booked female arrestees than the male sample was of the population of booked male 
arrestees. This is notable because, similar to DUF, female arrestees were selected via a 
convenience sample. Thus, the results of the study from Anchorage suggest that a non-
probability sample might include a similar subset of arrestees as the probability sample. 
Both studies only examined one site, however.  
Additionally, some research has been done examining the equivalence between 
Internet-based and paper-and-pencil data collection. This research suggests an overall 
equivalence between these two methods despite differences in the demographic profiles 
of the two samples (Epstein, Klinkenberg, Wiley, and McKinley, 2001; Krantz, Ballard, 
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and Scher, 1997; Pasveer and Ellard, 1998).  This supports the finings of the NIJ (1990) 
study which also found that demographic differences in the sample did not necessarily 
result in substantially different drug use information.  
Based on these studies, it is possible that the drug use information contained in the 
DUF sample is not substantially different from the ADAM sample. Thus, the current 
study attempts to assess the question whether the non-probability sample of DUF 
provides information about drug use prevalence and patterns that is comparable to that of 
ADAM in a more systematic fashion by examining all sites that have the same catchment 
area for DUF and ADAM. This study is possible because both DUF and ADAM 
examined drug use prevalence among arrestees.  Although ADAM had more sites and a 
more comprehensive interview instrument, there are nine sites that have the same 
catchment area and contain 14 variables for self-reported drug use and urine test results 
for the major drugs (i.e., marijuana, cocaine, and opiates), thus providing the necessary 
information for this assessment.  
This study is also unique because it uses equivalence testing to examine the 
proposed research question. Equivalence means that there are not substantial differences 
(Rogers, 1993).  Equivalence testing is an analysis strategy widely used among clinical 
researchers to assess whether two different drugs/treatments produce a comparable 
outcome. Equivalence testing assumes that two different drugs/treatments will always 
result in some differences, but these differences might not be of practical and/or clinical 
importance. Similarly, it can be assumed that two different samples will result in different 
outcomes. The crucial question, and the significant research question of the current study, 
is whether or not the sampling design and procedures used by ADAM resulting in an 
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approximation of a true probability sample produced results that are substantially 
different from DUF. Equivalence analysis is applied to assess this research question. 
Brief Overview of Equivalence Testing 
The method employed in this study is the confidence interval method first 
described by Westlake (1981).  Rogers et al. (1993) introduced the method to the field of 
psychology. The main idea of this method is to calculate confidence intervals for the 
proportions for the DUF and ADAM drug estimates and conduct a traditional hypothesis 
test and an equivalence test simultaneously. The outcome of these two tests will show 
whether the DUF and ADAM data are substantially different or whether they are 
sufficiently similar to be considered equivalent. Substantially different means that drug 
use estimates contained in DUF and ADAM are statistically different in the traditional 
null hypothesis test and not equivalent in the equivalence test. Overall, substantially 
different is defined as a difference of 20% or more between the drug use estimates of 
DUF as compared to ADAM. Equivalence is present if the drug use estimates are 
statistically significant in the equivalence test and not significant in the traditional null 
hypothesis test. Equivalence does not mean “exactly the same” rather it means the 
“absence of a meaningful difference” (European Medicines Agencies, 2000; Rogers, 
Howard, Vessey, 1993; Allen and Seaman, 2006; Tryon and Lewis, 2009). Thus, overall, 
equivalence is said to exist if the difference between the drug use estimates in DUF and 
ADAM is less than 20%. The exact method is described and demonstrated on an example 
in Chapter Four. 
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Possible Outcomes of the Analysis 
Four possibilities exist with regard to the outcome of the current analysis: 
1)          The drug use estimates of the DUF and ADAM samples are equivalent   
(Eq). 
2)  The drug use estimates of the DUF and ADAM samples are different (D). 
3)  The drug use estimates of the DUF and ADAM samples are different and 
equivalent (D&Eq). 
4) The drug use estimates of the DUF and ADAM samples are not different 
and not equivalent. They are statistically indeterminate (ND&NEq). 
Possibilities one and two are fairly straightforward. First, the drug use estimates 
of the DUF and ADAM samples can be said to be equivalent if the drug use proportions 
are statistically equivalent and not statistically different. Second, the drug use estimates 
of the DUF and ADAM samples can be said to be different if the drug use proportions are 
statistically different and not statistically equivalent. Third, the drug use estimates of the 
DUF and ADAM samples can be said to be equivalent and different if the drug use 
proportions are statistically different but statistically equivalent. In this case the 
researchers suggest that the data might not be substantially different. Rather the 
differences can be said to be trivial (Allen and Seaman, 2006; Rogers et al. 1993). Fourth, 
if the drug use estimates of the DUF and ADAM samples are not statistically different 
and not statistically equivalent no conclusions can be drawn with regard to the question 
whether there exist substantial differences. The results would be ruled indeterminate 
(Rogers, et al. 1993; Tryon and Lewis, 2009). For an easier overview Figure 1.1 
demonstrates the four possibilities. 
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Figure 1.1. Possible Outcomes of the Analysis  
Equivalent 
 No Yes 
Yes 2 (D)  3 (D & Eq) 
 
 
 
 
Different 
No 4 (ND & NEq) 1 (E) 
 
 Before the question about the equivalence of the DUF and ADAM data can be 
assessed, it is critical to examine why it is important to study illicit drug use in general 
and why ADAM and DUF were crucial for researchers, communities, and policy makers 
in their assessment and efforts to reduce drug use. Thus, Chapter Two discusses the 
importance of studying illicit drug use in general, followed by a description of the 
importance of the DUF and ADAM programs for communities, policy makers and 
researchers, and why the original termination and subsequent revival of the study with 
only ten sites in 2006 constitutes a major loss and an obstacle to the goal of reducing drug 
use. Chapter Three lays out the methodology of DUF and ADAM and discusses the 
major criticisms of the GAO (1990) on the DUF program and the specific changes that 
were made by the National Institute of Justice to improve the program and develop a 
dataset that could be generalized to the greater population of booked arrestees within the 
geographic area studied. Chapter Four explains the analytical plan for the research 
question and the statistical analysis employed and a specification of the variables 
included in the current study. Chapter Four also presents the descriptive statistics for the 
demographic characteristics of the DUF and ADAM samples and drug use information. 
Chapter Five presents results for the equivalence analysis determining the comparability 
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of the DUF and ADAM data with regard to drug use prevalence and patterns. Finally, 
Chapter Six concludes by summarizing and discussing the results of the analysis and 
providing implications of the results for future research. 
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CHAPTER TWO 
RESEARCH ON ILLICIT DRUG USE 
Why is it Important to Study Illicit Drug Use? 
Budget Spent on Combating Drug Use 
Illicit drug use is a problem of high priority in the United States (Reuter, 2006). 
One indicator of the importance of reducing illicit drug use is the amount of monies spent 
by the government on decreasing illicit drug use as compared to other expenditures. The 
Office of National Drug Policy (ONDCP) estimates the costs of drug expenditures of the 
federal government. Until 2002, the ONDCP combined drug-targeted (e.g., domestic and 
international enforcement) and drug-related (e.g., prevention and treatment) expenditures 
in their drug expenditure estimation. The drug-related expenditures also included 
substance abuse and rehabilitation research (ONDCP, 2002).  Using this comprehensive 
approach, the ONDCP estimated that the government would spend $19.2 billion on the 
national drug control budget for the fiscal year 2002 (ONDCP, 2002). This estimate 
decreased to $12.9 billion when expenditures associated with the consequences of drug 
use (e.g., cost of incarceration) were excluded (ONDCP, 2002).   
For the year 2010, the federal government has provided a budget of $15.1 billion 
(ONDCP, 2009). This budget includes funding for treatment, prevention, domestic law 
enforcement, interdiction, and international counterdrug support. In comparison, the U.S. 
Department of Justice is allocated a total budget of $26.5 billion, and the budget for the 
U.S. Department of Education is $46.7 billion. Also, the budget allocated to combating 
illicit drug use is greater than the total budget for the U.S. Department of Commerce, 
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which receives only $12 billion. In sum, the federal government allocates a significant 
amount of money to reduce illicit drug use. 
In addition to the fact that the government spends a considerable amount of 
money on combating illicit drug use as compared to other expenditures, these 
expenditures have significantly increased within the past four decades. Specifically, the 
budget of the Drug Enforcement Agency (DEA) increased from $65.2 million in 1972 to 
$15.1 billion for 2010. At the same time, the number of total employees increased from 
2,775 in 1972 to 10,891 in 2006 (Drug Enforcement Agency, 2007a). State and local 
agencies also spend a sizable amount of their budgets on drug law enforcement. For 
example, New York and California each spend about $1 billion per year on law 
enforcement efforts related to the prohibition of marijuana use alone (Drug Reform 
Coordination Network, 2005). Overall, drug law enforcement receives a sizable amount 
of funding at the federal, state, and local levels.  
Policies and Programs Combating Drug Use 
The importance of combating illicit drug use and abuse is also illustrated by the 
fact that the government has implemented a considerable number of policies and 
programs targeting illicit drug use. The policies and programs are aimed either at drug 
supply reduction or drug demand reduction. An example of a program targeting drug 
supply would be the Organized Crime Drug Enforcement Task Force, which combines 
the expertise and resources of all federal agencies involved in drug law enforcement 
(including the FBI, the Bureau of Immigration and Customs Enforcement, the Bureau of 
Alcohol, Tobacco, Firearms and Explosives, and the U.S. Marshals Service) with the goal 
of combating major drug trafficking and money laundering (DEA, 2007b). An example 
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of a drug demand reduction program would be the Drug-Free Schools and Communities 
Act administered by the U.S. Department of Education. The proposed goal of the act is to 
educate school children of the dangers of alcohol and illicit drug use and to prevent such 
illicit drug use (Office of Safe and Drug Free Schools, 2006).   
Importance of Studying Drug Use for Researchers 
Illicit drug use is of great importance not only for law enforcement but also for 
researchers. There is a large amount of research examining drug use prevalence and 
patterns across different population groups, predictors of drug use, evaluation of drug 
prevention programs (school- and community programs) and drug treatment programs, 
the cost-effectiveness of treatment programs, and the effectiveness of drug courts. This 
section reviews the research relevant to the current study – drug use prevalence and 
patterns as shown in the major national drug studies. This is important because it will 
demonstrate how important DUF and ADAM were for drug researchers and why it is 
imperative for the advancement of drug researchers and the implementation of effective 
drug reduction programs to systematically monitor drug-abusing behaviors among 
arrestees across the United States. 
Ongoing National Studies of Drug Use Prevalence and Patterns: Why ADAM 
Should Be Implemented Nationwide 
 The government has collected drug use data via self-report surveys administered 
to nationally representative samples of households (National Survey on Drug Use and 
Health) and youths (Monitoring the Future) for more than thirty years. Although both 
studies survey a nationally representative sample of individuals, they rely on data sources 
with low credibility (self-report) and they survey population groups who are not heavy 
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substance users. Additionally, the Substance Abuse and Mental Health Administration 
(SAMHSA) sponsors the Drug Abuse Warning Network (DAWN) program, which 
monitors drug related emergency room visits. Next, a brief overview of the NSDUH, 
MTF, and DAWN will be provided for a better understanding of their drug estimates and 
why these surveys have not played much of a role for drug researchers and policy 
makers.  
The National Survey on Drug Use and Health (NSDUH) 
The National Survey on Drug Use and Health (NSDUH), formerly known as the 
National Household Survey on Drug Abuse (NHSDA), was implemented by the Federal 
Government as an annual survey in 1971. The NSDUH targets a representative sample of 
the civilian, non-institutionalized population aged 12 years and older via face-to-face 
interviews in all 50 states and the District of Columbia (Department of Health and 
Human Services, 2006). Thus, the survey intentionally excludes persons who are 
institutionalized, such as persons in jail, prison, or mental hospitals. The survey also 
excludes persons who have no fixed address (i.e., homeless and transient persons), and 
military personnel.  
The NSDUH inquires about alcohol and drug use for the following drug classes: 
alcohol, marijuana, cocaine, heroin, hallucinogens, inhalants, psychotherapeutics, and 
tobacco (SAMHSA, 2005). The questionnaire first asks participants whether they have 
ever used any of these drugs. If the participants report drug use for any of these drug 
classes, the interviewer continues with more detailed questions for each drug used, 
including the last time used and age of first use. The survey also includes a number of 
questions regarding demographic characteristics, such as age, gender, pregnant women, 
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education, and employment. Additionally, participants provide information about 
previous drug treatment, need for drug treatment, needle sharing, experienced 
consequences of drug use, and their criminal history (SAMHSA, 2005).  
Over time, the NSDUH underwent a number of methodological changes, which 
included changes to the sampling method, the interview method, and the questionnaire 
(Gfroerer, Eyerman, and Chromy, 2002). The latest change in the sampling procedure 
was implemented in 2005. The NSDUH now employs a multi-stage probability sampling 
design consisting of three phases: (1) Stratification of States into 900 State sampling 
regions; (2) Selection of 48 census tracts per State sampling region, (3) Selection of area 
segments (census blocks). From these area segments, four samples are drawn—one for 
each quarter of the calendar year—allowing for continuous data collection. For each area 
segment, a listing of the addresses are obtained and sampling units selected. Finally, the 
interviewer randomly selects the sample person via a computerized procedure 
(SAMHSA, 2007). 
Changes to the NSDUH also include modifications to the interview method. Until 
1998, the survey was conducted via paper and pencil method. In 1999, the paper and 
pencil method was changed to a computer-assisted method to increase the response rate. 
Computer-assisted methods have been shown to result in higher reports of drug use, 
typically attributed to the higher degree of confidentiality. Respondents stated that they 
were more truthful because the interviewer would not know about their drug use 
(SAMHSA, 2000). 
Several other methodological changes were also implemented (SAMHSA, 2007). 
The name of the program was changed from National Household Survey to National 
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Survey on Drug Use and Health (NSDUH). More importantly, survey participants now 
receive a payment of $30, which has substantially increased the response rate. 
Additionally, the data quality control procedure (including training sessions for staff, 
higher degree of supervision of the interviews, evaluation of interviewers) was improved 
during 2001 and 2002. The sampling weighting procedures of the 2002 survey are based 
on the 2000 decennial data, whereas the sampling weighting procedures for previous 
years are based on the 1990 decennial data (SAMHSA, 2007).   
In 2007, SAMHSA conducted a study examining the impact of the 
methodological changes in the NSDUH. Results showed that the response rate had 
improved significantly, which was probably due to the $30 incentive and the 
implementation of the computer-assisted interviewing method. Also, the reported drug 
prevalence rates were significantly higher, which was attributed to the increased quality 
control procedures and the computer-assisted interviewing method (SAMHSA). The 
results of the analysis suggest that the 2002 data should not be compared to the results of 
previous years because the methodological changes had a significant impact on the study 
outcomes. This also implies that researchers interested in changes in drug prevalence 
would not be able to use all data between 1971 and 2002 (SAMHSA, 2007).  
Although the NSDUH is representative of the general population of the United 
States, it has some major limitations. First, the NSDUH excludes population groups that 
have been shown to be at high risk of drug use, specifically, institutionalized persons and 
homeless persons. As described previously, there is considerable evidence that persons 
who are institutionalized in jails, prisons, and mental hospitals have much higher rates of 
illicit drug use than the civilian, non-institutionalized population. These civilian, non-
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institutionalized persons are likely only occasional users who mostly use marijuana, and 
increasingly prescription medication, but who do not provide information about recent 
changes in drug paraphernalia and the introduction of new or modified drugs (i.e., 
methamphetamine, crack cocaine). It is, however, the regular use of hard drugs (such as 
cocaine, heroin, methamphetamine) and the introduction of new and/or modified drugs 
and changes in drug prevalence and patterns that are the most crucial for researchers, 
policy makers, local law enforcement, and communities in their attempts to develop 
programs that effectively reduce drug use. The occasional user of marijuana is not the 
major problem.  
Second, the NSDUH relies on self-report data. As will be described in more detail 
in the next section, self-report data has been shown to greatly underestimate drug use. 
This limitation is a major one, as it may lead to conclusions about illicit drug use that are 
not correct. The use of incorrect information about drug use by law enforcement and 
policy makers can result in the implementation of policies that are determined to be 
ineffective when evaluated. The implementation of ineffective drug combating strategies 
is a waste of resources that could be used more effectively elsewhere.  
Third, the NSDUH assesses geographic differences in drug use for the four major 
areas: the West, Midwest, Northeast, and South. The results suggest that overall drug use 
is quite similar across the United States. In 2007, the West had an overall drug use rate of 
9.3%, the Midwest had an overall drug use rate of 7.9%, the Northeast had an overall 
drug use rate of 7.8%, and the South had an overall drug use rate of 7.4%. The NSDUH 
does not track changes and differences for individual drugs for these geographic regions. 
This is important because monitoring local areas can be of great help for local law 
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enforcement and communities because they are able to target hot spots of drug sellers and 
users. As mentioned earlier, it is also important for the implementation of local programs 
providing drug abuse treatment and for the reduction of the spread of infectious diseases. 
This type of information cannot be provided by the NSDUH because the civilian, non-
institutionalized population very likely does not “hang out” at such hot spots and can 
therefore not provide information about it. Yet, it is these “hot spots” and the persons 
who are dealing and using drugs that cause the major problems for communities.  
Monitoring the Future (MTF) 
Another national survey on drug use and abuse is Monitoring the Future (MTF). 
The MTF is a longitudinal survey implemented in1975 with the intent to collect data 
about attitudes towards drugs and drug using behaviors among high school children in the 
United States (Bachman, Johnston, O’Malley, and Schulenberg, 2006). The goal is to 
collect data from a nationally representative sample of high school students within the 48 
contiguous states. 
The MTF surveys approximately 50,000 high school children in the spring of 
each year. The survey includes approximately 110-120 public high schools and 15-20 
private high schools. The data is collected via a stratified, multi-stage sampling 
procedure: (1) selection of the geographic area, (2) selection of schools in the selected 
geographic area, and (3) selection of participants in each school. The survey is then 
administered during regular class periods. 
The survey asks extensively about the use of licit and illicit drugs including 
marijuana, sedatives, tranquilizers, hallucinogens, amphetamines, cocaine, heroin, 
inhalants, steroids, alcohol, tobacco, stimulants, diet aids, and creatine. The survey also 
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asks the participants about attitudes towards drugs, consequences of their drug use, and 
whether they believe that they could stop or reduce their drug abusing behaviors 
(Bachman, et al., 2006). Additionally, the MTF asks a series of questions about 
demographic characteristics, including race, gender, parental education, and questions 
about school performance and satisfaction with school (Bachman, et al., 2006).   
The survey’s greatest value lies in its ability to track changes in drug use over 
time, because the survey is administered repeatedly to the same segments of the 
population in private and public high schools (8th, 10th, 12th graders, college students, and 
young adults). As a result, the MTF allows researchers to assess changes in drug use 
prevalence and patterns in four areas: (1) Period effects (changes across all age groups for 
a certain year), (2) Age effects (changes in drug use for all panels), (3) Cohort effect 
(differences among cohorts throughout the life cycle), and (4) Differences attributable to 
differences in the environment (e.g., high school, employment) and changes in life (e.g., 
marriage, military, parenthood) (Johnston, O’Malley, Bachman, and Schulenberg, 2007).  
The MTF, however, also suffers from a number of limitations. First, similar to the 
NSDUH, the survey only collects data via self-report surveys. Second, school drop-outs 
are not captured in the data. This is problematic because research has demonstrated that 
drug users are overrepresented among high school drop-outs (ADAM, 2000). Third, some 
schools may decline participation. These schools might differ from schools that are 
participating in ways that could bias the sample. Fourth, the MTF does not provide 
representative data for local areas (only at the national level). Combating drug abuse, 
however, is very important for local law enforcement and communities. The data from 
the MTF is not especially helpful for such purposes.  
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As stated earlier, both the NSDUH and the MTF are quite expensive surveys that 
accomplish very little with regard to providing useful information about drug use, 
especially hard drugs such as powder cocaine, crack, heroin, and methamphetamine. 
They are also not helpful in determining drug use hot spots and the emergence of new 
drugs. It might be time to examine whether part of the funding that goes to these two 
surveys can be redistributed to a national survey that studies drug use among arrestees. 
Approximately 70% of jail inmates (BJS, 2002) and 83% of state prison inmates (BJS, 
2004) reported drug dependency issues, but only about 9.5% of school children, 19.7% of 
young adults between 18 and 25, and 5.8% of persons 26 years of age or older have used 
illicit drugs (SAMHSA, 2008). Considering the fact that jail inmates and prisoners are 
using illicit drugs at much higher rates than the general population, it would be more 
useful to examine arrestees than school children and non-institutionalized adults with 
regard to illicit drug use, drug market activity, and criminal behavior associated with drug 
use.  
Drug Abuse Warning Network (DAWN) 
A third national data collection tool that provides information about the extent of 
illicit drug use is the Drug Abuse Warning Network (DAWN). DAWN, also sponsored 
by SAMHSA, was first implemented in 1988 as a program that monitors drug-related 
emergency room visits and drug-related deaths (SAMHSA, 2008). In 2003, a new 
methodology was implemented with the goal to improve the quality and utility of the 
monitoring system. Changes were made to the following areas: sample, target population, 
geographic boundaries, definition and method of finding dawn cases, data content, and 
supervision of data quality. Due to the changes in the methodology, SAMHSA data from 
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1988 until 2002 cannot be compared to the data collected in 2003 and later years 
(SAMHSA, 2008). 
The new DAWN collects data from a sample of hospitals representative of 50 
states and the District of Columbia. Eligible hospitals are short term hospitals, general 
hospitals, and non-federal hospitals operating 24-hour emergency departments (ED’s). 
The new DAWN includes all types of drug-related ED visits regardless of the patient’s 
intent or age. Medical charts of ED visits are retrospectively reviewed, and cases that 
meet the criteria are selected. Demographic information and self-reported drug use 
information obtained from the patient is recorded. DAWN collects information about all 
types of drugs, including illegal drugs, alcohol, alcohol in combination with other drugs, 
dietary supplements, prescription and over-the-counter drugs, and non-pharmaceutical 
inhalants. The new DAWN program also includes toxicology results as a validation 
technique for the self-reported drug use. Before 2003, toxicology results were not used as 
a confirmation method (SAMHSA, 2008).  
The greatest strength of the new DAWN program is that it uses toxicology reports 
to confirm self-reported drug use and that it is a representative sample of the complete 
United States. Despite the changes in the methodology, there are two major limitations to 
the DAWN program. First, the data provided by DAWN is an incidence measure of the 
consequences of drug use (which could be first time or long-term drug use) and does not 
provide information about the prevalence of drug use. Second, the data provides 
information about emergency room incidents, not the number of patients, because one 
patient could be treated in the emergency room several times and it would be recorded as 
a separate case each time. Thus, it is not clear how many people use drugs, how often 
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they use drugs, where they buy their drugs, and other information crucial for researchers 
and policy makers in combating illicit drug use.  
Advantages of DUF and ADAM Over Other National Surveys 
The DUF and ADAM program not only complemented the NSDUH, MTF, and 
DAWN, but also had a number of advantages over the other three surveys that greatly 
benefited researchers, policy makers, local law enforcement agencies, and communities 
in ways that none of the other three surveys could. The exact methodology of DUF and 
ADAM will be explained in Chapter 3. This section will focus on examining the 
advantages of DUF and ADAM as compared to the NSDUH, MTF, and DAWN and why 
the DUF and ADAM program were so important for researchers, law enforcement, and 
policy makers. 
The three major advantages of the DUF and ADAM program were: (1) They 
assessed drug use among arrestees - a population group shown to be at great risk of drug 
use, (2) they used bioassays to validate the self-report data, and (3) they provided local 
data for every quarter of the year for a period of 15 years.  
As discussed in the previous chapters, DUF and ADAM focus on a very different 
population group than the other three national surveys.  Specifically, they focus on 
arrestees, a subpopulation with a significantly higher rate of drug use than the general 
population or school children. For instance, the Bureau of Justice Statistics (2004b) has 
found that 53% of state and 45% of federal prisoners have substance abuse issues. These 
rates are significantly higher than in the general population. The results from the National 
Survey on Drugs and Health (NSDUH) show that only about 8% of people 12 years and 
older have substance abuse issues (SAMHSA, 2007). This means that prisoners are about 
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5 times more likely to use illegal substances than the general population.  
Another important difference is that psychotherapeutic drugs are among the 
preferred drugs used in the general population. Psychotherapeutic drugs include anti-
anxiety drugs (i.e., Xanax, Valium), antidepressant drugs (i.e., Zoloft, Proxil), antimatic 
drugs (i.e., Eskalith), and antipsychotic drugs (i.e., Thorazine). These psychotherapeutic 
drugs are not the preferred drugs of prisoners and arrestees. In sum, drug use behaviors 
among arrestees, prisoners, and the general population vary significantly. Studying drug 
use among the general population and not among arrestees and other population groups at 
high-risk of illegal substance use will result in misleading conclusions about drug use in 
the United States. Overall, researchers estimate that the national surveys miss the vast 
majority of the drugs that are being used. For instance, Kleiman (2004) states that the 
NSDUH accounts for only about 30 metric tons out of about 300 metric tons of the 
cocaine consumption. Thus, when policy makers implement strategies aiming to reduce 
cocaine demand based on the household survey, they are relying on information from the 
wrong population group.   
Until 2003, the DUF and ADAM programs were the only national drug study that 
allowed researchers to assess the validity of self-reported drug use. This is important 
because the main criticism of self-reported behaviors pertains to the question of how 
valid the results are. Validity for this purpose refers to the question “whether the data 
recorded by the researcher accurately reflect the phenomenon under investigation” 
(Harrell, 1985). Stated differently, do people answer questions in self-report surveys 
truthfully? 
Since 2003, the DAWN program also uses bioassays to confirm self-reported drug 
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use. The NSDUH and the MTF still rely on self-report only. This is a major limitation. 
Thus, not only do these two expensive national surveys assess drug use among the 
general population, which only accounts for a minimal part of the drug use activity, but 
these surveys also do not validate the self-report data via objective validation techniques.  
Validity of Self-Report Data 
Self-report surveys have a long history and the validity of the obtained data has 
been suspect to many researchers because the collected data might be erroneous (Stone, 
Turkkan, Bachrach, Jobe, Kurtsam, and Cain, 2000).  As early as the late 1940s, 
researchers found systematic biases in self-reported behaviors, probably due to incorrect 
information provided by the study participants (Stone, et al., 2000). 
Although early research on the validity of illicit drug use suggested that 
respondents reported drug use fairly accurately, more recent improvements in technology 
have allowed researchers to employ more sophisticated validation techniques which have 
led to a different conclusion (Harrison, 1995). The results of these more recent studies 
suggest that self-reported drug use is not reported as accurately as thought. Rather, 
respondents are likely to underreport drug use. For example, Fendrich, et al. (1999) found 
that respondents from a high-risk community sample heavily underreported cocaine and 
heroin use. They found that only 20% of cocaine-positive respondents also admitted to 
current use of cocaine. Similarly, Appel et al. (2001) found that only 26% of the 
respondents from a sample of homeless and transient persons in New York who tested 
positive for cocaine use also reported their drug use.  
There is, however, some research suggesting that the underreporting of self-
reported drug use might not be as large as believed. A recent SAMHSA study suggests 
  30
that there is a high degree of agreement between self-reported drug use and urine test 
results among the general population. Specifically, for marijuana use there was 89.9% 
agreement and for cocaine use there was 98.5% agreement (Harrison, Martin, Enev, and 
Harrington, 2007). Other studies show that the agreement between self-reported 
delinquency (as measured by self-reported arrests) and official data (arrest records) is 
between 50% and 83% (Hindelang, et al., 1981; Hindelang & Krohn, 2000). Hindelang 
and Krohn (2000) conclude that these agreement rates are reasonably high. It is, however, 
impossible for researchers to know whether 50% or 80%of their study participants told 
the truth unless the data is verified via objective measures, such as official arrest records, 
criminal records, or urine analysis. It appears that it would be of great importance to 
know if only 50% of the subjects gave true answers. Thus, although some research 
suggests that self-report data can be a valid measure of delinquency and drug use, there is 
a substantial amount of research suggesting otherwise. 
 A number of researchers have also demonstrated that the accuracy of self-
reported drug use depends on the type of drug and the population subgroup. The more 
stigmatized the drug, the less likely respondents report its use (Harrison, 1992, 1995; 
Mieczkowski, et al., 1991). Using data from the DUF program, Harrison (1992) found 
that arrestees most accurately report use of opiates (60%), followed by marijuana (55% 
concordance). Arrestees were least likely to report the use of cocaine (50% concordance) 
and amphetamines (40%). This also holds true for other population subgroups. A study 
by Hser, Maglione, and Boyle (1999) suggests that self-reported drug use among 
emergency room patients (ER) and patients with sexually transmitted diseases (STD) was 
more accurate for marijuana as compared to any other drug. Hser’, et al., (1999) study 
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also demonstrates that different population subgroups are more or less likely to accurately 
report drug use. ER patients and STD patients, as compared to arrestees, were less likely 
to report drug use overall, but especially the use of hard drugs. The reason may be that 
ER patients and STD patients perceived the social stigma associated with illicit drug use 
to be greater than arrestees, who were already stigmatized due to the arrest itself and 
admitting using drugs may be a minor issue compared to their arrest (Hser et al., 1999). 
More recent research by Golub, et al. (2005) has found that disclosure rates also vary 
across geographic locations.  
Epidemiological research suggests that people even fail to disclose illicit drug use 
in situations where a failure to do so might potentially harm them. For instance, 
Tassiopoulos, et al. (2004) found that 34.2% of out-of-treatment heroin users did not 
admit that they were also using cocaine. In an emergency situation, failure to disclose the 
use of an illicit drug may have a negative impact on medical care. It appears that the 
stigma associated with drug use is perceived to be so strong that it is kept secret even in 
life-threatening situations. If individuals do not disclose drug use in situations where their 
health is at stake, why would they disclose such behaviors to an interviewer? 
Though there is considerable evidence that drug use is generally underreported, 
there are exceptions. Persons who have either recently been admitted into a drug 
treatment program or who have recently finished a drug treatment program report drug 
use fairly accurately. A study by Hindin, et al. (1994) using data from persons entering a 
residential drug treatment program found that 89% percent of the respondents who tested 
positive for cocaine use also reported such use. The concordance rate for heroin was even 
higher, with 96% of the individuals who tested positive for heroin use also reporting such 
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use.  
In some instances, over-reporting can occur. For instance, arrestees may over-
report drug use if they believe that it may increase their chances to enter a drug treatment 
program instead of going to jail (Hser, 1999). Arrestees may also over-report drug use if 
they have been arrested for a violent crime and anticipate a long prison sentence. Drug 
use in this case may serve as a mitigating circumstance and make them appear less 
culpable (Nurco, 1985). Other population subgroups may also over-report drug use. For 
example, adolescents and college students might over-report drug use to make their 
behavior patterns fit the behavior that is accepted among their peers. Johnston and 
O’Malley (1997) found that adolescent males as well as male and female college students 
reported fewer incidents of drug use in a follow up interview. The researchers concluded: 
“the ‘revised’ may well be the more accurate number, and the answers given at earlier 
ages . . . may be inflated” (p. 78). Both under-reporting and over-reporting can lead to 
inaccurate conclusions about drug use. DUF and ADAM were unique because they 
validated self-reported drug use with drug tests, therefore providing a more objective 
measure of drug use among arrestees. Without the validation of self-reported drug use via 
bioassays, researchers and policy makers are left guessing about how accurate the 
collected data is.  
Explanations for the Failure to Report Behaviors Truthfully 
Several explanations have been advanced to explain the under-reporting of drug 
use. Threats to the validity of self-report data are typically said to stem from the failure to 
remember events accurately and the failure to report behaviors truthfully (Harrell, 1985). 
For researchers studying the prevalence and patterns of illicit drug use and other 
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stigmatized behaviors, threats to validity stem mostly from the second category—the 
failure to report behaviors truthfully. To further explore this question, researchers have 
proposed a number of theoretical explanations of why respondents may not answer 
questions in self-report interviews truthfully even though they are assured that the 
answers are kept fully confidential or that the answers are anonymous (Sloan III, 
Bodapati, and Tucker, 2004). One of these explanations is the “Social Desirability 
Theory.” 
The purpose of the self-report surveys is typically very obvious to the respondent, 
and as a result it is rather easy for the respondents to manipulate the answers (Cook and 
Selltitz, 1964). The underlying assumption of the social desirability theory about human 
nature is that humans are social beings and that their behavior is oriented on the 
behaviors of others (Weber, 1968). Accordingly, social desirability theory advances the 
thesis that persons will respond to questions in a way that is consistent with social norms, 
expectations, and “socially desirable traits” (Zerbe and Paulhus, 1987, p. 250). In other 
words, people will respond to questions in a way that places them in a good light. 
Researchers have found support for the social desirability theory in a variety of topics. 
The social desirability thesis first received empirical support from a study conducted in 
1953 by Edwards. Edwards (1953) found that there is a relationship between what survey 
respondents believed to be the socially desirable answer and the answer given by these 
respondents. Additionally, Willis and Schechter (1997) examined how study participants 
felt about what the interviewer might think about them and react towards them if they 
disclosed their drug abusing behaviors. Their study demonstrated that individuals were 
very concerned about interviewer reactions and preferred not to talk about their drug 
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using behaviors because they felt that they were being judged.  
There is considerable evidence that self-reported behavior is biased towards 
normative behavior. For instance, the Magazine Audience Group by Crossley 
Incorporated (1941) examined the validity of self-reported educational attainment. The 
results of this study showed that individuals exaggerate their educational attainment 
regarding graduation from the various educational institutions (e.g., grade school, high 
school, and college) (Parry and Crossley, 1950). In a study about redeeming war bonds, 
Hyman (1944) found that individuals were likely to deny that they had redeemed war 
bonds. The denial of redeeming war bonds was greater for individuals with a higher 
income status. Presser (1990) found that people over-reported voting behavior and the 
attendance of religious services.  
To control for a social desirability bias, researchers have included measures in 
their questionnaires meant to provide information about whether the participant may have 
altered his/her answers because he wanted to give the “correct” answer. The most 
commonly used measure for this purpose is the Marlowe-Crowne Social Desirability 
Scale (Crowne and Marlow, 1964). Unfortunately, the purpose of this scale is quite 
transparent to the respondents and respondents may answer the questions of the scale 
honestly but not the questions about drug use. As a result, researchers might interpret the 
self-reported behavior as accurate when it is really not (Richter and Johnson, 2001).  
Threats to the validity of self-reported drug use also arise from the fact that people 
may not recall events accurately. Even when the respondent is motivated to provide 
accurate information about self-reported drug use or other behavior, they may simply not 
remember which drug they used at what point in time or how often they used it. The drug 
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use itself may distort their recall of events (Catania, 1993). Harrell (1985) suggests that 
general behaviors are easier to recall than specific behaviors. For example, drug users 
might recall accurately having used a certain drug in the last few days, but may not 
remember how often they have used the drug or how much of the drug they used.  
Additionally, more recent events are recalled more accurately than events that 
occurred a while ago (Harrell, 1985). This is also referred to as recall decay (Johnson, et 
al. 1997). A study by Roberts, et al. (2005) suggests that individuals underestimate 
violent behaviors within a 1-3 year time period using a life-events calendar. This type of 
calendar was also used by the ADAM study to assess drug use prevalence and patterns 
within the past 12 months. Recall decay is not only a problem for researchers studying 
drug using or criminal behaviors but also for researchers in other fields including 
medicine. Studies have found that individuals will significantly underestimate injury rates 
if asked more than 2 months after the incident (Jenkins, Earle-Richardson, Slingerman, 
and May, 2002).  Considering that many people cannot accurately remember which 
injuries they suffered or violent behaviors, recall decay is a serious threat to the validity 
of drug use data. 
Additionally, individuals may believe that a certain event occurred more recently 
than it actually did. This is called forward telescoping. Individuals might fairly accurately 
recall whether they ever used a certain drug, but they might not be accurate in recalling in 
which year or during what time period the drug was used (Johnson and Schultz, 2005). 
Telescoping is especially a problem when an event occurs regularly and is not salient in 
the sense that it would be remembered easily (Magnusson and Bergman, 1990). Many 
drug users use drugs regularly, some several times a day. It is unlikely that these regular 
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drug using behaviors are particularly salient, and as a result it cannot be expected that 
drug use is being recalled accurately.  
Implications of the Lack of Reporting for Researchers and Policy Makers 
The implications of the lack of complete reporting are manifold. For instance, it 
has implications for researchers who are drawing conclusions about the relationship 
between drug use and crime, changes in drug use prevalence and patterns, and other 
issues. A lack of truthful reporting will necessarily lead to inaccurate conclusions. If the 
goal of research is to advance the knowledge in a certain field publishing results based on 
incorrect information would be counterproductive. The most important implication of a 
lack of truthful reporting behaviors of drug use probably pertains to the implementation 
of policies meant to reduce drug use, provide treatment to drug users, and prevent the 
spread of infectious diseases, including HIV and Hepatitis (Des Jarlais, 1998). If 
programs are based on invalid data, then the effectiveness of these programs might be 
quite low. Additionally, a lack of truthful reporting (mostly under-reporting) might lead 
to the conclusion that drug abuse treatment programs are not needed in a certain 
community. As a result, drug users will not receive treatment and continue to use drugs, 
increasing the  likelihood of the spread of infectious diseases and criminal behavior 
associated with drug use.   
Due to the great likelihood that self-reported data is inaccurate, especially for 
sensitive and stigmatized behaviors (such as illicit drug use), researchers need to validate 
data whenever possible. The ever-present issue is what measure could be used to assess 
the truthfulness of the provided information.  
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Validation Methods for Self-Reported Drug Use 
In the case of illicit drug use, researchers have a variety of validation techniques 
available, including the analysis of urine specimens, hair samples, sweat, or saliva (Cone, 
1997). Each of these methods is unique and provides different types of information. Each 
method also has its strengths and weaknesses. The usefulness of a certain drug testing 
method depends on a number of factors, which all relate to the accuracy with which a 
certain method is able to detect drugs in biological fluid or tissue (Cone, 1997).  The 
factors influencing the usefulness of a testing method are (1) sensitivity, (2) specificity, 
and (3) accuracy. Sensitivity refers to the “least amount of detectable drug,” meaning that 
the more sensitive the test, the lower the concentration of the drug that can be measured 
(Cone, 1997, p. 109). Specificity refers to “how selective the assay is for the drug” or the 
ability of the test to distinguish between different drugs (Cone, 1997, p. 109). The higher 
the specificity of a test, the more accurately it can determine the presence of a certain 
drug.  The most common method utilized in drug use research is urine testing.  Both DUF 
and ADAM employed this method. Research has demonstrated that, at the current time, it 
is the most accurate drug screening method for recent drug use (2-4 days) as compared to 
hair, saliva, or sweat (Mieczkowski and Newel, 1997).  
Urine Testing 
Urine can be used for drug screening because urine is produced by the kidneys, 
which reabsorb and eliminate substances (such as drugs) that are waste products for the 
body (Cone, 1997). As a result, the substances that are being eliminated from the body 
will show up in the urine specimen. Most illicit drugs will be eliminated from the body 
within 48 hours of administration. If drugs are taken consistently and over longer periods 
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of time, the detection time can be longer. The detection time also depends on the drug. 
For example, heroin, cocaine, and marijuana have a detection time of 1-3 days. 
Barbiturates, amphetamines, methadone, and methamphetamine have a detection time of 
2-4 days (Cone, 1997). Thus, urine testing is very useful for the detection of short term 
drug use, but it is not useful for assessing drug use that occurred more than a few days 
ago. This also means urine testing cannot be useful to examine drug use over long periods 
of time.  
Another problem with urine testing is that the cut-off levels for detecting the 
drugs are considerably different depending on the drug, meaning that some drugs are 
detected at much lower doses than others. For instance, the cut-off level for marijuana is 
as low as 20 ng/ml, whereas the cut-off level for methamphetamine is 1000 ng/ml. 
Additionally, delay in drug testing (due to holding the specimen for a certain period of 
time before testing it) may also lead to a failure to detect drug use because the dose of the 
drug might have fallen below the cut-off level.  
Despite these shortcomings, urine testing has been shown to be a valid measure of 
recent drug use. The advantages of urine tests have not only been demonstrated by social 
and behavioral research, but they have also long been recognized in the criminal justice 
system. For example, urine tests are used by courts to monitor abstinence and relapse, 
because offenders will very likely not report drug use to the Court (Bureau of Justice 
Assistance, 1999). These studies and practices by the criminal justice system demonstrate 
the importance of using bioassays as a validation technique for self-reported drug use. In 
sum, the decision made by NIJ to opt for urine analysis as a validation method for recent 
self-reported drug use for the DUF and ADAM programs appears to be an adequate 
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decision and was the major strength of DUF and ADAM over other national drug studies 
(such as the NSDUH and the MTF). The use of bioassays as a validation technique of 
self-reported drug use was not the only advantage of DUF and ADAM over the NSDUH 
and the MTF. Another important advantage was the collection of localized data.  
Localized Data Collected Every Quarter Over 15 Years 
As described earlier, the NSDUH, MTF, and DAWN provide national data on 
drug use only. Although they provide data for the major geographic areas (sub-state 
areas) of the United States, there is little data at the county and city levels. This county 
and city level data, however, is very useful for local law enforcement agencies and 
communities in their efforts to target hot spots of drug use and drug sale. DUF and 
ADAM filled that gap by providing county and city level data for the major drugs used. 
This site-specific information is important because the results of DUF and ADAM have 
consistently demonstrated that there are significant differences in drug use by geographic 
region and over time. For instance, the DUF program showed that methamphetamine use 
in the United States was modest, with about 6%, but it was becoming a great problem in 
the western part of the country (NIJ, 1996). Specifically, the six sites with the highest 
methamphetamine use rates were San Diego (37.1%), Phoenix (21.9%), Portland 
(18.7%), San Jose (18.5%), Omaha (8.1%), and Los Angeles (7.5%) (NIJ, 1996).   
A study by the National Institute of Drug Abuse (NIDA) examining 
methamphetamine use in 21 areas across the United States supports the results found by 
DUF and ADAM (NIDA, 2006). Methamphetamine use is mostly a problem of the 
Western states of the United States, especially Honolulu, San Diego, Seattle, San 
Francisco, and Los Angeles. Additionally, methamphetamine use increased over time, 
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which showed especially in the number of drug treatment admissions and emergency 
room visits. Specifically, emergency room visits for methamphetamine related problems 
(provided by the Drug Abuse Warning Network) increased by 70% between 1999 and 
2002 (Franco, 2007). Additionally, drug treatment admissions (provided by the 
Treatment Episode Data Set collected by SAMHSA) for methamphetamine use have also 
greatly increased, not only in the Western United States, but across the country. In 1992, 
only 5 states reported a high number of drug treatment admissions. In 2002, 21 states 
reported high number of drug treatment admissions (NIDA, 2006).  
The results from the MTF also demonstrate that methamphetamine was much 
more widespread in the western part of the United States. Unfortunately, questions about 
methamphetamine use were not included in the survey until 1999. Since 1999, the MTF 
suggests that methamphetamine use has been declining, from 8.2% in 1999 to 4.5% in 
2005. The DUF data showed that methamphetamine began to rise sharply in the early 
1990s. For instance, Herz (2000) using data from the DUF program for Omaha, Nebraska 
showed that methamphetamine use increased from 1% in 1990 to 10% in 1999. Being 
able to notice early when a certain drug is on the rise is important to prevent it from 
becoming an epidemic. Research suggests that recently implemented compstat systems 
can be used to track drug activity. These systems help local police departments determine 
areas with high crime and drug activity. For instance, the cities of Lowell and Newark 
were able to allocate police officers depending on the need of certain communities by 
using the compstat system (Willis, Mastrofski, and Weisburg, 2003). One problem with 
the local compstat systems is that they don’t exist across the entire country. Also, the data 
collected by these systems is not send to a national data collection agency.  As a result, 
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these data are not available to researchers and others who are looking at trends across 
different geographic locations.  
Early knowledge about a rising drug problem enables law enforcement and the 
government to implement supply reduction strategies that reduce the availability of the 
drug on the streets and increase the prices for the drug. These federal and local prevention 
and intervention programs are only possible, however, if the problem is known not only 
to the local police department who uses a compstat system but also to departments in 
surrounding geographic locations. This is important because of a possible displacement 
of drug use and drug crime to other areas as a result of the increased police presence in 
areas with high drug use. As stated before, the distribution of the data is a necessary 
prerequisite to combating illicit drug use. DUF and ADAM were doing that by collecting 
data at the local level and making it available to researchers and policy makers.  
This systematic data collection and distribution contributed to the implementation 
of local programs. In 1996, the government implemented the Comprehensive 
Methamphetamine Act, which aimed to reduce drug trafficking and reduce the 
availability of chemicals needed to produce methamphetamine. Researchers suggest that 
this Act was a direct response of the White House to the rising levels of 
methamphetamine use as documented by the DUF program (National Criminal Justice 
Association, 1999). Although the DUF program was not the only data that showed the 
regional increases of methamphetamine use, it provided important information that 
helped getting the attention of policy makers.  For instance, Oregon reduced the 
availability of drugs (mainly pseudoephedrin) needed to produce methamphetamine (as 
provided by the Comprehensive Methamphetamine Act). Studies showed that during the 
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time of supply disruption, methamphetamine use decreased substantially (Cunningham 
and Liu, 2003; 2005). The reduction of methamphetamine after the implementation of the 
Act was also evident in California and other states ((National Criminal Justice 
Association, 1999).). Without DUF and other programs, the sharp rise and extent of the 
methamphetamine problem might have gone unnoticed. As a result, the rising levels of 
methamphetamine use in the western part of the country might have further increased. 
Similar to the MTF, NSDUH data also failed to show the substantial rise in 
methamphetamine use in the West. Specifically, the NSDUH show that 
methamphetamine use was less than 2% until 1994 and rose between 1994 and 2001 to 
4%. Also, as described above, the MTF suggests that methamphetamine use has declined 
since 1990. In contrast, data from the ADAM program demonstrate that for some sites 
methamphetamine use has increased. Specifically, in San Jose, San Diego, and Phoenix, 
methamphetamine use increased substantially between 2000 and 2003. These results are 
also supported by the DAWN data, which shows an increase in emergency room visits 
for methamphetamine use between 1995 and 2002 in Los Angeles, Minneapolis, St. 
Louis, Seattle, Atlanta, New Orleans, and New York. Thus, the national data provided by 
the NSDUH and the MTF provide the false impression that methamphetamine is on the 
decline in general, when there are significant regional differences. Whereas 
methamphetamine use is declining in some regions, it is still increasing in others (Hunt, 
et al., 2006).  
The revived ADAM II program, conducted by the ONDCP, also supports the 
finding that there are large regional differences in methamphetamine use and while some 
regions, such as Washington, DC and Portland, still show a decrease in 
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methamphetamine use between 2003 and 2007, other sites (including Atlanta, 
Minneapolis, Sacramento, Indianapolis, Charlotte, and Chicago) have remained stable 
(Office of National Drug Control Policy, 2008).  
Some police departments collect data on drug use in their community. For 
instance, the police department in High Point, North Carolina collects data about drug 
markets with the goal of targeting drug dealers more effectively (High Point Police 
Department). Although that is a viable approach if the goal is to target drug dealers and 
dismantle drug markets in a specific area, this does not necessarily advance research or 
help policy makers implement strategies for a greater region or nationwide because the 
data is not collected systematically. Instead, each local agency uses its own methods (e.g. 
surveys, GIS, crime reports) to determine hot spots of drug dealers and high drug market 
activity. This data is not comparable across agencies. Additionally, the local agencies do 
not submit their data to a national data bank where researchers could access such data. 
Systematic data collection at the national level ensures that researchers have data 
available to advance our knowledge about drug use and related issues. It is especially 
important to implement a national study that collects data systematically from arrestees 
because their drug using behaviors are substantially different from those of the general 
population and school children.  
The NSDUH data not only failed to show the geographic differences for 
methamphetamine use but also greatly underestimated the extent of the 
methamphetamine problem. In fact, critics of the anti-methamphetamine drug policy 
argued that the NSDUH data does not support the degree of attention given to 
methamphetamine (Franco, 2007). This is problematic because research has shown that 
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methamphetamine has stronger and longer lasting toxic effects than amphetamines or 
cocaine. For instance, smoking methamphetamine can create a high for 8 to 24 hours. In 
comparison, cocaine creates a high for only about 20 to 30 minutes. Additionally, the 
amount of dopamine released to the brain is three times higher for methamphetamine 
than for cocaine.  
Also, it takes approximately 12 hours for half of the methamphetamine to be 
metabolized (half-life). The half-life of cocaine is only one hour. Methamphetamine has 
also been shown to increase the likelihood of HIV and Hepatitis infections due to risky 
sexual behavior.  These findings indicate the great health consequences of 
methamphetamine use, and as a result the need to contain methamphetamine use when it 
first started to become more popular. In the 1990s, when neither the MTF nor the 
NSDUH provided valid information about methamphetamine use, DUF and ADAM were 
crucial to proving to critics that the implemented drug policies were very necessary to 
decrease the use of methamphetamine in the western part of the country and to hinder the 
further spread of methamphetamine use to other parts of the United States. 
After having described the major advantages of the DUF and ADAM programs 
over the other national drug use monitoring programs the following section will now 
expand on differences and similarities between drug use data from the DUF and ADAM 
programs as compared to the NSDUH, MTF, and DAWN programs because these 
differences will demonstrate the importance of implementing a national program that 
systematically tracks drug use among arrestees. 
Changes in Drug Use Prevalence and Patterns between 1988 and 2002  
Research from the DUF/ADAM programs, the NSDUH, and the MTF 
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demonstrate that changes in drug use prevalence and patterns tend to show up among the 
criminal justice population first (DUF/ADAM data) and then spread to the general 
population (NSDUH and MTF data). With regard to marijuana use among arrestees, three 
waves (or generations) are visible between 1987 and 1998 (Golub and Johnson, 2001). 
First, marijuana use declined in the 1980s until about 1992. Second, beginning in 1992, 
marijuana use started to increase and then stabilized until about 1996. The third wave is 
characterized by a significant increase in marijuana use in 1996. This third wave 
appeared to plateau in 1999. Although these three waves are also apparent in the NSDUH 
and MTF, the beginning of a new wave showed up in the arrestee data from the DUF and 
ADAM data first and only later in the general population (Golub and Johnson, 2001).  
 Specifically, the increase in marijuana use became obvious first among youthful 
arrestees in the DUF data in 1991. This increase did not surface among the general 
population until about one or two years later (Golub and Johnson, 2001). The results 
further suggest that the rise in marijuana use was more pronounced among the criminal 
justice population, indicating that it spread more widely among this population as 
compared to the general population (Golub and Johnson, 2001). Additionally, the 
NSDUH shows a general decrease of marijuana use as individuals get older, the increase 
and decrease of marijuana use among arrestees was more dependent on geographic 
location. In some areas, marijuana use increased among older (born before 1967) 
arrestees (i.e., Los Angeles, Dallas, Denver, Houston), in other areas, marijuana use 
decreased among older arrestees (i.e., Portland, San Diego, San Jose) (Golub and 
Johnson, 2001).  
There were also significant differences with regard to crack cocaine. Crack 
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cocaine first appeared in the United States in the 1980s and quickly became popular 
(Golub and Johnson, 1997). Golub and Johnson (1997) examined the prevalence of crack 
cocaine between 1987 and 1996 using the DUF data. Their major findings demonstrate 
that crack cocaine became popular first among older, more experienced drug users, who 
then introduced crack to young and new users. Crack cocaine was cheap, easy to use 
(smoking), and widely available. Crack cocaine became an epidemic in the late 1980s 
and began to decline around 1996 mostly because younger drug users began to look down 
on crack users (also referred to as “crackheads”) (Golub and Johnson, 1997). The rising 
disdain of young drug users for crack resulted in the decline of crack cocaine use. In 
contrast, the decrease in crack cocaine use among older, more experienced users was 
much less dramatic. In sum, the decline in crack cocaine use was not the result of a 
similar decline in the use of crack among all birth cohorts, but was caused mainly by the 
fact that youthful users stopped using crack cocaine (Golub and Johnson, 1997).  
Whereas the DUF data showed that crack cocaine was being used widely between 
1982 and 1996, the NSDUH did not distinguish between crack and powder cocaine until 
1988. By that time, crack cocaine use was already decreasing, especially among young 
users. Thus, the NSDUH could not provide data about crack cocaine use in the general 
population at the time when crack was at its peak. Without the DUF and ADAM 
programs, researchers, law enforcement, and policy makers might not have known the 
true extent of the crack epidemic at the local and national levels. As stated above, even 
though local agencies might have had that information for their jurisdictions, this data is 
not available in a national database to researchers and policy makers.  
The data also suggests that there was great geographic variation in the extent of 
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crack use.  The crack cocaine epidemic did not decline at the same rate across the 
country. Rather, the DUF data indicates that there was a significant decrease in crack 
cocaine use at 17 sites, still at its peak at five sites, and two sites did not have an 
epidemic. The popularity of crack cocaine varied even across sites that were 
geographically close. For instance, the decline of crack cocaine use in San Diego started 
in 1992 and was quite dramatic. Specifically, crack cocaine use declined from 37% in 
1991 to 13% in 1996 among youthful offenders (23% decline). The decline of crack 
cocaine use in Los Angeles began around 1989, but was very slow. In Los Angeles 
between 1988 and 1996, crack cocaine use declined from 60% to 46% (14% decline). As 
was the case for marijuana and methamphetamine, the NSDUH data gives the impression 
that the rise and decline of crack cocaine happens at the same time across geographic 
locations in the country. As shown by DUF and ADAM, as well as DAWN, that is not 
correct. Again, this information is detrimental to the implementation of effective policies. 
There is no need for policies if crack cocaine is not being used. Similarly, the assumption 
that crack cocaine use is declining equally at all sites might lead to an abandonment of 
specific law enforcement strategies that might still be needed.  
In sum, the findings of the DUF and ADAM programs demonstrate the 
differences in drug use prevalence and patterns found in the general population versus the 
population of arrestees. It also shows how important it is to monitor drug use among 
arrestees because trends tend to show up in the criminal justice population before they 
spread to the general population. DUF and ADAM were not only crucial for researchers 
examining drug using behaviors and the validity of self-reported drug use, but also to 
policy makers and law enforcement working to reduce drug use.  
  48
Drug Court Movement 
The development of drug courts and diverting drug offenders into treatment 
services within the community has shown to be beneficial for the drug offenders and the 
community (ONDCP, 2003). Specifically, comprehensive drug treatment costs about 
$2,500 per year. In comparison, the costs of incarceration range anywhere between 
$20,000 and $50,000 per year for each person.  Thus, drug treatment instead of 
incarceration can save states a sizable amount of money. Drug abusing offenders who 
receive treatment also have a significantly lower recidivism rate than drug abusing 
offenders who do not participate in drug court programs. The Office of National Drug 
Control Policy (2003) suggests that the recidivism rate of drug court graduates is less 
than 4%, compared to 66.7% of drug offenders released from prison (BJS, 2002).  
DUF and ADAM provided information essential to the implementation of 
treatment and prevention programs for drug using offenders in communities by providing 
local data about drug using behaviors. As a result, it furthered efforts to lower recidivism 
rates among these drug abusing offenders. For instance, the ADAM data aided in the 
implementation of a new drug policy (Proposition 36) in Los Angeles County (Drug Use 
Alliance, 2006). Proposition 36 enables courts to place non-violent offenders with 
substance abuse issues in treatment programs rather than sending them to jail or prison. 
The DUF and ADAM data were important because they helped change the attitudes of 
policy makers and the public towards the treatment approach. The result of Proposition 
36 is that in 2006 over 140,000 non-violent drug offenders received treatment (Drug Use 
Alliance, 2006).  
This is important because the lifetime prevalence rates for substance abuse 
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disorders among prisoners are between 68% and 74% (Karberg and James, 2005). The 
vast majority of these prisoners eventually return to the community, where they continue 
their drug using behaviors. Illicit drug use causes great costs for society because drug 
using prisoners have a high rate of recidivism and are very likely to engage in criminal 
activity. Specifically, Langan and Levin (2002) estimate that approximately two-thirds of 
drug involved offenders are re-arrested within three years of release from custody. These 
repeat offenders cause significant costs to the criminal justice system. The DUF and 
ADAM studies aided in the increase of funding for drug treatment in correctional 
facilities and encouraged the drug court movement.  The drug court movement diverts 
drug abusing offenders away from the criminal justice system and provides them with 
drug treatment. There is considerable evidence that comprehensive drug treatment can 
effectively reduce drug use and recidivism. This is especially true when the drug 
treatment is followed by an aftercare program (Hora, Schma, and Rosenthal, 1998; 
Inciardi, Martin, & Butzin, 2004; Martin, Butzin, Saum, and Inciardi, 1999; Office of 
Justice Programs, 1998; Prendergast and Wexler, 2004).  
DUF and ADAM were important for the progress made with regard to diverting 
drug offenders to drug courts for two reasons: (1) DUF and ADAM caught the attention 
of policy makers by showing the great extent of the drug use problem within the criminal 
justice population; and (2) by demonstrating the association between drug use and 
criminal behavior. For instance, the DUF findings indicate that increases in drug use and 
addiction lead to an increase in the crime rate (Fagan and Chin, 1990; Goldstein, 1990).  
Drug Treatment in Correctional Facilities 
Additionally, correctional facilities have also expanded their treatment services. 
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According to the Bureau of Justice Statistics (2004a), the percentage of jail inmates who 
received drug treatment increased from 39% in 1996 to 47% in 2002. Similarly, drug 
treatment programs have also increased for state and federal prisoners(BJS, 2002). DUF 
and ADAM provided crucial information to jail administrators implementing drug 
treatment programs.  
Data for Local Police Agencies 
Furthermore, DUF and ADAM provided information about drug use, drug 
markets, and hot spots for local police agencies. By providing local data about drug 
prevalence and patterns, specifically information about where arrestees buy their drugs 
and where they use drugs, DUF and ADAM helped local police agencies in their efforts 
to target drug sellers and users more effectively. Local police are a critical group in 
reducing the sale and use of illegal drugs. The ability to target specific areas known to be 
hot spots for drug sellers and users aids in the decrease of drug activity in those areas. 
This is also true for firearms. DUF addenda collected data on firearm use which helped 
local police agencies. For instance, in Kansas City, police were able to target hot spots of 
firearm violence with gun seizures and significantly reduce the gun crime in these areas 
as a result (Decker, Pennell, and Caldwell, 1997).  
DUF and ADAM were, however, important not only for law enforcement but also 
for policy makers and communities dealing with disease control. There is a strong 
connection between drug use and HIV and other infectious diseases. (i.e., hepatitis, 
tuberculosis) (Foundation of Drug Research, 2008). Among drug users, these infectious 
diseases are often spread via needle sharing and risky sexual behaviors (Zack, 2008). The 
Center for Disease Control and Prevention (CDC) found that 42% of AIDS cases stem 
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from behaviors associated with drug use, either via needle sharing or unprotected sex. 
Additionally, 81% of AIDS cases in children are associated with transmission from the 
mother infected via drug injection and/or unprotected sex with a drug injecting person 
(CDC, 2004). Research has shown that substance abuse treatment is effective in reducing 
drug use and risky sexual behavior among offenders (World Health Organization, 2004).  
For instance, the city of San Diego used information provided by the ADAM data 
to implement the Clean Syringe Exchange Program, which was found to reduce needle 
sharing and the spread of infectious diseases (Burke, 2004; City of San Diego, 2001). 
Similarly, research using the DUF data in combination with data from the Needle 
Exchange Program (NEP) has demonstrated that cities which implemented the NEP 
reduced needle sharing and drug injection, as a result decreasing the spread of HIV and 
other infectious diseases (DeSimone, 2005). This, in turn, reduces the costs for medical 
treatment and other services. The implications of these findings are that communities 
would benefit from educating drug users about the risks of unprotected sexual behaviors 
and needle sharing. Communities would also benefit from programs that proactively 
reduce risky behaviors, such as needle exchange (or similar) programs for drug users 
(Stephenson, et al., 2005).  
Educational Attainment and Drug Use 
Finally, data about drug use prevalence and patterns among arrestees is important 
because it demonstrates how crucial it is to keep kids in school and further educational 
attainment. There is a strong connection between educational attainment and drug use.  
As a result, there is also a connection between drug use and the number of unemployed 
people and people with low paying jobs. There is considerable evidence that people with 
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low educational attainment are overrepresented among arrestees and especially among 
arrestees with substance abuse issues (Harder and Chilcoat, 2007). For example, DUF 
and ADAMclearly demonstrates that the population of arrestees consists in great part of 
individuals with low educational attainment (i.e., no high school diploma), low income, 
and a lack of health insurance. This hinders their ability to seek treatment and other 
services that would increase their chances to break the cycle of drug use and offending.  
Specifically, on average 30% of arrestees did not have a high school diploma, 
about 34% were unemployed, and a substantial proportion (15%) had no fixed address 
(NIJ, 2000). Research has also shown that a higher educational achievement is related to 
a better understanding of risky behaviors and the ability to find resources and treatment 
options that help address substance abuse issues and modify behaviors (Link and Phelan, 
1995). These findings have implications for communities as they pertain to the 
importance of education in reducing drug use. Communities would benefit from 
programs that keep kids in school. Educational programs are certainly cheaper than the 
medical and criminal justice costs associated with drug offenders. These examples 
demonstrate the importance of systematically studying drug using behaviors among 
arrestees. Only if we understand these drug using behaviors can communities and law 
enforcement implement effective programs that aim to reduce drug use and provide 
services to individuals who are using drugs. 
Lack of a National Study Monitoring Drug Use Among Arrestees 
To reiterate, currently there is no national study examining drug use prevalence 
and patterns among arrestees because the revived ADAM II program (conducted by the 
ONDCP) only collects data for 10 counties within the United States. To reiterate, even 
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though local agencies might be collecting similar drug use data, this is not a systematic 
data collection and therefore results in a number of problems associated with the use of 
such data. These problems are: (1) it makes it more difficult for researchers to obtain such 
data, (2) it is not publicized widely where such data exists, and (3) methodological 
differences between local data collection might make it difficult to compare data across 
sites.  
Researchers argue that the money spent on examining drug using behaviors is 
distributed improperly. The National Household Survey costs $50 million a year, but it 
examines a population group that is at low risk of using drugs. Kleiman (2004) stated that 
for cocaine, the NSDUH accounts for about 10% of the actual cocaine consumption, 
leaving the other 90% unexplained.  
Additionally, the NSDUH also does not examine the revenues of illicit drug 
markets or the crimes associated with drug use. The amount of drugs consumed, illicit 
drug markets, and the relationship of crime with drug use is arguably more important 
than simply knowing the number of people who has used drugs in the last year (Kleiman, 
2004). Drug markets and crime constitute a significant problem for society and are one of 
the top priorities of the government. Research has demonstrated that, in many cases, 
criminal behavior (e.g., property crime, prostitution, drug sales) results directly from 
attempts to support a drug habit. For instance, Corman and Mocan (2000), in their time-
analysis study in New York City, found that robberies, burglaries, and motor vehicle theft 
increased during the time period of increased drug use. Additionally, according to a 
survey by the Bureau of Justice Statistics (2004b) of federal and state prison inmates, an 
estimated 17% of state prisoners and 18% of federal prisoners reported committing 
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offenses in order to support their drug habit.  
The next chapter will introduce the DUF program, examine the criticisms brought 
forth by the GAO and analyze the changes made to the new ADAM program.  
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CHAPTER THREE 
METHODOLOGY OF DUF AND ADAM 
Overview of the DUF Study 
Underlying Assumptions of the DUF Study 
 The DUF study was developed under the assumption that drug users are likely to 
be among the population of arrestees (BJS, 1998, Mallender, Roberts, and Seddon, 2002). 
A number of researchers have supported that assumption (Brook, Whiteman, Finch, and 
Cohen, 1996, Wish and Gropper, 1990), and several explanations have been advanced 
regarding this finding. First, drug users are more likely to be involved in criminal 
behavior because they need a certain supply of money to pay for the drugs and have to 
use illegal means (such as burglary and robbery) to obtain such monies (Petersilia, 
Greenwood, and Lavin, 1978, Goldstein, 1987). Second, drug users may be more likely 
to engage in violent behavior due to emotional and/or mental reactions such as 
aggressiveness and irritability caused by certain drugs (Bickel and DeGrandpre, 1996). 
Third, drug users are more likely to deal drugs to support their drug habit and more likely 
to get into ”turf wars’” amongst drug dealers and as a result get arrested (Goldstein, 
1987). There is also evidence, however, that the relationship between violent crime and 
drug use may not be as strong as assumed and that higher arrest rates of drug users for 
violent crime may instead be due to drug enforcement policies and procedures 
(Resignato, 2000). Said differently, the number of drug users who commit violent crimes 
may not be significantly different from the number of violent crimes committed in the 
whole population, but because police resources focus on drug users/drug dealers, they are 
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overrepresented among arrestees.   
Regardless of the reasons, the high likelihood of finding a larger number of drug 
users among arrestees makes prison and jail populations the most suitable sampling frame 
when studying drug use, changes in drug patterns, and characteristics of drug users, 
because arrestees were seen as the leading indicator as compared to other population 
groups. Stated differently, the sampling frame was based on research showing that new 
drug use patterns and drug paraphernalia show up first among arrestees and then spread 
to other population groups.  With this approach, the DUF study filled an important gap in 
the research on drug use prevalence and patterns because other drug studies (e.g., the 
National Household Survey and Monitoring the Future) studied populations such as 
households and school children, among which drug use is much less widespread. 
Additionally, no other national drug study besides DUF used bioassays as a validation 
technique for the self-reported drug use, making DUF an incredibly valuable tool for 
researchers studying not only prevalence and patterns of drug use but also the validity of 
self-reported drug use.  
Data Collection in the DUF Study 
The quarterly data collection was based on voluntary participation of arrestees for 
bot the self-report interview and the urine test. The data collection began in 1987 in 12 
cities across the United States. DUF increased the number of sites steadily over time from 
12 sites in 1987 to 21 sites in 1988, 22 sites in 1989 and 24 sites for the years 1990 until 
1997 (National Institute of Justice, 1998). The 24 sites were Atlanta, Birmingham, 
Chicago, Cleveland, Dallas, Denver, Detroit, Ft. Lauderdale, Houston, Indianapolis, 
Kansas City, Los Angeles, New York (Manhattan), Miami, New Orleans, Omaha, 
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Philadelphia, Phoenix, Portland, St. Louis, San Antonio, San Diego, San Jose, and 
Washington, DC. The DUF sites were not distributed evenly across the United States, 
however. Rather, the majority of sites were concentrated in the Pacific region, the 
southern part of United States, the middle of the United States, and the East Coast. 
California (4), Texas (3), and Florida (2) had multiple sites (National Institute of Justice, 
1998).  
Number of Arrestees  
The number of booked male arrestees varied from year to year. As can be 
expected, with the increasing number of sites, the number of male arrestees also 
increased. The increase was, however, not consistent. The number of arrestees peaked in 
1991 with 22,335 male arrestees and then declined steadily to 19,736 male arrestees in 
1997.  For an easier overview, Table 3.1 shows the number of male arrestees and number 
of sites for each DUF year (National Institute of Justice, 1998).  
Table 3.1. Number of Male Arrestees and Sites by Year – DUF 
Year      Male Arrestees  Number of Sites 
1987     2,993   11 
1988   10,548   20 
1989   16,186   21 
1990   20,556   23 
1991   22,335   24 
1992   22,265   24 
1993   20,551   23 
1994   19,987   23 
1995   20,737   23 
1996   19,835   23 
1997   19,736   23 
1998   20,715   35  
 
 
The table shows that the number of interviewed arrestees increased 
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simultaneously to the increasing number of sites between 1987 and 1991. Within that 
time period, the number of interviewed arrestees increased from 2,993 arrestees and 23 
sites during the first year of the program to 22,556 arrestees and 24 sites in 1991 and 
22,265 arrestees and 24 sites in 1992. In 1993, the sample size declined somewhat, 
probably due to the reduction of sites from 24 to 23. In the following years, the number 
of interviewed arrestees remained relatively stable and the number of sites was 23 until 
1998. Even though 1998 is considered by NIJ to be the first ADAM year, the probability 
sampling procedure was not implemented until the second half of the year 1999. For the 
purpose of this research, the year 1998 will be considered a DUF year because the 
sampling method was the same as in the previous years.  
Description of Variables 
The collected data includes information for the following five topics: (1) drug use 
by type of drug and for each individual offender (self-report and urine analysis), (2) 
dependency on alcohol/drugs (self-report), (3) need for treatment (self-report), (4) 
relationship between drug use and crime (offenses), and (5) indicators of self reported 
drug use compared to indicators of drug use according to the urine analysis (National 
Institute of Justice, 1997).  
Arrest records were used to obtain information about birth year, race, and the top 
charge. The DUF questionnaire included items regarding participant demographic 
characteristics (e. g., age, gender, race, marital status, educational attainment, 
employment status, and living circumstances; National Institute of Justice, 1998) and 
lifetime and recent drug use (within the past three days) of 22 drugs for the years 1987 till 
1995 and 15 drugs for the years 1996 and 1997.   
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For each drug, arrestees were questioned regarding: (1) age of first use (2) 
frequency of use during the past month, (3) recent drug use (past three days), (4) route of 
administration, (5) perception of past dependency, (6) perception of current dependency, 
and (7) past drug treatment. Additionally, arrestees were questioned regarding arrests 
during the past 12 months and whether they were under the influence of drugs at the time 
of the crime. Besides questions about demographics, drug use, and arrests, the 
questionnaire contained items regarding how much money arrestees spent on drugs 
during an average week and whether they had been in the emergency room for drug-
related incidents (National Institute of Justice, 1998).   
Additionally, NIJ used several addenda to assess topics of interest that were not 
typically part of the survey. For example, in 1995, the survey included a heroin 
addendum and in 1996 a heroin and gun addendum. Another addendum asked arrestees 
about their knowledge and consideration of AIDS when using intravenous drugs 
(National Institute of Justice, 1997). These addenda were not collected systematically; 
rather, they were only collected at certain sites for a limited period of time (National 
Institute of Justice, 1997). 
Response Rate 
The datasets provided by NIJ only include data on arrestees that agreed to the 
interview and completed both the self-report interview and the urine analysis. 
Approximately 90% of those asked to participate agreed to do so and of those, 80% 
provided a urine sample (National Institute of Justice, 1997). There is, however, no 
information about arrestees who were either not asked to participate or did not consent to 
an interview.  
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Drug Testing 
The urine analysis included screening for 10 drugs (marijuana, opiates, cocaine, 
barbiturates, amphetamines, PCP, methadone, benzodiazepines (Valium), methaqualone, 
and propoxphene (Darvon) via radioimmunoassay (National Institute of Justice, 1995). 
To ensure that positive urine tests for amphetamines were correct, gas chromatography 
was used. The urine tests for all DUF sites were done at a central location. The outcome 
of all urine tests was dichotomous: either positive or negative for the tested drug (NIJ, 
1995). 
DUF Sampling Procedures 
 The sampling design was a non-probability sample guided by target numbers of 
interviews (250 males and 100 females) and a priority charge system. The data was 
collected over a period of 10 days or until the target sample number had been reached 
(McBride and Swartz, 1990).  The problems associated with this type of sampling will be 
explained in greater detail in the next section when discussing the GAO report and the 
criticisms brought forth by the GAO. 
The process of obtaining participants involved a number of steps. First, arriving 
arrestees were brought into the booking area of the facility (holding cell, central booking 
area, or other applicable area); second, the site administrator explained the study and 
asked for volunteers. The site administrator told the arrestees only about the self-report 
interviews. At that time, the arrestees did not know that they would also be asked to 
provide a urine sample. As an incentive to participate, most sites offered candies, 
cigarettes, or coffee. Third, the site administrator recorded the top charges for each 
arrestee and recruited participants based on the priority charge system. The site 
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administrator attempted to recruit volunteers with non-drug felony charges, followed by 
non-drug misdemeanor charges, and finally offenders with drug-related charges. Fourth, 
each participant received an ID that matched the survey and the urine test. Fifth, the 
participant completed the interview. After the completion of the survey, the participant 
was asked to provide a urine sample. If the arrestee provided the urine sample, a staff 
member would then collect the sample and label it with the same ID as the questionnaire 
(Swartz, 1990).  
All self-report interviews and the urine test results were gathered after each 
quarter by NIJ. NIJ checked the accuracy of the data by looking at the consistency of 
answers and undocumented codes. The NIJ staff also standardized the missing data codes 
across all sites. The self-report data was then merged with the urine test data and the 
complete dataset was re-formatted to make it usable for researchers. Finally, the datasets 
were made available to researchers via the Inter-University Consortium for Political and 
Social Research (www.icpsr.umich.edu) (National Institute of Justice, 1997). The 
following section will discuss the criticisms brought forth by the GAO and how these 
criticisms led to a change from a non-probability sample to a probability sample 
implemented in 1998. 
GAO Report Criticisms 
Although the GAO report (1993) highlighted the strengths and unique features of 
the DUF program, especially the collection of drug use data from arrestees in different 
cities across the country and the validation of the self-report data via urine analysis, the 
report also heavily criticized the non-probability sample used by DUF, stating that due to 
its non-probability sample and lack of standardization across sites, the sample of arrestees 
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in the DUF study may not provide accurate information about arrestees in general and 
thus results obtained from the study about drug use prevalence and patterns may not be 
accurate (GAO, 1993). The GAO report criticized DUF for three major reasons, all of 
which pertained to the sampling design: (1) the selection of booking facilities included in 
the study, (2) the subject sampling procedure, and (3) the inclusion and exclusion criteria 
in selecting arrestees within the booking facilities for the interview.  
(1) Criticism on the Selection of Booking Facilities 
The DUF program collected self-report data and urine tests at central booking 
facilities in a number of cities across the country. The GAO report criticized that the 
different booking facilities represented very different geographic units including entire 
cities or even counties, parts of a city or a county, or a central city plus additional cities. 
The GAO report took issue with the fact that booking facilities encompassed very 
different geographic areas, as a result making it difficult to draw conclusions about drug 
use prevalence and patterns for the greater area. The GAO report stated that the 
limitations of the study due to the selection of booking facilities hindered the 
development of drug policy and programs: “There is no evidence to support generalizing 
partial data to an entire city or county” and “Caution is warranted in using these data to 
determine booked arrestee drug prevalence rates” (GAO, 1993, p. 52). This statement 
leads us to the second major criticism regarding the sampling design: the subject 
sampling procedure. 
(2) Criticisms of the Subject Sampling Procedure 
The DUF program used a judgment-based sample of arrestees based on a target 
number of interviews (225 male and 100 female arrestees per quarter per facility). 
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Starting in 1990, the sampling of the subjects was based on the 20% rule, meaning that 
every fifth arrestee interviewed should have been charged with a drug offense (GAO, 
1993). The GAO pointed out that the 20% rule lead to unpredictable consequences. It can 
either lead to an underestimation of the drug use prevalence among arrestees if more than 
20% of the arrestee population uses drugs, or it can lead to an overestimation of the drug 
use prevalence among arrestees if less than 20% of the arrestees use drugs (GAO, 1993). 
The criticisms pertaining to the target rate of offenders and the 20% rule are closely 
related to the inclusion and exclusion criteria of arrestees in the DUF study.    
(3) Criticism of the Inclusion and Exclusion Criteria 
The third major sampling issue highlighted by the GAO report pertains to the 
criteria used to select arrestees—the inclusion and exclusion criteria. The criticisms by 
the GAO focused on the fact that there were no standardized procedures across sites. 
Each DUF site used its own criteria within some set standards. For example, the DUF 
program established a rank order of criminal charges that was used to select male 
arrestees. Each DUF site, however, made its own decisions about which types of 
offenders would be interviewed. For instance, the San Diego site eliminated all 
misdemeanor offenders, and the Miami site only interviewed male offenders arrested on 
felony charges. Additionally, in New York (Manhattan) the booking facility limited the 
number of misdemeanor offenders, as a result decreasing the number of misdemeanor 
offenders available for interviewing. In Omaha, Nebraska, all male arrestees were 
interviewed (disregarding the charge rank-order altogether) due to the small arrestee pool 
available.  Six sites (Denver, Detroit, Fort Lauderdale, Kansas City, Houston, and 
Indianapolis) had access to arrestees who committed criminal offenses in court, in jail, or 
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in custody. The other sites either eliminated this offender group or simply did not have 
access to them.  For female arrestees, there were no rank orders or other guidelines 
besides the target interview number of 100 females per quarter per site (GAO, 1993).   
In sum, each DUF site worked differently, and the implications of these 
differences were heavily criticized by the GAO concluding: “Evaluators of the data are 
thereby unable to determine whether decreasing or increasing drug use scores represent 
statistically significant shifts in actual drug use. An individual’s conclusion about drug 
use patterns and trends must therefore rely on intuitive reactions rather than being 
statistically based” (GAO, 1993, p.57).  
The GAO report and the criticisms brought forth therein had great consequences 
for the study. In 1996, NIJ began restructuring the methodology of the drug use 
forecasting study and it was re-named the Arrestee Drug Abuse Monitoring Program 
(ADAM). The purpose of the restructuring was to enable the researchers to use inferential 
statistics and obtain results that could be generalized to the larger population. In 1998, 
NIJ implemented the ADAM study. With the implementation of the new study came a 
number of changes in the data collection process as well as the questionnaire itself.  
Overview of the ADAM Study 
 The redesign of DUF/ADAM began in 1997 and consisted of three components: 
(1) expansion of the program, (2) implementation of a probability sample, and (3) 
implementation of a redesigned data collection instrument (Yacoubian, 2004). The goal 
of these changes was to produce results that could be generalized to the target population 
of booked arrestees and to make the program more valuable and useful for practitioners 
and policy makers (NIJ, 1998). The first changes to the study were made in 1997 and 
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1998 by expanding the number of sites from 23 to 35 and by standardizing the sampling 
procedure across sites (Yacoubian, 2004). NIJ began implementing the redesigned study 
in the second half of 1999, but it was not fully implemented until the beginning of the 
year 2000 (Arrestee Drug Abuse Monitoring (ADAM)). Next, the new sampling 
procedure will be described, followed by a description of the expansion of the program 
and the new data collection instrument.    
Starting in 1999/2000, NIJ implemented complex data collection procedures that 
would ensure standardized outcomes. The study attempted to collect data on offenses, 
offenders, and drug use that would be a representative mix of the larger population. To 
achieve this goal, NIJ applied the same definitions of “catchment areas” to all sites. 
“Catchment areas” are “regions from which arrestees are drawn at the sites” (NIJ 2000, p. 
178). The definition of these “catchment areas” are as follows: (1) persons taken to a 
booking facility, and (2) the “catchment area” is a county.  
In addition, NIJ standardized the definitions of offenses because of the wide 
variety of definitions for certain offenses among counties and states. First, in order to 
ensure that all arrested persons had the same probability of being sampled, only “booked 
arrestees” were included in the study. This specification was necessary to avoid a bias in 
the sample towards more serious offenses, because not all counties handle arrests the 
same way. Some counties arrest and book all persons; others arrest but then release the 
persons if the offense committed was a misdemeanor. Second, NIJ standardized the 
definitions for terms such as misdemeanors and felonies vary. What is defined as a 
misdemeanor offense in some counties is considered a felony offense in other counties, 
depending on state law. Some counties distinguish misdemeanors from felonies in 
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regards to the length of jail time; other counties distinguish misdemeanors from felonies 
based on the seriousness of the crime (NIJ 2000).  
NIJ also standardized training procedures for all sites to guarantee that the data 
collection procedures were not only the same at each site but also fully followed at each 
site. NIJ staff monitored the training as well as the data collection by implementing 
performance standards and feedback to each site after every data collection cycle. In 
addition, follow-up training sessions were conducted at regular time intervals to ensure 
that the interviewers followed the procedures strictly and consistently (NIJ 2000).    
Sampling Procedures 1998 
In 1998, ADAM expanded the number of sites considerably from DUF (24 sites) 
to a total of 35 sites for adult male arrestees, 32 sites for adult female arrestees, 13 sites 
for juvenile male arrestees, and 8 sites for juvenile female arrestees where interviews 
were completed and urine specimen collected. Interviews were conducted with arrestees 
who had been at the facility for no more than 48 hours. In 1998, NIJ responded to one of 
the criticisms of the GAO by standardizing the catchment areas. The catchment area was 
now the same for all sites—the county (NIJ, 1998).  
The target number of interviews plus urine specimens was 225 for adult male 
arrestees (all 35 sites), 100 for adult female arrestees (32 sites), 100 for juvenile male 
arrestees (13 sites), and 100 for juvenile female arrestees (8 sites) per quarter. However, 
the sampling was still conducted on a voluntary basis as a judgment-based sample.  
Sampling Procedures 1999 
 In the third and fourth quarter of 1999, NIJ began for the first time to employ a 
probability sample. The sampling plan is very similar to the sampling plan for the years 
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2000 to 2003 (explained in detail below). The differences are: (1) in 1999, interview 
shifts lasted between 4 and 8 hours, whereas interview shifts lasted 8 hours starting in 
2000 and (2) in 1999, the sampling, data collection, and training procedures were still in 
process of being fully implemented.   
Sampling Procedures 2000 to 2003 
Beginning in 2000, NIJ fully implemented the changes to the design of 
DUF/ADAM.  The sampling plan included a probability-based sampling design for all 
persons arrested and booked at each site. The sampling method was tailored to each 
county and its characteristics. In addition, the sampling strategy itself was tailored to each 
site and the sample was weighted.  The goal behind this new sampling design was to 
“represent with known probability the likelihood that a male arrestee was selected for an 
interview and to use that information to weight each sample case” (NIJ, 1998, p. 7). 
Another change to the design was that now every day of the week and every hour of the 
day were represented in the sample to ensure that no bias would occur due to the 
possibility that interviewers were not present at the time the person was arrested and 
booked. Hence, all persons arrested within the last 48 hours of the beginning of the work 
shift were included in the population from which the sample was drawn. In addition, the 
new design included booking facilities representing all types of facilities from small to 
large, urban and rural, quick release and slow release to avoid a bias and include all types 
of offenders (NIJ, 2000).    
The Site’s Sampling Design 
  NIJ employed one of four sampling models depending on the characteristics of 
the county. A total of four sampling models were necessary to ensure that the sampled 
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persons would be representative of the population of the whole county. First, the “single 
jail” sampling model was developed specifically for counties where data was collected 
only in one jail. Second, for counties in which there were between two and six jails, a 
“stratified” sampling model was employed. The “stratified” model allowed for data 
collection in all jails by determining a target number of arrestees to be sampled. In each 
jail the target number of arrestees to be sampled was proportionate to the number of 
arrestees booked. Third, a “stratified cluster” model was utilized in counties with more 
than six jails. Each jail was included in the strata. From each stratum one or two jails 
were sampled. Fourth, NIJ developed a “feeder” model from the stratified cluster sample 
for counties with booking facilities which transferred booked arrestees very quickly to a 
central holding facility. The “feeder model” became necessary in those counties because 
the booked arrestees would have been inaccessible for interviews. In counties where the 
“feeder” model was utilized, booked arrestees were interviewed at the holding facilities 
and in the jails that transferred arrestees to those holding facilities (NIJ, 2000).    
Weighting Procedure 
In addition, the data was weighted to guarantee that the sample was representative 
and generalizable to the county population. ADAM employed a non-traditional method to 
determine the weights, because at the time of the sampling it was unknown who would be 
arrested. Hence, the probability with which one were to be sampled for the interview was 
also unknown. The weighting of the data was based on the following assumptions: (1) 
“Arrestees charged with more serious crimes spend more time in jail facilities than those 
arrested on less serious charges,” (2) “Arrestees booked at the same time of day are 
processed similarly; that is, they all spend approximately the same amount of time in the 
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jail before arraignment and/or transfer to another holing facility,” (3) “The stock and flow 
model may mean more serious offenders will be over-represented in the stock population, 
while the flow sample should represent all charges.” The assumption was that by using 
this procedure all arrestees should have a similar chance of being selected into the 
sample, and (4) Arrestees who are booked on days where many arrestees enter the facility 
had a lower chance of being selected for the sample than if they were arrested on days 
when few arrestees enter the facility (NIJ, 2000, p. 181).    
A “post-sampling stratification” design was developed to calculate the 
“probability of inclusion in the sample of like groups of arrestees” (NIJ, 2000, p. 181). 
NIJ collected census data for the total population of arrested individuals for each 
collection site. Each collection site also provided demographic, booking, and offense 
information about all persons arrested and booked at the site where the interviews took 
place. The information obtained from each site was then compared to the sample 
collected at each site and match with the county population. Furthermore, based on the 
information about the characteristics of arrestees and the county population, the 
population was divided and strata developed. Each stratum contained a certain number of 
arrestees and from this information the probability of each arrestee to be sampled 
compared to all other arrestees was calculated (NIJ, 2000).    
  The weighing process can be affected by three problems: (1) Ineligibles, defined 
as persons that are not eligible to be part of the study, such as persons on extradition, 
court, and federal holds, (2) Duplicates, defined as persons that are entered into the 
system more than once because of aliases or mistakes of the staff, and (3) Inconsistent 
booking times because jails vary on their definition of booking times (intake v. time of 
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intake) and the time at which the booking time is logged by the jail (NIJ, 2000, p. 181).    
The Facility-Level Sampling Design 
 The sample size for each facility was proportionate to the number of persons 
arrested and booked in each county. The arrest and booking information was provided 
either by the site staff of the facility (if possible) or by the FBI’s Uniform Crime Reports 
(if the information was not available from the site staff). The number of booked arrestees 
to be sampled was proportionate to the number of facilities in the county and the number 
of persons booked at each facility. The target number of interviews (per quarter) 
depended on the sampling design of each facility and the number of booked arrestees in 
each facility. Interviews were conducted every day of the week for one-to-two weeks 
during the 8-hour-period in which the intake was at its highest. The number of 
interviewers remained constant throughout the work shift (NIJ, 2000, p. 181).    
As stated above, the population to be sampled must include all persons arrested 
and booked, at all days of the week and all hours of the day. To facilitate such a sampling 
design, each day was split into “Stock” and “Flow” periods. The “stock” period is the 
part of the 16 hours per day in which interviewers are not present. In order to sample 
persons from the “stock,” the jail staff provided a list of all persons booked during those 
16 hours of the day. From that list, which is ordered by the booking time, booked 
arrestees were sampled depending on the target number in even intervals. The “stock” 
interviewers stopped working once they reached the target number. Once determined, the 
number of interviewers did not change at the sites. This was mostly done due to practical 
reasons to make the implementation of the new sampling procedures easier and to avoid 
problems with the weighting procedure (NIJ, 2000).   
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The “Flow” period represented the part of the day during which arrestees were 
interviewed, which was eight hours each day. The “Flow” hours were tailored to each 
site, with the goal to have interviewers present during the 8 hours of the day in which the 
number of arrested and booked persons was the highest. Persons were sampled from each 
period, the “Flow” and the “Stock.” Flow interviewers work continuously during these 8 
hours regardless of whether the target number of interviews for the day has been reached. 
After each interview, the ADAM staff sampled the persons booked closest to the time of 
the completion of the interview (NIJ, 2000, p. 181). The sampling was carried out for 
one-to two-weeks at the time (NIJ, 2000).    
Face-Sheets  
The ADAM staff filled out a face-sheet (information about booking and charges) 
for each arrestee sampled, regardless of whether the arrestee agreed to interview and 
regardless of whether the arrestee was available for an interview. This procedure 
decreases potential bias that could occur and enables the site staff to check whether the 
correct sampling procedure has been followed (NIJ, 2000).  In facilities where arrestees 
are transferred to other facilities very quickly or released very quickly it sometimes 
became impossible for the ADAM staff to meet the quota for the stock interviews. In 
such cases, it was possible to have separate interview periods for stock and flow (NIJ, 
2000).  
Response Rate 
 The response rate for male arrestees in 2000 was 56.3%. Of the non-respondents, 
13.6% declined to interview, 22.8% were not available (either released, in a holding cell, 
or in medical unit), and 7.3% were not asked to participate. Of those 56.3% that agreed to 
  72
interview, 89.9% also provided a urine sample. Similar to the year 2000, the overall 
response rate for male arrestees in 2001 was 55.1%. Of the arrestees that did not respond, 
12.2% refused to interview, 22.5% were not available (either released, in a holding cell, 
or in medical unit), and 10.2% were not asked to participate for various reasons. Of those 
who interviewed, about 90.5% percent also provided a urine sample. It is difficult to 
compare these response rates to that of DUF because DUF used a convenience sample 
and therefore contains no information about non-respondents. The DUF documentation 
also does not include information on how exactly the response rate was calculated. 
Arrestees who were available for the interview might differ in their drug using 
behaviors from arrestees who were available for the interview. For instance, arrestees 
who had already been released were more likely to have committed misdemeanor 
offenses and/or were less likely to have used drugs. Similarly, arrestees who were 
dangerous or violent might also differ in their drug using behaviors as compared to 
arrestees who were compliant with law enforcement. There exists no data on these 
unavailable arrestees that would allow for a comparison. Although this is speculative, it is 
possible that the probability sample of ADAM might have included arrestees very similar 
to the arrestees in the DUF program, which is arrestees available at the time of the 
interview and who were willing to participate.  
The ADAM data also suggests that for both years, 2000 and 2001, the response 
rate of arrestees who were asked to participate in the ADAM study varied greatly 
depending on the site. In 2000, there were 35 sites at which data was collected for at least 
one quarter. Half of these sites had a response rate of 81% or higher for arrestees who 
were available and asked to participate. Overall, the response rate varied between 5.9% 
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and 40.1%, with Fort Lauderdale being the lowest and the Charlotte Metro area being the 
highest (NIJ, 2003). Similarly, the percentage of interviewees who agreed to the urine test 
also varied considerably between 74.7% and 96.6%, with the Albany/Capital Area having 
the lowest rate and Fort Lauderdale having the highest rate (NIJ, 2003). These response 
rates were lower as compared to the DUF data, which had a 90% response rate for 
interviews. This is about 9% higher than the average response rate for the ADAM 
program (U.S. Department of Justice, 1998). Again, for the DUF data there is no data that 
would allow for a comparison of the arrestees who refused to the arrestees who 
participated. The differences in the response rates for DUF and ADAM can likely be 
attributed to the differences in the sampling method. During the DUF study, the local 
DUF interviewers had some discretion in whom to ask to volunteer. The sample was not 
a probability sample of all booked arrestees, rather the interviewers would ask for 
volunteers (based on certain criteria described earlier). Additionally, many sites offered 
incentives to the arrestee to increase their willingness to participate. This might explain 
the higher response rates for DUF as compared to ADAM.    
Contrary to DUF, the ADAM program included a face sheet for all arrestees 
selected for the sample. The face-sheet included information about gender, race, age, 
residence, charge type, and charge seriousness. A study by Myrstol and Langworthy 
(2005) used this face-sheet data to compare the realized sample of arrestees in Anchorage 
with the arrestees who were not included in the sample. The authors showed that despite 
a relatively high attrition rate, both the male and female realized sample was 
representative of the population of booked arrestees.  
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Drug Testing 
 Table 3.2 shows cut-off levels and detection period for the drugs examined in the 
ADAM study. Contrary to DUF, all ADAM sites sent the urine specimen to a central 
facility where it was tested for 10 drugs, as a result standardizing the drug testing. The 
table includes cut-off levels and detection periods for each drug. The cut-off level is 
defined as the “amount of the drug in nanograms per milliliter below which the amount is 
considered undetectable and the result is negative” (NIJ, 2003, p. 16). The detection 
period is defined as the “number of days after ingestion during which the drug can be 
detected in the body” (NIJ, 2003, p. 16). 
 
Table 3.2. Cut-off Levels and Detection Periods for 10 Drugs 
Drug   Cut-off Level  Detection Period 
Cocaine     300ng/ml         2-3 days 
Marijuana       50ng/ml            7 days (infrequent use) 
              30 days maximum (chronic use)   
Methamphetamine    300ng/ml         2-4 days 
Opiates     300ng/ml         2-3 days 
PCP        25ng/ml         3-8 days 
Amphetamines 1,000ng/ml          2-4 days 
Barbiturates     300ng/ml            3 days 
Benzodiazepines    300ng/ml            2 weeks maximum 
Methadone     300ng/ml         2-4 days 
Methaqualone     300ng/ml          10 days maximum 
Propoxyphene     300ng/ml         3-7 days 
 
Sites 
 The ADAM study started with a considerable increase in the number of sites and 
states included in the study compared to DUF. ADAM started out with 35 sites in 1998, 
12 sites more than the DUF study had in 1997. ADAM then increased the number of sites 
to 39 sites in 2001. The 39 sites were Albany/Capital Area (NY), Albuquerque (NM), 
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Anchorage (AK), Atlanta (GA), Birmingham (AL), Charlotte-Metro Area (NC), Chicago 
(IL), Cleveland (OH), Dallas (TX), Denver (CO), Des Moines (IA), Detroit (MI), Ft. 
Lauderdale (FL), Honolulu (HI), Houston (TX), Indianapolis (IN), Kansas City (MO), 
Laredo (TX), Las Vegas (NV), Los Angeles (CA), New York (NY), Miami (FL), 
Minneapolis (MN), New Orleans (LA), Oklahoma City (OK), Omaha (NE), Philadelphia 
(PA), Phoenix (AZ), Portland (OR), Sacramento (CA), Salt Lake City (UT), San Antonio 
(TX), San Diego (CA), San Jose (CA), Seattle (WA), Spokane (WA), St. Louis (MO), 
Tucson (AZ), and Washington, DC.   
Although NIJ added a considerable number of sites (14) to the ADAM study, the 
distribution patterns is similar to the distribution of sites in the DUF study. The majority 
of sites were concentrated in the Pacific region, the southern part of United States, the 
middle of the United States, and the East Coast. California (4), Texas (4), Florida (2), 
Missouri (2), and Arizona (2) had multiple sites. The ADAM sites were distributed across 
26 states.   
Number of Arrestees 
 The number of arrestees increased steadily between 1998 and 2001. Table 3.3 
represents the number of male arrestees for each year congruent with the increasing 
number of sites where data was collected. Between 1999 and 2001, the number of 
interviewed arrestees steadily increased without an increase in the number of sites. By 
2001, the sample size was nearly twice that of the last DUF years. 
Table 3.3. Number of Interviewed Arrestees and Number of Sites by Year 
Year       Male Arrestees  Number of Sites 
1999   31,210    35 
 2000   35,784    35 
 2001   39,406    39 
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Description of Variables - Redesigned Data Collection Instrument 
 Similar to DUF, arrest records were used to obtain information about race, 
gender, birth year, and top charge (NIJ, 2003). Also similar to DUF, ADAM collected 
information on demographic characteristics, recent and long term drug use, and drug use 
patterns (NIJ, 2003).    
There were, however, a number of modifications to the ADAM questionnaire. 
The ADAM questionnaire was expanded to include screening questions for drug 
dependence and need of treatment, information about drug use within the previous year 
via the calendar method, drug market activity, and drug treatment by drug within the past 
year. The drug dependence and need of treatment screening consisted of questions 
regarding the frequency of drug use, thoughts about drug use, reasons of drug use, 
intentions to reduce or stop drug use, and objections from friends or family to the drug 
use (NIJ, 2003). 
Calendar Method 
The implementation of the calendar method was probably the most important 
change in the questionnaire (NIJ, 2003). The main purpose of the calendaring method 
was to collect drug use information within the past year and to improve the validity of 
self-reported drug use among arrestees. The basic idea was to examine annual patterns of 
drug use and related behaviors over time because asking arrestees about drug use only 
during the last 30 days does not capture the complexity of drug use patterns (NIJ, 2003). 
The method of calendaring was utilized to help the respondents remember drug using 
behaviors over such a long period of time. To help arrestees remember what drugs they 
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used and how frequently they used them, interviewers first asked arrestees about major 
events during the last year (e.g., birthday, holidays, family events, and life events) with 
the purpose of conceptually dividing the year into manageable time periods for the 
respondents. The major events reported by the arrestee serve as an “anchor” helping them 
remember their drug using behavior at that time. Using this method, data on drug use 
patterns was collected for each drug month by month (NIJ, 2003).  
As stated above, one of the main goals of the calendaring method was to improve 
the validity of self-reported drug use. Whether this goal was accomplished has not been 
extensively assessed. A study by Yacubian (2003b) concluded that the calendaring 
method did not influence the validity of self-reported drug use. The results demonstrated 
that the concordance rate between self-reported drug use and the urine analysis tests for 
the ADAM years during which the calendaring method was used (2000) were similar to 
the concordance rate for those years during which the calendaring method was not used 
(1999). Specifically, for the year 1999 (no calendaring) the concordance rate was 64% for 
marijuana, 48% for cocaine, and 8% for heroin. Similarly, in 2000 (calendaring was 
used) the concordance rate was 59% for marijuana, 47% for cocaine, and 6% for heroin. 
Thus, the calendaring method did not improve the validity of self-reported drug use.  
     The modified ADAM questionnaire also included a section on drug market 
activity including questions about drug purchase patterns, place and neighborhood of 
purchase, and difficulties purchasing drugs (NIJ, 2003). More specifically, arrestees were 
asked a battery of questions about how often they bought drugs, how much they bought, 
who they bought drugs from, how they contacted the drug dealer, the relationship of 
buyers and sellers, how much they paid for the drugs, the payment method, the 
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neighborhood in which they bought the drugs, how they located drugs, difficulties in 
locating and buying drugs, and why drug purchases failed. This information was 
collected for each drug (NIJ, 2003). How accurate this information is unknown. It could 
be expected, however, that recall decay and forward telescoping might factor into this 
issue.     
Drug Treatment Data 
Finally, the modified ADAM questionnaire included a section on drug treatment 
within the past year (NIJ, 2003). Arrestees were asked about drug treatment in inpatient 
and outpatient treatment facilities. This information was obtained for each drug and each 
month for the last 12 months (NIJ, 2003). Although the data obtained from the ADAM 
sample are now said to be representative of the population of booked arrestees within the 
catchment areas, problems and limitations with sampling arrestees and other populations 
have likely led to limitations on the representativeness of the data, a number of which are 
similar to limitations of the DUF data. These limitations that apply to both DUF and 
ADAM and their implications will now be discussed. 
Methodological Issues of DUF and ADAM 
The DUF and ADAM programs had similar goals. The redesign of the DUF 
program and the implementation of ADAM were meant to improve the program and 
increase the quality of the data. Although the program made every effort to meet these 
goals, the problems associated with interviewing arrestees across the United States posed 
serious limitations. The major goal of ADAM was the identification of the drug use 
prevalence and patterns among arrestees. The goal was to produce results that were 
representative of the arrestees within the catchment area. This may not be the case, 
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however. Even though ADAM used a sophisticated, probability-based sampling method 
to determine the sites within counties and the persons to be interviewed within sites, the 
total sample was determined by the cost structure of each site (Yang, 2004). Thus, similar 
to DUF, sampling in the ADAM program was not uniform for all jurisdictions. Some 
sites excluded booking facilities with a low volume (e.g., Cleveland). Other sites 
interviewed arrestees in only a few of their several booking facilities (Birmingham). 
Additionally, some sites only interviewed felony offenders (e.g., Chicago) and males 
(e.g., Sacramento) (NIJ, 2003). For both DUF and ADAM, it is likely that the exclusion 
of booking facilities with certain characteristics influenced the results across sites 
because different booking facilities might have different arrestees with regard to 
demographic characteristics and drug use (Yacoubian, 2000).  
Availability of Arrestees. Additionally, both DUF and ADAM were only able to 
sample arrestees who were held long enough in the facility to be interviewed. This is 
typically true for more serious offenders and indigent offenders who do not have the 
financial means to make bail. Research suggests that felony offenders use different drugs 
(crack, cocaine, heroin) than misdemeanor offenders (marijuana, ecstasy).  For instance, 
Webb and Delone (1996) found that felony arrestees were significantly more likely to test 
positive for cocaine use. There is also a substantial amount of research showing that 
indigent individuals use different drugs as compared to individuals with greater financial 
means. A study by Peters, et al. (2002) using the ADAM data suggested that arrestees 
living under the poverty line were more likely to use opiates and benzodiazepines as 
compared to arrestees living above the poverty line.  
Additionally, crack cocaine is much more widespread among poor black drug 
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users than any other population group. For instance, Hartley, Maddan, and Spohn (2007) 
found that among black persons facing drug charges, 85.3% used crack cocaine. Among 
white offenders, only 5.8% faced charges for the possession and/or sale of crack cocaine. 
White offenders were more likely to use powder cocaine. Other research supports the 
notion that crack users are disproportionately more often minorities and poor as 
compared to users of other drugs (Beckett, Nyrop, and Pfingst, 2006).  
Although the ADAM weighting procedure attempted to ensure that the different 
types of offender populations were represented equally in the sample, the weighting 
procedure was not able to solve the problem associated not having access to certain 
offender groups because they are released immediately or who don’t make it to the 
facility in the first place because the arresting officer decides to issue a citation instead of 
an arrest (Yacoubian, 2000). These problems associated with collecting data from 
arrestees were present for both DUF and ADAM. Thus, both samples should contain 
information that is representative of more serious and indigent offenders. Myrstol and 
Langworthy (2005) found that for the ADAM data from Anchorage, the realized male 
arrestee sample was indeed slightly biased towards felony offenders. This might also be 
similar for the DUF data. 
Determining the Specific Drugs Used Within a Certain Jurisdiction.  Another 
goal of ADAM was to determine the specific drugs used within a certain jurisdiction 
(NIJ, 2003). Yacoubian (2004) suggests that this goal might not have been met due to the 
short time period during which interviewers collected data. At most facilities, data 
collection took place 56 days in one calendar year (14 days per quarter). Similarly, DUF 
also collected data for each quarter of the calendar year. The difference was that DUF 
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used a predetermined number of interviews (for male offenders it was 225). Once the 225 
interviews were completed, data collection stopped. When ADAM was redesigned, the 
assumption of the data collection by NIJ was that if these 56 days were spread out evenly 
across the calendar year, all types of drugs used would be detected, and the magnitude of 
a certain drug’s representation could be computed. This assumption is somewhat 
problematic. Although it is possible that the different types of drugs used in a certain 
jurisdiction might be detected within the interviewing period, the relatively short period 
of data collection per year might not have allowed ADAM to accurately determine the 
magnitude of the drug’s representation in that jurisdiction (Yacoubian, 2004). For 
instance, a certain drug could have started to become more popular during the end of the 
quarterly data collection period and then leveled out before the new data collection period 
started. Regardless of whether that is the case or not, it is a problem that applies to DUF 
as well as to ADAM, which might have resulted in data that is not substantially different. 
Table 3.4 presents the sample size for each quarter by site and year. It appears that 
the DUF sample for each quarter and each site is very consistent Thus, both studies 
collected data for a certain period of time and a limited number of arrestees.  
Number of Interviews for Each Quarter.  Some other patterns emerge from the 
data. In general, the number of interviews conducted during each quarter in the DUF 
sample is substantially greater than in the ADAM sample. The exception is Phoenix, 
where the sample size is somewhat greater for the ADAM data. The ADAM program did 
not collect data for 2001 in Miami and only collected data for the first quarter of 2001 for 
Dallas. Additionally, the ADAM sample for the first quarter of the San Antonio sample 
has only 65 cases, which is less than half as many as for the other three quarters.  
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The DUF data also has some sites that did not collect data for each quarter and 
year. Portland did not collect data for the fourth quarter in 1997. Also, the DUF sample 
for three sites (Dallas, Indianapolis, and Phoenix) has no data for one quarter for 1998 
and two sites (Miami and San Jose) are missing data for two quarters of 1998. The DUF 
reports do not include an explanation why some sites did not collect data for a certain 
quarter. The sample sizes for DUF, however, were somewhat greater than for ADAM 
(with the exception of Phoenix) which means that the sample size is not a major problem 
for DUF. The sample sizes for DUF are probably greater because of the sample target 
number. Each site attempted to collect 225 interviews per quarter for male arrestees. 
During ADAM, the sites collected interviews within a certain time period. Additionally, 
due to the fact that the ADAM questionnaire was much longer than the DUF 
questionnaire not as many interviews could be completed during ADAM.  
Table 3.4 presents the sample sizes for each quarter for DUF and ADAM. These 
sample sizes were aggregated to represent one year. Finally, the analysis includes two 
years for DUF and for ADAM. The data for the two years for DUF were aggregated and 
the data for the two years for ADAM were aggregated, resulting in a fairly large sample 
for DUF and ADAM. Specifically, the sample sizes for DUF range from 1,272 to 1,959 
with the lowest sample size for Miami and the highest sample size for New Orleans. The 
sample sizes for ADAM ranged from 535 to 2,850. For ADAM Miami had the fewest 
cases and Phoenix had the most cases. Overall, both samples have a large enough sample 
size for the analysis (as will be described in the following chapter). 
 
  83
Table 3.4. Sample Size for Each Quarter by Site and Year  
               DUF              ADAM 
Quarter 1997  1998  2000  2001 
Dallas 
     Q1   247   199   182   178 
     Q2   240       0   266       0 
     Q3   245   193       0       0 
     Q4   248   175     76       0 
     Year  980   567   524   178 
     Total   1,547      702 
 Denver 
     Q1   227   248   125   175 
     Q2   241   247   150   171 
     Q3   244   215   166   173 
     Q4   240   246   177   182 
     Year            952   956   618   701 
     Total   1,908    1,319 
Indianapolis 
     Q1   224   231   135   191 
     Q2   247   239   146   180 
     Q3   241       0   173   175 
     Q4   225   138   176   186 
     Year  937   608   630   732 
     Total  1,545    1,362 
Miami 
     Q1   222   219   156       0 
     Q2   196   199   182       0 
     Q3   219       0   197       0 
     Q4   217       0       0       0 
     Year            854   418   535       0 
      Total  1,272        535 
New Orleans 
     Q1   246   246   147   158 
     Q2   249   247   156   154 
     Q3   249   230   150   157 
     Q4   250   242   151   163 
     Year  994   965                  604   632 
     Total  1,959    1,236 
Phoenix 
     Q1   247   195   251   411 
     Q2   250   195   331   381 
     Q3   248       0   339   389 
     Q4   238   238   345   403 
     Year  983   628           1,266           1,584 
     Total   1,611    2,850 
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               DUF              ADAM 
Quarter 1997  1998  2000  2001 
Portland 
     Q1   243   215   101   190 
     Q2   253   212   155   166 
     Q3   149   178   165   181 
     Q4       0   151   180   157 
     Year  645    756   601   694 
     Total  1,401    1,295 
San Antonio 
     Q1   230   228     65   124 
     Q2   234   227   124   163 
     Q3   230   228   153   137 
     Q4   237   226   178   178 
     Year  931   909   520   602 
     Total   1,804    1,122 
San Jose 
     Q1   215   225   124   183 
     Q2   221   209   127   166 
     Q3   214       0   141   186 
     Q4   235       0   134   187 
     Year  885   434   526   722 
     Total   1,319    1,248 
 
 
Participants are Volunteers.  Most importantly, similar to DUF, the ADAM 
sample also consists of volunteers because self-selection bias applies to ADAM as well. 
Even though a probability sample is drawn from the persons arrested, arrestees still had 
the choice whether to agree to the interview and the urine sample or not. This means that 
even a probability sample is made up of volunteers, which may differ in their 
characteristics and drug use from persons who denied participation in the study. For 
ADAM, refusal rates varied considerably across sites, with a low of 5.9% in Fort 
Lauderdale to a high of 40.1% in the Charlotte-Metro area. This data was not available 
for DUF.  However, the annual reports from the DUF years 1997 and 1998 estimate the 
refusal rate to be around 10% for the interviews. It can be expected that the refusal rate 
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for DUF also varied depending on the site. It is possible that the refusal rates of DUF 
were similar to ADAM because both studies collected data on a sensitive topic in a 
comparable setting (jail) from booked arrestees. Unfortunately, this question cannot be 
assessed in depth due to a lack of data for the DUF study. It is likely, however, that self-
selection bias might have influenced the data collected in both studies 
Also, a number of arrestees did not provide urine specimens. NIJ estimated that 
approximately 20% of all interviewed arrestees in the DUF program did not provide a 
urine sample (U.S. Department of Justice, 1998). For the ADAM sample, refusal of urine 
analysis ranged from a high of 25.3% in Albany/Capital Area, New York to a low of 
2.1% in Oklahoma City, Oklahoma. The average refusal rate was 10.8%. Research 
suggests that arrestees who refused to provide a urine specimen are more likely to be 
drug users compared to those who agreed to the urine sample (Chen, Stephens, Cochran, 
and Huff, 1997). This causes an underestimation of drug use among offenders and 
influences the results and thereby the policy implications drawn from such results. To 
reiterate, this shortcoming is similar for DUF and ADAM, and for other studies that use 
bioassays.  
Limitations of Urine Testing.  Also applicable to both DUF and ADAM are the 
limitations of urine testing. First, drug testing via urine analysis can only assess drug use 
for the last 2-4 days, depending on the drug. Second, some drugs are harder to detect than 
others, which means there is an unknown amount of false negatives. ADAM improved 
the quality of the urine testing procedure by having all urine samples shipped daily to a 
central lab.  This allowed for an immediate processing of the urine specimen and the 
testing was completed at the same lab, as a result providing consistent testing. In 
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comparison, during the DUF program, urine samples were shipped to the lab weekly or, 
at some sites, the urine samples were processed in the lab on site. Riley, Lu, and Taylor 
(2000) examined the impact of the differential shipment procedures and found that the 
drug testing results were very consistent. Specifically, the concordance rate was 99%. 
Thus, it can reasonably be believed that the delay in shipping did not significantly change 
the drug testing outcomes. For an easier overview, Table 3.5 summarizes the 
methodology, procedures, and response rates for the DUF and ADAM data.  
In sum, there are several limitations that are applicable to both DUF and ADAM 
that can potentially have a substantial influence on the drug use information obtained 
from the arrestees. The crucial question is whether these limitations result in similar data 
in the sense that the drug use information contained in both datasets is not substantially 
different. Drawing on the two studies conducted by NIJ (1990) and Myrstol and 
Langworthy (2005) this possibility cannot be ruled out. Based on the limitations faced by 
both studies and previous research it is hypothesized that the drug use estimates 
contained in DUF and ADAM are not substantially different despite differences in the 
sampling method.  
 The following chapter will describe the data and research strategy used to assess 
the current research question. Due to the fact that the analysis strategy employed in the 
current study is rarely used in social sciences, the analytic strategy will be explained by 
using data from Dallas, Texas, as an example. The results of each step and how they lead 
to the next step will be discussed. Then, the results for all nine sites will be presented and 
discussed. 
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Table 3.5: Comparison of DUF and ADAM 
 
 
Variable            DUF 1997/1998        1998/Q1,Q2 1999                   ADAM 2000/2001 
Annual Cost           appr. $1 million                  appr. $8.4 million 
Sampling Method                        Non-probability sample           Non-probability sample             Probability sample  
                  (Availability-Judgmental sample)      (Availability-Judgmental sample) 
Standardization of Sites                No                  Yes        Yes 
Number of Sites 
Beginning Number        12                  36               39        
Final Number       23      36         40 
Representative for U.S.    No      No         No 
Selection of Booking Facilities 
 Representative for U.S.    No       No         No 
 Consistent Catchment Area    No      No         Yes 
Facility-level sampling  
Sample Size                          Target number of interviews             Target number of interviews                 Proportionate   
           to persons 
                     arrested  
  
Inclusion/Exclusion Criteria    Priority charge system  Priority charge system                    Random sample   
    Twenty percent rule                                Twenty percent rule      from booking lists 
Urine  
Analysis across sites    Central Lab and at Sites        Central Lab                         Central Lab 
Shipment Procedures       Every two weeks                            Daily          Daily          
Number of Drugs      Between 3 and 10      Between 3 and 10         10 
Response Rate 
 Interview       90%     90%          56% 
 Urine Specimen         80%     80%          91% 
(of those who interviewed)        
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CHAPTER FOUR 
DATA DESCRIPTION AND ANALYTICAL STRATEGY 
Major Research Question of the Current Study 
To reiterate, the major research question of the current study is: Are the drug 
estimates of the Drug Use Forecasting Program (DUF), using a non-probability sample, 
and drug estimates of the Arrestee Drug Abuse Monitoring Program (ADAM), using a 
probability sample, substantially different or are they similar enough that they can be said 
to be equivalent? This research question is based on the criticisms of the sampling 
procedure of the DUF study by the GAO, that is, it is unknown whether the drug use data 
contained in the non-probability sample of DUF can be said to be representative of the 
drug using behaviors among arrestees. This question has not been widely explored. Yet, 
researchers have used both data sets, DUF and ADAM, to conduct cross-sectional and 
longitudinal research and make policy recommendations. Assuming that the probability 
sample of ADAM resulted in a sample and drug use information that can be generalized 
to the population of arrestees in that specific geographic area (catchment area) the drug 
use information in the ADAM data will be used as the baseline data and compared to the 
DUF data.  
Data 
The datasets used in this study were obtained from the Interuniversity Consortium 
for Political and Social Research (ICPSR) and the National Institute of Justice. For DUF, 
data was available from 1988 until 1998. For ADAM, data was available for the years 
2000 and 2001. The DUF data includes data for males and females for the years 1988 - 
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1997 and for males, females, boys, and girls for the years 1994 till 1997. The ADAM 
data includes data for males and females for 1998 and 1999 and for males only for 2000 
and 2001. The current study will only use data on male arrestees because those data are 
available for all years for DUF and ADAM and because the ADAM female sample was 
not a probability sample (NIJ, 1998). Both DUF and ADAM utilized three data sources: 
(1) arrest records, (2) face-to-face interviews, and (3) urine specimen (NIJ, 1998).  
Which Years are Included in the Analysis?  For the analysis, the ADAM data 
includes the years 2000 and 2001 and the DUF data includes the years 1997 and 1998. 
The most appropriate years would be 1998 and 1999 for DUF because those would be the 
closest to the ADAM years. It is important to use the most consecutive years for the 
analysis because changes in drug use prevalence and patterns over time could bias the 
analysis. Research from DUF and ADAM has shown that the popularity of a certain drug 
varies over time. For instance, Golub and Johnson (2001) demonstrated that marijuana 
use among arrestees changed substantially between 1991 and 1996. Specifically, in 1991 
about 25% of youthful arrestees used marijuana, whereas five years later 57% reported 
the use of marijuana—a significant increase of 30%. Additionally, Golub and Johnson 
(1997) found that crack cocaine use declined in Fort Lauderdale from 50% in 1987 to 
19% in 1990. This means that within three years crack use dropped by 31%. Using the 
most consecutive years is thus crucial for the current analysis. Similarly, a study by 
Yacoubian, et al. (2004) implied that methamphetamine use dropped by more than 50% 
between 1995 and 1996 for several cities included in the DUF program.  
Other drug use surveys also support this result. The NSDUH demonstrates that in 
1997 approximately 32.9% of persons 12 years or older had used marijuana in their 
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lifetime and 5.1% had used it within the past month. In 2001, 34.2% of persons 12 years 
or older had used marijuana in their lifetime and 4.8% had used it within the past month. 
This demonstrates that the percentage of persons who had “ever used marijuana” 
increased by 1.3%, but marijuana use in the past month decreased by .03% (NHSDA, 
1997, 2001).  
These examples show that drug use prevalence is not stable even within a few 
years. This is of great importance for the current study because the goal is to determine 
whether the drug use information contained in DUF and ADAM is comparable. Natural 
fluctuations in the data can have a great impact on the findings. Thus, it is crucial to use 
the most consecutive years in the current analysis. The year 1999 cannot be included in 
the analysis, however, because it represents a hybrid year. Part of 1999 was a DUF year 
in which data was collected from a non-probability sample, but during the latter part of 
1999 data was collected with the newly implemented probability sampling method.  The 
year 1999 is divided into quarters 1 and 2 for DUF and quarters 3 and 4 for ADAM 
because the ADAM report from 1999 states that the new probability sampling procedure 
was established in 1999. The main problem is that there appears to be no consistent date 
at which the probability sample was implemented for each site. The reports states: “in the 
third and fourth quarters of 1999, ADAM sites began implementing new sampling 
procedures” (NIJ, 1999, p. 7). This statement implies that the realization of the 
probability sampling procedure did not occur at the beginning of the third quarter at all 
sites. Rather, the probability sample was established at different times across sites. Also, 
the 1999 data does not include face sheet data as is provided starting in 2000. The face 
sheet data shows the basic demographic data for all arrestees selected into the sample. 
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This allows for a comparison of the arrestees who refused or could not be located to those 
arrestees interviewed. Thus, the lack of face sheet data and the statement in the 1999 
report imply that 1999 is not an appropriate year for the purpose of the current study 
because it is important that the comparison is conducted between the non-probability 
sample and the probability sample to ensure the validity of the analysis. Thus, the 
analysis will consist of 1997 and 1998 for DUF and 2000 and 2001 for ADAM.  
Which Variables are Used in the Analysis?  As described in the previous 
chapter, the main goal of DUF and ADAM was to collect data about drug use prevalence 
and patterns among arrestees. Thus, the current analysis will focus on the variables 
measuring drug use. The current study will also examine the demographic profile of DUF 
and ADAM to assess whether differences in the demographic profile also reflect in 
differences in drug estimates. Table 4.1 presents and defines the demographic variables 
use in the study. Table 4.2 shows the codings and descriptions of the drug use variables 
included in the current analysis.  
Table 4.1. Codings & Descriptions for Demographic Variables 
Variable Name Variable Description  Coding 
Race Race of Arrestee Black = 1; White = 2; Hispanic = 
3; Other = 4; Not obtained = 99 
Employment Employment Status of Arrestee Full Time = 1; Part Time = 2; 
Unemployed = 3; Other = 4; Not 
obtained = 99 
Highschool 
Graduate 
Arrestee has Graduated from 
Highschool 
Yes = 1; No = 0 
Offense Category Arrestees Highest Charge  Violent = 1; Property = 2; Drug = 
3; Other = 4 
Age Arrestee Age at the Time of the 
Offense 
 >18 
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 Table 4.2. Codings & Descriptions for Drug Use Variables 
Variable 
Name 
Variable Description  Coding 
MJ Urine Test Result for Marijuana Yes = 1; No = 0 
COC Urine Test Result for Cocaine Yes = 1; No = 0 
OP Urine Test Result for Opiates Yes = 1; No = 0 
MJ72 Self-Reported Marijuana Use Within the Past 72 
Hours 
Yes = 1; No = 0 
COC72 Self-Reported Powder Cocaine Use Within the 
Past 72 Hours 
Yes = 1; No = 0 
CRK72 Self-Reported Crack Cocaine Use Within the Past 
72 Hours 
Yes = 1; No = 0 
HER72 Self-Reported Heroin Use Within the Past 72 
Hours 
Yes = 1; No = 0 
PCP72 Self-Reported PCP Use Within the Past 72 Hours Yes = 1; No = 0 
AMPH72 Self-Reported Amphetamine Use Within the Past 
72 Hours 
Yes = 1; No = 0 
BARB72 Self-Reported Barbiturate Use Within the Past 72 
Hours 
Yes = 1; No = 0 
EVERMJ Self-Reported Drug Use – Ever Used Marijuana Yes = 1; No = 0 
EVERCOC Self-Reported Drug Use – Ever Used Powder 
Cocaine 
Yes = 1; No = 0 
EVERCRK Self-Reported Drug Use – Ever Used Crack 
Cocaine 
Yes = 1; No = 0 
EVERHER Self-Reported Drug Use – Ever Used Heroin Yes = 1; No = 0 
MJALL Urine Test Result and Self-Reported Drug use for 
Marijuana (Combines MJ, MJ72, and EVERMJ) 
 
COCALL Urine Test Result and Self-Reported Drug use for 
Cocaine (Combines COC, COC72, CRK72, 
EVERCOC,  and EVERCRK) 
 
OPALL Urine Test Result and Self-Reported Drug use for 
Opiates (Combines OP, HER72, and EVERHER) 
 
 
The differences and similarities of the demographic profile and the drug use 
frequencies will be compared based on the percentage change between the DUF years 
1997 and 1998. The percentage difference represents the difference as a percentage of the 
baseline value (ADAM data). To calculate the percentage difference the difference 
between the two proportions is calculated and then divided by the baseline value.  
The formula for calculating the percentage difference of two proportions is: 
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%Diff = (p1-p2)/p1 
For example, 32.7% of the ADAM arrestees and 43.3% of the DUF arrestees 
tested positive for marijuana. The calculation would be: 
  %Diff = (.434 - .327)/.327 
  %Diff = .327*100 
  %Diff = 33%  
The percentage difference of the demographic variables for the DUF and ADAM 
data can be considered a straightforward way to get a preliminary overview of the 
magnitude of differences between DUF and ADAM. 
To further assess the question of whether the drug use information contained in 
the DUF and ADAM samples are substantially different, the current study will conduct 
equivalence testing, an analysis technique typically used by clinical researchers who are 
examining whether two drugs or treatments produce outcomes that are not substantially 
different, meaning that this difference would be of clinical importance. Equivalence 
testing has been used for a long time by medical researchers and in clinical trials. Since it 
was first introduced for the use in psychological research by Rogers, et al. (1993) 
equivalence testing has also become more widespread in other fields as well (Hersen and 
Gross, 2008). For instance, Epstein, et al. (2001) employed this technique to assess 
whether web surveys would produce results similar to the traditional paper-and-pencil 
surveys. Leff, et al. (2005) employed equivalence analysis to compare the quality of 
services across different health care providers. The following section will now in detail 
describe equivalence analysis, why it is appropriate for the current study, what the 
possible outcomes are, and how they will be interpreted. Additionally, since this type of 
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analysis is very rarely used by social scientists, an example will be presented for a better 
understanding of the statistical technique. 
Introduction to Equivalence Analysis 
As stated earlier, the main goal of this study is to assess whether the drug use 
information in DUF and ADAM are substantially different or whether they can be said to 
be equivalent. Research suggests that equivalence testing is an appropriate method when 
comparing outcome measures for two different groups or samples (Hauck and Anderson, 
1986; Rogers, et al. 1996; Stegner, Bostrom, and Greenfield, 1996; Tryon, 2001). 
Equivalence testing has been used extensively in biomedical research where the 
main goal is to determine whether two drugs or treatments produce equivalent outcomes 
(Cleophas, Zwinderman, Cleophas and Cleophas, 2009). For this purpose, the researcher 
compares the outcomes and side effects of the new drug/treatment to the established 
drug/treatment. Equivalence testing is based on the underlying assumption that two 
treatments or drugs will always lead to some differences in the outcome. The important 
question is whether these differences in the outcome are of clinical and/or practical 
importance (Pocock, 2003). For instance, researchers are introducing a new cancer 
treatment that has fewer side effects. The new treatment with the fewer side effects is 
only useful, however, if it is equally effective in treating the illness as compared to the 
standard treatment. Thus, the goal is to assess the equivalence of these two drugs with 
regard to the treatment effect or outcome.  
Similarly, the current study seeks to determine whether the drug use information 
in DUF and ADAM are equivalent despite differences in the sampling methods. For the 
purpose of the current study, the ADAM data will be considered to be the “established 
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treatment” and DUF as the “new treatment.” Whereas clinical studies aim to assess the 
effect a new treatment has as compared to the standard treatment, the current study 
examines whether the profile of percentage outcomes (the effect) of 14 drug use variables 
is equivalent for DUF and ADAM.  Equivalence does not mean “exactly the same,” 
rather it refers to the “absence of a meaningful difference” (European Medicines Agency, 
2000; Rogers, et al. 1993; Allen and Seaman, 2006; Tryon and Lewis, 2009). Stated 
differently, the question is whether the profile of percentage outcomes of the 14 drug use 
variables is “comparable” (Hersen and Gross, 2008). Hersen and Gross (2008) suggest 
that the determination of whether effects are comparable should be made based on “real 
world outcomes” (p. 216).  
  Equivalence can be assessed by constructing the confidence interval for 
proportions, in the current study drug use proportions. Specifically, an equivalence limit 
or margin (-Δ to +Δ) is chosen defining how different the groups or samples can be 
before the difference is of practical importance (European Medicines Agency, 2000; 
Tryon, 2001; Wiens, 2001). After defining the equivalence margin, the two-sided 
confidence interval is calculated, representing the range of differences between two 
samples. If the two-sided confidence interval lies within the equivalence limit, then the 
two groups or samples can be said to be equivalent or “comparable” (Allen and Seaman, 
2006; European Medicines Agency, 2000; Hersen and Gross, 2008; Rogers, et al., 1993). 
The ADAM data will be used as the baseline value and to calculate the equivalence 
margin because it constitutes a representative probability sample. 
Equivalence analysis as described by Rogers, et al. (1993) and Allen and Seaman 
(2006) consists of two parts: traditional null hypothesis test and equivalence test using the 
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confidence interval approach proposed by Westlake (1981). The researcher can then 
evaluate the results of these two tests and determine whether the two groups/proportions 
are substantially different or equivalent. This section will describe how these two tests are 
carried out and how the outcomes can be interpreted. 
Traditional Null Hypothesis Testing 
Examining the differences between two groups has traditionally been based on 
null hypothesis testing. Null hypothesis testing might, however, not be the best strategy 
when comparing differences between two groups or samples. In the case of null 
hypothesis statistical testing (NHST) the researcher tests the hypothesis of “no 
difference,” specifically, whether an observed difference between two groups or samples 
is due to chance (Harris, 1997). Researchers who fail to find significant differences 
sometimes conclude that the two groups are equivalent. This is not correct, however. A 
finding of “no difference” does not show that the two groups or samples are equivalent 
(Gladstein and Makuch, 1984). Another issue is that a statistically significant difference 
is not necessarily a difference substantial enough to be of practical importance. However, 
researchers who do find significant differences often conclude that the two groups are 
indeed different, regardless of how trivial these differences might be or whether they are 
of practical importance (Rogers, 1996, Tryon, 2001).  
Another issue with traditional null hypothesis testing is that it can be overly 
conservative, increasing the chances of making a Type I Error of rejecting the hypothesis 
of “no difference”. In the current study the z-score will be employed as the test of 
statistical significance. The associated p-value represents the probability of a Type I 
Error. A Type I Error means that the null hypothesis will be falsely rejected, that is, the 
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null hypothesis of “no difference” is rejected although it is in fact true and there really is 
“no difference”. For the purpose of the current study, the p-value represents the 
probability that the researcher concludes that there is a statistically significant difference 
between the DUF and ADAM data when in fact there is “no difference.”  The current 
study uses an α-level of .05, which is a standard level in criminology and other fields. An 
α-level of .05 means that if the test would be carried out 100 times, 5 of these tests would 
suggest significant differences, and as a result rejecting the null hypothesis of “no 
difference” when in fact the null hypothesis is true and there is “no difference” (Moses, 
1992).   
Accordingly, the hypothesis of “no difference” is rejected if either of the two-
tailed tests is significant, that is, the z-value with a 95% confidence interval and an α-
level of .05 must be greater than 1.96 or below -1.96 (Agresti and Finlay, 2007). Z-values 
that lie in the middle of the normal distribution (e.g. in between -1.96 and +1.96) are 
indicative of the norm, whereas extreme values (values in the tails of the normal 
distribution) represent the unexpected, something out of the ordinary or “significantly 
different” (Agresti, 2007). For instance, the p-value for a z-score of 1.97 is .048, which is 
statistically significant at the .05 level. As the result, the null hypothesis of “no 
difference” would be rejected. If the z-score is .876, however, the associated p-value 
would be .38, which is not equal to or lower than .05, and the researcher would not reject 
the null hypothesis. The equations used for the traditional hypothesis test are shown 
below: 
Calculation of the Traditional Null Hypothesis Test 
The traditional z test is computed as: 
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z = (p1 - p2)/SE    p = corresponding to the calculated z value 
The standard error is calculated as: 
SE =   
 
The 95% Confidence Interval is:  
LCL (p1-p2) – zα/2(SE) 
LCL (p1-p2) + zα/2(SE) 
 
The current study uses the two-tailed p-value with an α – level of 5% because that 
is the level used regularly in criminology. Accordingly, the p-value is significant if it is 
smaller than .025 in the table of the standard normal distribution. In this example, the z-
score corresponds to a p-value of .044 in the table of the standard normal distribution. 
This p-value of .044 constitutes the one-tailed p-value for the null hypothesis. Thus, the 
two-tailed p-value would be 2*.044 = .088, which is >.05 the predetermined α – level of 
5%, indicating that the value is not significant. The null hypothesis of “no difference” 
cannot be rejected. This result implies that the hypothesis of no difference between DUF 
and ADAM cannot be rejected. As stated previously, however, this cannot be interpreted 
as equivalence. To determine whether these two proportions can be said to be equivalent, 
an equivalence test is conducted simultaneously to the traditional null hypothesis test. 
Equivalence Testing 
In contrast to traditional null hypothesis testing, equivalence testing reverses the 
null hypotheses. Thus, the null hypothesis is the hypothesis of a “difference,” 
specifically, “the null hypothesis states the difference among group means is greater than 
some minimal difference representing practical equivalence” (Allen and Seaman, 2006, 
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p.1). For the current study, the null hypothesis will be examined with regard to group 
proportions, that is, proportions of booked arrestees who used a specific drug. Similar to 
traditional significance testing, the goal is to reject the null hypothesis. This reversal of 
the null hypothesis allows the researcher to draw a conclusion of whether there is 
equivalence between the two groups or proportions (Hauck & Anderson, 1986; Rogers, et 
al. 1993). Thus, equivalence testing can be seen as a complementary test that allows the 
researcher to better assess the magnitude of differences (Allen and Seaman, 2006; Hauck 
and Anderson, 1986; Rogers, 1996). The equations employed for the equivalence test are 
as follows: 
Equivalence Test 
Calculation of the Equivalence Test 
The equivalence z test is computed as: 
z1 =  (p1 - p2) – δ1/SE  p1 = corresponding to the calculated z-value 
z2 =  (p1 - p2) – δ2/SE  p2 = corresponding to the calculated z-value 
The equivalence margin is computed as ±20% of the baseline value (explained 
below) or stated as an equation: (equals the computation of the percentage 
difference described above) 
δ1 =   - 20% * p1  
δ2 =   +20% * p1  
The equivalence confidence interval is calculated as: 
LCI: (p1 - p2) - zα(SE) 
UCI: (p1 - p2) + zα(SE) 
The standard error is calculated as: 
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SE =   
 
For calculation purposes, only the lower z-value with the higher corresponding p-
value needs to be computed (indicating that equivalence does not exist) because it has a 
greater likelihood of being non-significant than the higher z-value with the lower 
corresponding p-value. For demonstration purposes, this calculation is shown at the end 
of this chapter using Dallas as an example.  
Possible Outcomes and Interpretation 
Four main outcomes are observed: (1) The drug use information in DUF and 
ADAM is substantially different (D), (2) The drug use information in DUF and ADAM is 
equivalent (Eq), (3) The drug use information in DUF and ADAM is different and 
equivalent (D&Eq), and (4) The results are statistically indeterminate (ND&NEq) (Allen 
and Seaman, 2006; Rogers, et al., 1993; Tryon and Lewis, 2009).  
First, the results are substantially different if the traditional test is statistically 
significant at the .05 level and if the equivalence test is not statistically significant at the 
.05 level. Second, the results indicate equivalence if the traditional test is not statistically 
significant at the .05 level, and the equivalence test is statistically significant at the .05 
level. Third, the analysis shows that the two proportions are statistically different but also 
equivalent. According to some researchers, in this case the difference can be said to be 
trivial (Allen and Seaman, 2006; Rogers, et al., 1993). The fourth possible outcome is 
referred to as statistically indeterminate because there is no clear evidence for either 
statistical difference or equivalence (Allen and Seaman, 2006; Rogers, et al., 1993; Tryon 
and Lewis, 2009). The results will be said to be statistically indeterminate if the results 
indicate that the drug use information is neither statistically different nor equivalent. For 
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a better understanding, Figure 1 demonstrates how the confidence interval can be used to 
determine whether there is equivalence between the DUF and ADAM samples.  
 
Figure 1: Confidence-Interval Approach for Equivalence Testing (Allen and Seaman, 
2006; Rogers, et al., 1993) 
 
Equivalent (E)  
Different (D) 
Different but Equivalent (DE) 
Not Different and Not  
Equivalent (NDNE) 
                                                   -Δ                       0                       +Δ 
          Equivalent 
 
As evident in Figure 1, statistical equivalence (E) exists if the confidence interval 
includes 0 and lies within the equivalence margin (-Δ to +Δ). For instance, the 
equivalence margin is -24 to +24 and the two-sided confidence interval is -10 and +10. A 
statistical difference (D) is observed if the confidence interval falls outside the 
equivalence margin and does not include 0. This would be the case if the equivalence 
margin is -24 to +24 and the two-sided confidence interval is + 20 and + 46. The results 
are said to be different but equivalent (DE) if the confidence interval lies within the 
equivalence margin but does not include 0. Finally, the results are indeterminate (not 
different and not equivalent) if the confidence interval is not contained within the 
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equivalence margin but does include 0. As shown in Figure 1, this could be the case if the 
two-sided confidence interval is partially inside and partially outside of the equivalence 
margin. For instance, the equivalence margin is -24 to +24 and the two-sided confidence 
interval is - 20 and + 46.  
Defining the Equivalence Margin 
One of the major issues is how to define an appropriate equivalence margin 
(European Medicines Agency, 2000; Wiens, 2001). Equivalence testing is mostly used in 
the field of biostatistics and in clinical trials to compare whether two treatments or drugs 
are equivalent with regard to their effectiveness (Hauck and Anderson, 1986; Wiens, 
2002). In the field of bioequivalence studies, the equivalence limit is typically defined as 
20% (European Medicines Agency, 2000). Additionally, the European Medicines Agency 
(2000) states that a 90% confidence interval is an acceptable equivalence interval to 
evaluate whether the average values of the outcome data are sufficiently close (European 
Medicines Agency, 2000). Rogers, et al. (1993) suggests that an equivalence interval of 
20% is appropriate (p. 557). Equivalence testing has only rarely been used in the social 
sciences field. For instance, Epstein, et al. (2001) compared the equivalence of internet 
versus paper-and-pencil assessments. They also used a 90% confidence interval and a 
20% equivalence margin. To further assess this issue of an appropriate equivalence 
interval, drug use research was examined. 
To date, there are no set standards in the field of drug use research for the 
question of what constitutes a substantial difference with regard to changes in the drug 
use prevalence over time or across different population groups. The term “substantial” is, 
however, used regularly by researchers to describe differences in the drug use prevalence 
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and patterns. What is substantial differs depending on the drug and the population group 
being examined. The current study looks at drug use among arrestees, and therefore the 
drug use literature examining this population group was investigated to determine what is 
typically considered a substantial change for the drugs included in the current analysis: 
marijuana, powder cocaine, crack cocaine, heroin, amphetamines, barbiturates, and PCP.  
Threshold Levels for the Major Drugs 
To reiterate, there exists no clear standard for the question of what constitutes not 
just a statistically significant change for but also a change that is of practical importance. 
The current study examines data that includes changes during a time period of five years 
(1997/1998 compared to 2000/2001). Thus, studies that include trend analysis over 
several years will be examined as well as reports that assess changes within the last 12 
months.  
Marijuana.  For marijuana, NIJ (1997) reported that for the time period 1996 to 
1997 “Marijuana positive rates for juvenile males showed moderate increases (2-8 
percentage points) in the majority of sites” (p. 8). Additionally, the DUF report by NIJ 
(1995) states that there were two sites with “sizable increases” between 1994 and 1995: 
New Orleans (up 9 points to 16%) and Washington, D.C. (up 8 points to 18%)” (p. 10). 
This statement implies that an increase of 7% or less is not substantial for a one-year time 
period. Golub and Johnson (2001) suggest that a percentage change of less than 5% 
within one year is probably due to random variation. Furthermore, a study by the 
Australian government examining the impact of legalizing marijuana use on the 
prevalence rate implies that a percentage of 4% is not substantial (National Drug and 
Alcohol Research Centre, 1996).  
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Overall, the examined studies suggest that an increase or decrease in marijuana 
use of less than 8% is not considered substantial. An 8% increase for marijuana use at a 
marijuana use rate of 35% corresponds to a percentage difference of 23% (calculated as 
described above). The annual report published by NIJ (1999) defines a substantial 
increase to be at least 10% (marijuana positive rates) within two years. The median rate 
of marijuana positive drug tests in 1999 was 39%. Thus, hypothetically, if there is an 
increase from 29% to 39% (10% increase), that corresponds to a percentage difference of 
34%. Thus, with regard to marijuana there seems to be consistency in the finding that a 
percentage difference of more than 20% is not necessarily considered substantial. Thus, 
the current study will use a margin (percentage change) of 20% of the baseline value.  
 Cocaine.  The threshold value for cocaine seems to be similar to that of 
marijuana. This is not necessarily surprising because cocaine is a popular drug that is 
used at high rates among arrestees. NIJ (1994) reported that there were a number of 
substantial increases in cocaine use. In their study, substantial was defined as percentage 
changes of more than 5% within one year. Golub and Johnson (1997) supported a larger 
threshold level of 10% within one year by arguing that: “A substantial decline of at least 
10 percent in the overall rate of detected cocaine/crack use was observed in Cleveland, 
Dallas, Detroit, Houston, Los Angeles, New Orleans, Philadelphia, San Diego, San Jose, 
and Washington, D.C” (p. 11). For a three-year period, however, Golub and Johnson 
(1997) state that a change of 9% is not substantial. Similar to marijuana, a threshold level 
of 8% would be a middle ground. Again, an 8% increase or decrease at a median use rate 
of 30% constitutes a percentage difference of 27%. According to these findings, an 
equivalence margin of 20% does not seem excessively liberal. 
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Opiates.  The annual DUF report from 1995 only highlighted changes in cities 
with 10% or more (NIJ, 1995), suggesting that percentage changes of less than 10% were 
not substantial enough to draw special attention. Furthermore, the ADAM report from 
1998 noted: “The most substantial declines for females were recorded in Washington, 
D.C. and Cleveland (24 percentage points in each) followed by Detroit (17.8), San Jose 
(17.6), Dallas (17.3) and San Diego (16.6). While it is not possible to know the standard 
error of these figures, variations of this size suggest substantial changes” (p. 10). Again, a 
threshold level of 10% for a five-year time period appears to be reasonable. The annual 
DUF report from 1999, however, defines substantial as an increase or decrease of 5%. A 
5% increase at a median use rate of about 10% would be a percentage difference of 50%. 
Thus, a percentage difference of 50% would be considered substantial. Additionally, the 
authors state that there was no substantial change between 1998 and 1999. The median 
drug use positive rate in 1999 was 8%, up 1% from 7% in 1998. This 1% increase results 
in a percentage difference of 12%. Similar to marijuana and cocaine, an equivalence 
margin of 20% seems to be reasonable for opiates. 
Barbiturates, Amphetamines, and PCP.  These three types of drugs are used 
much more rarely than marijuana, cocaine, or opiates. For instance, amphetamines were 
used by less than 3% of arrestees across sites. Similarly, barbiturates and PCP were 
typically used by only 1% of the arrestees. As a result, very small increases or decreases 
will result in a large percentage difference, and as a result smaller changes are considered 
substantial. For instance, an increase by 0.6% from 0.2% to 0.8% constitutes a percentage 
change of 65%.  
NIJ (1999) implies that for methamphetamine, a change of 3% can be considered 
  106
substantial.  NIJ (1995) states that a 5% change from 3% to 8% represents a “sharp 
increase” for methamphetamine. Methamphetamine is, however, used at higher rates than 
other amphetamines, barbiturates, or PCP. Thus, the threshold for these three drugs 
would be lower. A percentage difference of 20% (as proposed for marijuana, cocaine, and 
opiates) would translate into a change of about 0.2% at a use rate of about 1.2%, which 
appears to be average for the current data. In order to get a better understanding of what a 
20% equivalence margin means in absolute numbers, a series of examples will be 
considered. 
Sensitivity Tests 
Urine Analysis Test of Marijuana, Dallas  
The example used for this demonstration is drug positive tests of marijuana use in 
Dallas, Texas. The baseline proportion for the urine analysis test for marijuana use in the 
ADAM data is .327 or 32.7%, with a sample size of 802 arrestees. In actual numbers this 
means that 262 arrestees tested positive for marijuana. The following three equivalence 
margins will be considered: 5%, 10%, and 20%.  
First, an equivalence margin of 5% would result in an increase or decrease of 
1.6% (5%*.327), which is 4 arrestees (1.6%*262)/100. According to the drug use and 
epidemiological literature, a change of 1.6%is not a substantial change for marijuana use. 
Second, an equivalence margin of 10% would result in an increase or decrease of 3.3% 
(10%*.327), which equals 9 arrestees (3.3%*262)/100. A change by 3.3% for marijuana 
is also not considered substantial. Third, an equivalence margin of 20% corresponds to a 
change of about 6.5%, or 17 arrestees. According to the literature, a change of about 7% 
to 8% is considered substantial. Thus, the 20% equivalence margin appears to be a rather 
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conservative measure.  
Urine Analysis Test of Opiates, Dallas  
 Next, these sensitivity tests were repeated for opiates, which have a lower use rate 
than marijuana and cocaine. Specifically, only 4.2% (34) of the arrestees in Dallas tested 
positive for opiates in 2000/2001 (ADAM). A 5% equivalence margin is equal to a 
change of 0.2% or 1 arrestees (exact: .07). A 10% equivalence margin represents a 
change of .04 or 1 arrestee (exact: 1.4 arrestees). A 20% margin shows a change of 0.8% 
or 3 arrestees (exact: 2.7 arrestees). Similar to marijuana, a 5% and 10% equivalence 
margin do not correspond to a change in drug use prevalence that is considered 
substantial and important according to the literature.  
Self-Reported Drug Use of PCP within 72 Hours, Dallas 
PCP is used very rarely. In the current data, only 0.6% of arrestees (or 5 arrestees) 
reported having used this drug within the past 72 hours. In that case, a 5% equivalence 
margin means that there would be a change of .03% or .0015 arrestees. A 10% 
equivalence margin relates to a change of .06% or 0.3 arrestees. Accordingly, a 20% 
equivalence margin equals a change of .12% or 0.6 arrestees. Again, the 5% and 10% 
equivalence margin do not constitute a substantial difference. Thus, the 20% margin will 
be used.  
Power Analysis 
Both, the traditional test and equivalence test are algebraically similar to the 
“independent samples t-test,” which tests whether the means or proportions of two groups 
are statistically different from each other. As a result, the statistical power is also similar 
(Tryon, 2001). According to Cohen’s (1992) “Power Primer” the recommended sample 
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size for an independent samples t-test  in order to find a small effect for differences in 
proportions is N = 392 for an α-level of .05 and N = 584 for an α-level of .01.  The 
sample sizes in the current study are larger than these recommended sample sizes, 
including Miami which only has data for one ADAM year. Thus, there is sufficient power 
to conduct the traditional null hypothesis and the equivalence test. 
After having discussed why equivalence testing is an appropriate approach for the 
current study, that there is enough power to conduct the analysis, and how the 
equivalence margin will be defined, the following part shows the calculation of the 
equivalence test using the data from Dallas. 
Analysis of Dallas, Texas Data 
 For an easy overview, a summary of the key analysis steps is shown below:  
Step 1: Two simultaneous one-sided tests (using the equations provided above) 
a) Traditional Hypothesis Test  
The goal is to reject the null hypothesis of “no difference” or stated 
differently: “reject the null hypothesis asserting that the difference 
between two means (or proportions) is less than or equal to the smaller 
delta (δ1)” (Rogers, et al., 1993, p. 554). 
b) Equivalence Test 
 The goal is to reject the null hypothesis of a “difference” or stated 
differently: “reject the null hypothesis asserting that the difference is 
greater than or equal to the larger delta (δ2)” (Rogers, et al., 1993, p. 554). 
Step 2: Evaluation of the Outcome 
Four Possibilities: 
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(a) DUF and ADAM are equivalent (E) 
(b) DUF and ADAM are different (D) 
(c) DUF and ADAM are different but equivalent (ED) 
(d) DUF and ADAM are not different and not equivalent (NDNE) 
Analysis 
Example: Self-reported marijuana use in Dallas, TX (“Ever Used Marijuana”) 
Step1: Two simultaneous one-sided tests (using the equations provided above) 
a) Traditional Hypothesis Test  
p1 = 68.5% or .685, n = 802 (ADAM) 
p2 = 78.3% or .783, n = 1547 (DUF) 
Standard Error: 
SE = [(.685(1-.685))/802 + (.783(1-.783))/1547]1/2   
 
SE = .019 
 
Traditional 95% confidence interval  
LCL: (.685 - .783) – 1.96(.019) = -.136 
UCL: (.685 - .783) + 1.96(.019) = -.060 
Z-test 
z = (.685 - .783)/.019 
z = -5.035   p = .000 (one-tailed)  
The z-score when using a 95% confidence interval is below 1.96 and thus the p-
value is below the .025 level, implying a statistically significant difference for this 
specific drug variable. Thus, the null hypothesis of “no difference” can be rejected. As 
described previously, this is not sufficient to conclude that the two proportions are 
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substantially different. In order to draw that conclusion it has to be shown that the two 
proportions are statistically different and not statistically equivalent. Thus, next the 
equivalence test is computed. 
c) Equivalence Test 
Standard Error: 
SE = .019 (as calculated previously) 
Equivalence margin 20%: (equals the computation of the percentage difference 
described earlier) 
δ1 =   - 20% * .685  =  -.1370  
δ2 =   + 20% *.685 =    .1370 
δ = ±.1370 
The equivalence interval would be -.1370  to +.1370 or 13.7%. Next, the equivalence 
confidence interval will be calculated to see whether it is contained within this 
equivalence margin.  
Example 90% Equivalence Confidence Interval: 
LCL: (.685 - .783) - (1.645)(.019) = -.130 
UCL: (.685 - .783) - (1.645)(.019) = -.066 
The confidence interval does not include 0 but it falls inside the equivalence margin of 
±.1370.  
Figure 2 shows the equivalence margin and the confidence interval. 
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Figure 2: Example Equivalence Test 
                                                                              
 
                                                                                    -.130    -.066                          
 
           
-.1370              Equivalent                 +.1370 
 
To further assess whether substantial differences exists, the equivalence z will be 
computed. If both tests have a p-value with a α – level of .05 or less the null hypothesis of 
a “difference” can be rejected and the two proportions can be said to be equivalent. As 
described above, only the lower z-score with the higher p-value needs to be computed 
because it is more likely to be not statistically significant than the higher z-score with the 
lower p-value. 
Example Equivalence z: 
z1 =  ((.685 - .783) – (-.685))/.019 = 2.004  p = .000 
This finding indicates that the z-test with the higher p-value is significant for the 
one-tailed test at the .05 α – level because the z-score when using the 90% confidence 
interval is greater than 1.645. Accordingly, the null hypothesis of a “difference” can be 
rejected and equivalence can be concluded. This example implies that the DUF and 
ADAM data are statistically different but statistically equivalent. The following section 
will now present the results of the current study.  
Decision Rules 
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At this point it is important to lay out the criteria for the interpretation of the 
results and the hypotheses. As described at the beginning of this Chapter, there are four 
possible outcomes: 
(1) DUF and ADAM can be said to be equivalent (Eq) 
(2) DUF and ADAM are different (D) 
(3) DUF and ADAM are different and equivalent (D&Eq) 
(4) DUF and ADAM are not different and not equivalent (indeterminate) 
(ND&NEq) 
To reiterate, the main question is whether the drug use estimates of DUF and ADAM are 
substantially different. Two of the four possible outcomes are straightforward with regard 
to their interpretation.  If the variable is statistically different and not statistically 
equivalent (D), then the variable is classified as substantially different. If the variable is 
statistically equivalent and not statistically (Eq) different, it can be classified as not being 
substantially different. The other two outcomes are somewhat more ambiguous. If the 
variable is statistically different and statistically equivalent (D&Eq), it can be classified 
as not substantially different because even though the traditional null hypothesis test 
showed a statistically significant difference this difference was marginal in the sense that 
the confidence interval of the proportion still falls within the equivalence margin.  
Finally, if the variable is not statistically different and not statistically equivalent 
(ND&NEq), it cannot be classified as either substantially different or not substantially 
different. These variables are statistically indeterminate.  
 It is to be expected that each site will have several of these outcomes and thus 
there is the issue of how these multiple findings are to be interpreted. For example, for 
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Dallas 27% (3) of the variables fell into the category equivalent, 27% (3) were 
statistically different but statistically equivalent (D&Eq), and 45% (5) of the variables 
were not statistically different and not statistically equivalent (ND&NEq) and cannot be 
judged because they were statistically indeterminate.  The following decision criteria are 
proposed to judge these results. 
First, for the purpose of the current study the findings of Equivalent (Eq) and 
Different but Equivalent (D&Eq) will be combined and interpreted as not substantially 
different. Researchers suggest that a finding of Different but Equivalent (D&Eq) means 
that although there is a significant difference using the traditional null hypothesis test 
these differences might be trivial and not of practical importance. Specifically, Rogers, et 
al. (1993) states that the “difference was larger than the standard null value (usually zero) 
but smaller than a difference that would make the groups nonequivalent” (p.561). This 
interpretation is also supported by Allen and Seaman (2006) who state that “there is a 
difference, but it is trivial” (p. 78). They suggest that this finding might occur because the 
study was “overpowered.” This term refers to the possibility that with a large sample size 
it is possible to detect a significant difference when in fact the difference is “scientifically 
insignificant” (Frank and Althoen, 1994). This type of error (Type I Error) is also one of 
the main criticisms on traditional null hypothesis testing, namely that with large sample 
sizes researchers will often find a statistically significant difference (Batanero and Diaz, 
2006). Finding a statistically significant difference does not necessarily mean that the 
difference is of practical importance (Batanero and Diaz, 2006; Levin, 1998; Vacha-
Haase, 2001). Conducting the traditional null hypothesis test and the equivalence test 
simultaneously provides a better understanding of the magnitude of the actual 
  114
differences. In the current study, the percentage outcomes for certain drugs may be 
statistically different but at the same time statistically equivalent in the sense that the 90% 
equivalence confidence interval falls with the equivalence margin. Thus, these outcomes 
will be interpreted as not substantially different or similar. 
Second, sites will be classified as “unable to be assessed” if more than one third 
of the variables fall into the category “Not Statistically Different and Not Statistically 
Equivalent.”  In actual numbers, it means that sites will be said to be unable to be 
assessed if more than three variables are statistically indeterminate. Rogers, et al. (1993) 
suggest that such findings might be due to excessive “within group variation” and as a 
result the equivalence analysis is inconclusive. This is believed to be a conservative 
approach.  
Third, sites will be classified as substantially different if 20% or more of the drug 
use values show substantial differences. In actual numbers, that means that sites will be 
determined to be substantially different if three variables or more drug use values are 
classified as “Different.” As described in Chapter 2, drug use prevalence and patterns are 
not constant over time and a certain amount of changes can be contributed to these 
naturally occurring differences as long as the differences reflected in the current study are 
consistent with changes evident from other drug use studies. For example, urine test 
results for cocaine in Denver are substantially different. The DUF and ADAM data show 
that cocaine use declined consistently from 40.2% in 1997 to 32.8% in 2002 (see Table 
B.2., Appendix B). This decrease in cocaine use is supported by the data of the major 
national drug use surveys.  
Similarly, data from the DAWN study shows that emergency room visits due to 
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heroin use have increased by 33% between 1995 and 2001. This is a substantial increase 
and it can be expected that such increase will also reflect in the DUF/ADAM data. This 
study includes three measures of heroin use (MJ, MJ72, and EVERMJ), two of which 
refer to recent use (MJ and MJ72). These two variables measuring recent heroin use 
would likely be affected by the actual increase of heroin use as shown by the DAWN 
data.  
Data from the Treatment Episode Data Set (TEDS) also shows a decrease in 
emergency room admissions for cocaine use for Texas. The NSDUH also demonstrates a 
decline in cocaine use in Texas, albeit a smaller decline (SAMHSA, 2001, Appendix A). 
Additionally, the MTF suggests that cocaine use among school children declined from 
about 5.9% in 1997 to 4.8% in 2001. Considering the consistency of these findings with 
regard to a decline in cocaine use, the substantial difference found for the urine test result 
for cocaine in Denver might be attributable to an actual change in drug using behaviors 
rather than the change in the sampling method. Thus, it appears reasonable to expect 
some variables to be substantially different. Limiting the number of variables than can be 
substantially to two could be seen as a conservative approach considering the fact that the 
data covers a five year time period and that there are two measures of recent drug use for 
each drug, that is, the urine analysis result for marijuana, cocaine, and opiates, and drug 
use within the past 72 hours for marijuana, cocaine, and heroin.  
In summary, the following decision criteria are proposed: 
1) The findings of Equivalent (Eq) and Different but Equivalent (D&Eq) will be 
interpreted as not substantially different or similar. 
2) Sites will be classified as “unable to be assessed” if more than one third of the 
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drug use values fall into the category “Not Statistically Different and Not 
Statistically Equivalent” (ND&NEq). 
3) Third, sites will be classified as substantially different if 20% or more of the drug 
use values show substantial differences (D). 
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CHAPTER FIVE 
RESULTS 
 
 This Chapter presents the results of the equivalence analysis. This section will 
begin by examining the demographic profile for DUF (1997/1998) and ADAM 
(2000/2001) to get a general overview of the similarities and differences in the two 
datasets. After the assessment of the demographic profile, the current analysis will take a 
look at the drug use frequencies for DUF (1997/1998) and ADAM (2000/2001). The 
purpose of examining the drug use frequencies is twofold: (1) to  provide an overview of 
the prevalence of each drug among arrestees and (2) to decide which drug use variables 
will be excluded from the equivalence analysis. Finally, the results of the equivalence 
analysis will be presented to assess whether the drug use estimates of DUF and ADAM 
are substantially different. The results of the equivalence analysis will be presented in 
two parts: (1) overall results for the equivalence tests, and (2) site specific results. The 
decision criteria described in Chapter Four will be used to interpret the findings. 
Descriptive Statistics 
Demographic Profile 
Tables A.1. to A.9. in Appendix A display the demographic profile of the sample 
for the nine sites included in the current study. The data shows that the demographic 
profile of DUF (1997/1998) and ADAM (2000/2001) has similarities and differences. 
The results are presented by demographic category.  
Race.  The racial distribution is described for each racial category, including 
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Black, White, Hispanic, and Other. The percentage of Black arrestees appeared to be 
similar for Indianapolis, New Orleans, Phoenix, San Antonio, and San Jose. These sites 
had a difference of less than 5% between DUF and ADAM. Specifically, in Indianapolis, 
57.2% of arrestees were Black in the DUF sample, and 56.5% were Black in the ADAM 
sample. In New Orleans, 87% of arrestees were Black in the DUF sample, and 86.6% 
were Black in the ADAM sample. In Phoenix, 13.7% of arrestees were Black in DUF and 
11.9% in ADAM. In San Antonio, 11.3% of arrestees were Black in the DUF sample, and 
12.7% were Black in the ADAM sample. Finally, in San Jose, 11.1% were Black in the 
DUF sample, and 11.9% were Black in the ADAM sample.   
Four sites had a difference of 6% or more. These sites are Miami, Portland, 
Dallas, and Denver. The largest difference was apparent in Dallas, where 58.4% of 
arrestees in the DUF sample were Black, but only 49.1% of arrestees in the ADAM 
sample were Black. Additionally, the difference in Miami was 6.7%, in Portland 5.4%, 
and in Denver 8.2%. There was no consistent pattern with regard to the direction of the 
difference; that is, in Portland, Dallas, and Denver, the DUF sample had a greater number 
of Black arrestees as compared to the ADAM sample, whereas in Miami the DUF sample 
had fewer Black arrestees than the ADAM sample. 
The findings for White offenders demonstrate that Portland, Indianapolis, New 
Orleans, Denver, San Antonio, and San Jose have differences of less than 5% between 
DUF and ADAM. In Portland, the DUF sample included 61.7% White arrestees; the 
ADAM sample included 64.6% White arrestees. Indianapolis had 37.9% White arrestees 
in the DUF sample, and the ADAM sample had 42.4%. The DUF sample in New Orleans 
consisted of 11% White arrestees, whereas the ADAM sample consisted of 12.9%. The 
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Denver site had 28.6% White arrestees in the DUF sample and 27.6% in the ADAM 
sample. San Antonio included 32.9% White arrestees in the DUF sample and 35.3% in 
the ADAM sample.  Finally, the DUF sample in San Jose consisted of 32.1% White 
arrestees and the ADAM sample of 30.4%.  
Phoenix, Miami, and Dallas showed differences that were larger than 5%. The 
largest discrepancies were found in Miami, where about 15.7% of arrestees were White 
in the DUF sample, but 43.2% of arrestees were white in the ADAM sample. The 
remaining two sites demonstrated a difference of 6.6% (Phoenix) and 6.5% (Dallas). 
Again, no consistent pattern for the direction of the discrepancies emerges. Phoenix and 
Miami had fewer White arrestees in the DUF sample and more in the ADAM sample. 
Contrary, in Dallas the DUF sample included a greater number of White arrestees than 
the ADAM sample.  
The assessment of differences for Hispanic offenders is more complicated 
because the percentage of Hispanics in the sample varies greatly. Three sites had less 
than 7% Hispanic offenders in the sample overall. These sites were Portland, 
Indianapolis, and New Orleans. With regard to the differences between DUF and ADAM, 
the data shows that in Portland the DUF sample had 5.6% Hispanic arrestees, whereas the 
ADAM sample had 7.3% Hispanic offenders. Indianapolis had 4.1% Hispanic arrestees 
in the DUF sample but only 0.8% in the ADAM sample. In New Orleans, the DUF 
sample consisted of 0.8% Hispanic offenders and the ADAM sample of 0.2%.    
The vast majority of sites show substantial differences. The greatest differences 
were found in Miami, where the DUF sample included 37.7% Hispanic arrestees, but the 
ADAM sample only had 3.9% Hispanic offenders. Also, in Denver 33.8% of the DUF 
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sample were Hispanic arrestees, but 41.5% of the ADAM sample were Hispanic 
offenders. In Dallas, 9.8% of arrestees were Hispanic in the DUF sample and 14.8% in 
the ADAM sample. In Phoenix, 32.3% of arrestees in the DUF sample were Hispanic, 
and 25.6% of arrestees in the ADAM sample were Hispanic.  In San Antonio and San 
Jose, the percentage of Hispanics in the sample appeared to be similar, with differences 
of less than 3%. Of the three racial categories, Hispanic arrestees showed the greatest 
discrepancies between DUF and ADAM. The important question is whether these 
differences in the racial distribution also lead to differences in the drug use estimates 
between DUF and ADAM. 
Employment.  For the percentage of arrestees employed full time, only one site 
had a difference of more than 5%. That site was Miami, with a difference of 6%. 
Conversely, the category part-time employment was substantially different for all sites 
with the exception of Phoenix, where the difference was only 2%. The remaining sites 
demonstrated differences of more than 6%. Similarly, the percentages of arrestees who 
stated they were unemployed were also substantially different at all sites. The DUF 
sample had much fewer arrestees who were unemployed at the time as compared to the 
ADAM sample. Specifically, at most sites more than twice as many arrestees in the 
ADAM sample fell into the unemployed category as compared to the DUF sample.  
Education.  The frequency distributions also suggest substantial differences with 
regard to the high school graduation rate of arrestees between the DUF and ADAM 
samples. The greatest discrepancies were found in San Jose and Miami. In San Jose, the 
difference was 27.8% because only 49.8% of arrestees in the DUF sample graduated 
from high school but 77.6% of arrestees in the ADAM sample graduated from high 
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school. Similarly, the difference in Miami was 26.8%; 40.3% of arrestees in the DUF 
sample graduated from high school as compared to 67.1% in the ADAM sample. The 
remaining sites had differences of 10% or more. There is a consistent pattern for this 
category—the ADAM sample has a higher percentage of high school graduates for all 
sites. Thus, there appears to be a systematic bias in the data for high school graduation 
rates. 
Charge distribution.  The charge distribution for DUF and ADAM were 
expected to be different because of the differences in the arrestee selection procedure. As 
described in Chapter Four, DUF used a priority charge system, whereas ADAM used the 
UCR in their determination of the sample. Despite these differences in the arrestee 
selection procedure, four sites appeared to have a similar charge distribution. 
Specifically, in Denver, Phoenix, Indianapolis, and Portland, the charge distribution for 
DUF arrestees was within 5% for all three categories (violent, property, and drug 
offenses) for that of ADAM. The other five sites demonstrated substantial differences, 
with discrepancies of 10% and more for each charge category (violent, property, and drug 
offenses). Again, these differences were to be expected because DUF and ADAM used 
different methods to determine how many arrestees should be included for each charge 
category.  
Age.  Contrary to the charge distribution, the average age of the arrestees in the 
DUF and ADAM samples was almost exactly the same for all sites. Specifically, for eight 
sites the average age was the same for DUF and ADAM. The sole exception is San Jose, 
where the average age of the arrestees in the ADAM sample was 32 as compared to 31 
for the DUF sample.  
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In sum, from the frequency distributions there appear to be a number of 
similarities between DUF and ADAM but also differences for the demographic profile of 
the two samples. This is not an unexpected finding because ADAM employed a 
probability sample and a weighting procedure to ensure that the arrestee sample was 
representative of arrestees booked in the catchment area, whereas DUF did not use these 
procedures. The main question is whether these differences influence the drug use 
estimates produced by DUF and ADAM in a way that makes them substantially different.  
Drug Use Frequencies 
Table 5.1. shows the prevalence rates for drug use by presenting the lowest, highest, and 
average prevalence rates for all sites combined. This data was compiled from Tables B.1. 
– B.9. in Appendix B, where the prevalence rates of drug use are displayed for each site 
for each year for DUF (1997 and 1998) and ADAM (2000 and 2001). The drug use data 
for both DUF and ADAM appears to be similar with regard to the prevalence of the drugs 
examined.  
The most-often used drug is marijuana (MJ). The high prevalence of marijuana 
shows in both the urine test results and the self-reported data for the DUF and ADAM 
data. Second, cocaine (COC) has the next highest prevalence rates for the urine test 
results and the self-report data for DUF and ADAM. The self-report data further shows 
that the average prevalence rate for crack cocaine (CRK) used within the past 72 hours 
was higher than for powder cocaine. Contrary, for lifetime use (ever used drug) powder 
cocaine had higher average prevalence rates than crack cocaine. Again, these patterns are 
consistent for both DUF and ADAM. Third, in both datasets, opiates (OP), including 
heroin (HER), had much lower prevalence rates than marijuana and cocaine, but were 
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more popular than PCP (PCP), amphetamines (AMPH), and barbiturates (BARB). 
Fourth, PCP, amphetamines, and barbiturates were used very rarely by arrestees in the 
DUF and ADAM samples. These overall findings will be examined in more detail now.  
First, the prevalence rates shown in Table 5.1. indicate that in the ADAM sample 
between 60.2% and 84.1% of arrestees stated that they have used marijuana at some point 
in their life (EVERMJ). On average, 74.2% of arrestees have previously used marijuana 
(EVERMJ). Similarly, the DUF data shows that between 63.3% and 87.4% of arrestees 
have used marijuana (EVERMJ). On average, 76.0% of arrestees admitted to having used 
marijuana (EVERMJ). 
With regard to recent use, the ADAM data implies that between 22.1% and 35.0% 
of arrestees reported having used marijuana within the past 72 hours (MJ72), with the 
average being 27.0% (MJ72). The DUF data suggests that between 18.9% and 34% have 
used marijuana in the past 72 hours (MJ72), with the average being 26.9%. Additionally, 
the ADAM data demonstrates that on average 38.4% of arrestees tested positive for 
marijuana (MJ) use. Similarly, in the DUF sample, 36.9% of arrestees tested positive for 
marijuana (MJ).  
Second, cocaine is also used regularly by arrestees. Specifically, the ADAM data 
demonstrates that between 3.0% and 9.7% of arrestees used powder cocaine within the 
past 72 hours (COC72) and between 3.3% and 11.2% used crack cocaine within the past 
72 hours (CRK72). On average, 5.8% of arrestees had used powder cocaine in the past 72 
hours (COC72) and 9.8% had used crack cocaine in the past 72 hours (CRK72). In 
comparison, the DUF data shows that between 3.2% and 11.3% of arrestees used powder 
cocaine within the past 72 hours (COC72) and between 2.8% and 17.2% used crack 
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cocaine within the past 72 hours (CRK72). For the DUF data, the average use rates 
within the past 72 hours were 7.1% for powder cocaine (COC72) and 11.8%% for crack 
cocaine (CRK72).  
The ADAM data also shows that between 27.9% and 50.8% of arrestees have 
used powder cocaine (EVERCOC) and between 14.8% and 41.1% have used crack 
cocaine (EVERCRK) at some point in the life. For the DUF data, the lifetime prevalence 
rates range from 32.3% to 54.1% for powder cocaine (EVERCOC) and 12.2% and 44.5% 
for crack cocaine (EVERCRK).  
Additionally, between 12.0% and 44.9% of arrestees in the ADAM tested positive 
for cocaine (COC), with the average being 28.9%. For the DUF data, the percentage of 
arrestees who tested positive for cocaine (COC) ranged from 11.8% to 53.9%, with an 
average of 33.9%. To reiterate, the urine analysis cannot distinguish between crack and 
powder. Thus, only overall cocaine use is reported.  
Third, opiate use (including heroin use) is rarer among arrestees as compared to 
marijuana and cocaine. On average, 7.1% of arrestees tested positive for opiates (OP) in 
the ADAM data and 6.8% in the DUF data. The urine positive tests ranged from 3.5% to 
15.1% for ADAM and 2.2% to 14.8% for DUF.  
With regard to lifetime heroin use (EVERHER), between 6.6% and 24.2% of 
arrestees in the ADAM data and between 7.6% and 31% of arrestees in the DUF data 
reported having used heroin. On average, 14.2% of ADAM arrestees 15.8% of DUF 
arrestees had used heroin at some point in their life (EVERHER).  
The data for recent heroin use (HER72) demonstrates that, on average, 4.4% of 
arrestees in the ADAM data and 4.5% of arrestees in DUF used heroin within the past 72 
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hours. Heroin use within the past 72 hours (HER72) ranged from 1.3% to 11.2% for 
ADAM and 0.3% to 11.0% for DUF. 
The descriptive analyses also show that the variables PCP72, AMPH72, and 
BARB72 have very low prevalence rates. Specifically, the prevalence rates for recent 
PCP use (PCP72) varied between 0.0% and 1.6% for ADAM and 0.1% to 0.8% for DUF. 
These percentages are equivalent to a range of 0 to 20 arrestees. On average, PCP72 was 
used by .04% of arrestees in the ADAM data and 0.3% of arrestees in the DUF data.   
The prevalence rate for recent use of amphetamines (AMPH72) ranged from 0.2% 
to 1.4% for ADAM and 0.0% to 3.4% for DUF.  On average, 0.7% of arrestees used 
amphetamines within the past 72 hours (AMPH72) in the ADAM data and 1.6% in the 
DUF data.  
Similarly, the prevalence rates for barbiturates (BARB72) were also very low, 
varying from 0.0% to 0.5% for ADAM and 0.4% to 2.0% for DUF. On average, 0.2% of 
arrestees used barbiturates in the ADAM data and 0.8% in the DUF data. These 
percentages equal a total number of arrestees between 0 and 16. Due to these very low 
sample sizes, the variables PCP72, AMPH72, and BARB72 were excluded from the 
equivalence analysis.  
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Table 5.1. Drug Use Frequencies for Total Sample – Lowest, Highest, and Average Prevalence Rates 
 
 ADAM 2000/2001 DUF 1997/1998 
Variable Lowest  Highest Average
N 
Average Lowest Highest Average
N 
Average 
Urine Test         
    MJ 32.7 48.7 38.4 1,308 27.5 44.3 36.9 1,600 
    COC 12.0 44.9 28.9 1,308 11.8 53.9 33.9 1,600 
    OP   3.5 15.1   7.1 1,308   2.2 14.8   6.8 1,600 
Self-Report Drug 
Use         
    Within 72 
Hours         
        MJ72 22.1 35.0 27.0 1,308 18.9 34.0 26.9 1,600 
        COC72   3.0   9.7   5.8 1,308   3.2 11.3   7.1 1,600 
        CRK72   3.3 12.6   9.8 1,308   2.8 17.3 11.8 1,600 
        HER72   1.3 11.2   4.4 1,308   0.3 11.0   4.5 1,600 
        PCP72   0.0   1.6   0.4 1,308   0.1   0.8   0.3 1,600 
        AMPH72   0.2   1.4   0.7 1,308   0.0   3.4   1.6 1,600 
        BARB72   0.0   0.5   0.2 1,308   0.4   2.0   0.8 1,600 
Ever Used Drug         
        EVERMJ 60.2 84.1 74.2 1,308 63.3 87.4 76.0 1,600 
        EVERCOC 27.9 50.8 38.9 1,308 32.3 54.1 40.3 1,600 
        EVERCRK 14.8 41.1 35.2 1,308 12.2 44.5 30.4 1,600 
        EVERHER   6.6 24.2 14.2 1,308   7.6 31.0 15.8 1,600 
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So far, the descriptive analysis has demonstrated that there are differences in the 
demographic characteristics of the DUF and ADAM samples. The descriptive statistics, 
however, also show that the overall prevalence of the different drugs included in the 
analysis appears to be similar. These findings support the findings of the NIJ (1993) 
study which found that even though the demographic characteristics and charge 
distribution of the DUF and ADAM samples were substantially different, the drug use 
estimates were similar. The following section will present the results for the equivalence 
analysis to determine whether these findings also hold up when a more rigorous statistical 
test is applied. 
Overall Results for the Equivalence Analysis 
 To reiterate, the research question is whether the drug use estimates for selected 
drugs are substantially different between DUF and ADAM. The main hypothesis is that 
the drug use estimates contained in DUF and ADAM are not substantially different 
despite differences in the sampling method. In order to assess the hypothesis, the DUF 
and ADAM data for the nine sites was compared to determine how many drugs and sites, 
if any, appear to be substantially different and how many, if any, appear to be similar. 
First, the drug use estimates for the 11 variables are similar and different for DUF and 
ADAM for all sites combined will be discussed. Tables 5.2. through 5.4. present this 
information.  
Table 5.2. shows how many variables are substantially different, how many are 
not substantially different or similar, and how many are statistically indeterminate for all 
sites combined. Each site had a total of 11 drug use estimates – one for each drug. The 
sites with the greatest number of substantially different drug use values are Phoenix with 
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36% (4 values) and Portland with 27% (3 values). In Denver and New Orleans, 18% (2) 
of the drug use values were classified as substantially different.  For the three sites 
Indianapolis, Miami, and San Jose, 9% (1) of the drug use values were substantially 
different. There are two sites where none of the drug use values were substantially 
different. These sites are Dallas and San Antonio. Altogether, out of a total of 99 drug use 
values (11 variables * 9 sites), 14 values were found to be substantially different. 
 As explained above, the categories “Equivalent” and “Different but Equivalent” 
will be counted as not substantially different or similar. Thus, these two categories will be 
evaluated together. The highest number of values that were classified as not substantially 
different was found in New Orleans with 81% (9 values). Specifically, four drug use 
values fell into the category “Equivalent” and five values were classified as “Different 
but Equivalent.” Several sites had 54% (8) of the drug use values that fell into either the 
“Equivalent” or “Different but Equivalent” category. These sites were Denver, Portland, 
San Antonio, and San Jose. In Denver, four drug use values were “Equivalent” and four 
values were “Different but Equivalent.” In Portland and San Jose, three drug use 
estimates showed “Equivalence” and five values were “Different but Equivalent.” 
Finally, in San Antonio, six drug use values were classified as “Equivalent” and two 
values were classified as “Different but Equivalent.” 
In Indianapolis and Miami, 45% (7) of the values showed no substantial 
differences. For Indianapolis, four values were “Equivalent” and three values were 
“Different but Equivalent.” In Miami, five values proved to be “Equivalent” and two fell 
into the category “Different but Equivalent.” 
Additionally, for two sites, a total of 36% (6) of the drug use values fell into either 
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of these two categories. In Phoenix and Dallas, three drug use values were classified as 
“Equivalent” and three values fell into the category “Different but Equivalent.”  No site 
had less than 36% (6 values) classified as either “Equivalent” or “Different but 
Equivalent.”   
Finally, there were also a number of sites with values that fell into the category 
“Not Different and Not Equivalent.”  These values are statistically indeterminate and 
cannot be judged as either substantially different or not. The greatest number of 
statistically indeterminate values had Dallas, where 45% (5) of the values fell into that 
category. Three sites had 27% (3) values that cannot be judged: Indianapolis, Miami, and 
San Antonio. In San Jose, 18% (2) values were indeterminate and in Denver and Phoenix, 
9% (1) value was indeterminate. At two sides, none of the values was statistically 
indeterminate, that is, all drug use values were categorized as either substantially 
different, equivalent, or different but equivalent. These sites were New Orleans and 
Portland.  
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Table 5.2. Equivalence Test Outcomes by Site 
 Number of Drug Use Variables  
Site Different Equivalent 
Different but 
Equivalent 
Not Different and 
Not Equivalent 
 Percent Total Percent  Total Percent   Total Percent      Total 
Dallas    0%         0  27%         3  27%          3  45%              5 
Denver  18%         2  36%         4  36%          4    9%              1 
Indianapolis    9%         1  36%         4  27%          3  27%              3 
Miami    9%         1  45%         5  18%          2  27%              3 
New 
Orleans  18%         2  36%         4  45%          5    0%              0 
Phoenix  36%         4  27%         3  27%          3    9%              1 
Portland  27%         3  27%         3  45%          5    0%              0 
San Antonio   0%          0  55%         6  18%          2  27%              3 
San Jose   9%          1  27%         3  45%          5  18%              2 
Total Values 14          35 32 18 
 
The results for each site as displayed in Table 5.2. gives a general overview of 
how many drug use values fall into each outcome category. This data does not provide 
information, however, of whether these outcome categories consist of the same variables 
across sites. For instance, Dallas, Phoenix, Portland, and San Jose have three drug use 
values that were categorized as “Equivalent.” The question is whether those three values 
are the same for the four sites or whether each site has different patterns with regard to 
the question how the drug use values are distributed over the outcome categories. Thus, 
the next step in the analysis was to examine the distribution of these drug use variables 
across the outcome categories to get a better understanding of possible patterns in the 
data. The results are presented in Tables 5.3. and 5.4. 
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Table 5.3. Classification of Drug Use Values Across the Outcome Categories for Each Site 
 Drug Use Variables 
Site MJ COC OP MJ72 COC72 CRK72 HER72 EVERMJ EVERCOC EVERCRK EVERHER 
Dallas D&Eq ND&NEq Eq D&Eq ND&NEq ND&NEq ND&NEq D&Eq Eq Eq ND&NEq 
Denver Eq D Eq Eq ND&NEq D D&Eq D&Eq D&Eq D&Eq Eq 
Indianapolis D&Eq Eq D&Eq D ND&NEq ND&NEq ND&NEq Eq Eq Eq D&Eq 
Miami Eq D D&Eq Eq ND&NEq ND&NEq D&Eq Eq Eq ND&NEq Eq 
New Orleans D&Eq D&Eq D&Eq Eq D&Eq D&Eq Eq Eq D D Eq 
Phoenix D&Eq D D D&Eq D ND&NEq D&Eq Eq Eq Eq D 
Portland Eq D&Eq D Eq D&Eq D&Eq D&Eq D&Eq D Eq D 
San Antonio Eq Eq ND&NEq Eq ND&NEq Eq ND&NEq D&Eq Eq D&Eq Eq 
San Jose D&Eq Eq D D&Eq ND&NEq Eq ND&NEq D&Eq D&Eq D&Eq Eq 
  D = Different; Eq = Equivalent; D&Eq = Different and Equivalent; ND&NEq = Not Different and Not Equivalent 
 
Table 5.4 Summary Table for the Distribution of Drug Use Values Across the Outcome Categories 
 Drug use Variables  
Outcome  MJ MJ72 EVERMJ COC COC72 EVERCOC CRK72 EVERCRK OP HER72 EVERHER Total 
D 0 1 0 3 1 2 1 1 3 0 2 14 
Eq 4 5 4 3 0 5 2 4 2 1 5 35 
D&Eq 5 3 5 2 2 2 2 3 3 4 1 32 
ND&NEq 0 0 0 1 6 0 4 1 1 4 1 18 
  D = Different; Eq = Equivalent; D&Eq = Different and Equivalent; ND&NEq = Not Different and Not Equivalent 
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Table 5.3. shows the classification for each drug use value and site. The drug use 
variables are ordered in their original way, that is, the first three variables are the urine 
test results, followed by the variables for self-reported drug use within the past 72 hours, 
and finally, the self-reported lifetime drug use. Table 5.4. shows the same data but 
summarized for each outcome category and drug use variable. Also, the drug use 
variables are ordered differently. The first three drugs are the variables for marijuana, 
followed by the variables for cocaine and finally opiates. This order makes patterns more 
obvious.  
The results show that there are indeed certain patterns with regard to the 
distribution of drug use values across the outcome categories. First, the marijuana 
variables fall almost exclusively into the two categories “Equivalent and Not Different” 
(Eq) and “Different but Equivalent” (D&Eq). Only one value (4%) for all marijuana 
variables shows substantial differences (D). This value is “Marijuana Used within the 
Past 72 Hours” in Indianapolis. None of the values for marijuana were classified as 
indeterminate. Thus, the drug use values for marijuana can be said to show no substantial 
differences for any site and overall for all sites combined. 
Figure 5.1. summarizes the distribution of the marijuana values across the 
outcome categories. For the purpose of simplification, the outcome categories were 
recoded to better reflect their meaning. The four original outcome categories were 
collapsed into three categories.    Specifically, the category “Statistically Different and 
Not Statistically Equivalent” was renamed into “Substantially Different.”  The outcome 
categories “Statistically Equivalent and Not Statistically Different” and “Statistically 
Different but Statistically Equivalent” were collapsed into “Not Substantially Different.” 
  133
Finally, the category “Not Statistically Different and Not Statistically Equivalent” was 
renamed “Indeterminate.”  Again, Figure 5.1. very clearly demonstrates that all but one 
variable show no substantial differences.  
Figure 5.1. Distribution of Marijuana Values Across the Outcome Categories 
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Second, for the drug use variables for cocaine use, the data displayed in Tables 
5.3. and 5.4. implies that the results are not as clear cut as for marijuana. The urine test 
results for cocaine (COC) show that three values were substantially different (Denver, 
Miami, and Phoenix), five values were not substantially different (Indianapolis, New 
Orleans, Portland, San Antonio, and San Jose), and one value could not be statistically 
determined (Dallas).  
For self-reported powder cocaine use within the past 72 hours (COC72), the 
analysis demonstrates that six values could not be statistically determined (Dallas, 
Denver, Indianapolis, Miami, San Antonio, and San Jose). Of the remaining three values, 
one value was substantially different (Phoenix) and two were not substantially different 
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(New Orleans and Portland).  
The pattern for self-reported crack cocaine use within the past 72 (CRK72) hours 
demonstrates that one value was substantially different (Denver), four values were not 
substantially different (New Orleans, Portland, San Antonio, and San Jose). Finally, four 
values were classified as indeterminate (Dallas, Indianapolis, Miami, and Phoenix).   
The outcomes for self-reported powder cocaine use over the lifetime (EVERCOC) 
suggest that two values were substantially different (New Orleans and Portland) and 
seven values were not substantially different (Dallas, Denver, Indianapolis, Miami, 
Phoenix, San Antonio, and San Jose). None of the values was indeterminate.  
Similarly, for self-reported crack cocaine use over the lifetime (EVERCRK), the 
distribution is as follows: one value was classified as substantially different (New 
Orleans), seven values did not show substantial differences (Dallas, Denver, Indianapolis, 
Phoenix, San Antonio, and San Jose), and one value was statistically indeterminate 
(Miami).  
Figure 5.2. summarizes the results for the drug estimates for cocaine. To reiterate, 
the following variables were included in this diagram: COC, COC72, CRK72, 
EVERCOC, and EVERCRK. Of the 45 values for cocaine, eight values (18%) fell into 
the category “Statistically Different and Not Statistically Equivalent;” 25 values (56%) 
were classified as either “Statistically Equivalent and Not Statistically Different” or 
“Statistically Different But Statistically Equivalent;” and 12 values (27%) were neither 
statistically different nor statistically equivalent. Even though the results for cocaine are 
not as clear as for marijuana, overall the conclusion would be that the drug use estimates 
are not substantially different because less than 20% of the drug estimates demonstrated 
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substantial differences. 
Figure 5.2. Distribution of Cocaine Values Across the Outcome Categories 
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 Third, Tables 5.3. and 5.4. also show the results for the opiate variables. The 
findings for the urine test results for opiates (OP) show that three values were classified 
as substantially different (Phoenix, Portland, and San Jose), five values did not show 
substantial differences (Dallas, Denver, Indianapolis, Phoenix, and Miami), and one 
value could not be assessed because it was not different and not equivalent (San 
Antonio).  
 The results for the values for heroin use within the past 72 hours (HER72) 
demonstrates that none of the values were substantially different, five values were 
classified as not substantially different (Denver, Miami, New Orleans, Phoenix, and 
Portland), and four values were statistically indeterminate (Dallas, Indianapolis, San 
Antonio, and San Jose).  
 With regard to lifetime heroin use (EVERHER), the analysis demonstrates that 
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two values were substantially different (Phoenix and Portland), six values did not show 
substantial differences (Denver, Indianapolis, Phoenix, Miami, San Antonio, and San 
Jose), and one value was statistically indeterminate (Dallas).    
Figure 5.3. summarizes the distribution of the values for opiates across the outcome 
categories. Of the 27 values, five values (19%) showed substantial differences, 16 values 
(59%) were not substantially different; and six values (22%) could not be statistically 
determined. Overall, the conclusion is that the drug use estimates for opiates are not 
substantially different because less than 20% of the values demonstrated substantial 
differences. After having discussed the overall results and the results for each drug 
category, the next section analyzes the findings for each site. 
 
Figure 5.3. Distribution of Opiate Values Across the Outcome Categories 
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Site-Specific Findings 
Dallas 
Table 5.5. presents the results of the equivalence analysis for Dallas. The findings 
demonstrate that none of the drug use variables fell into the category different, that is, 
none of them were statistically different and not statistically equivalent (D).  Further, 
three variables (27%) were not statistically different in the traditional test and statistically 
equivalent in the equivalence test, which means that they were classified as equivalent 
(E). These three variables were “Urine Test Result for Opiates,” ”Ever Used Powder 
Cocaine,” and “Ever Used Crack Cocaine.” The smaller equivalence z with the higher p-
values for these three variables is larger than 1.645, indicating that they are equivalent 
between DUF and ADAM. The z-values for the traditional test were not larger than 1.96, 
which means that they were not statistically different. The 90% confidence intervals of 
these three variables fall within the equivalence interval and include zero. For instance, 
the equivalence interval for “Ever Used Powder Cocaine” is ±.0648. The 90% confidence 
interval has a lower limit of -.040 and an upper limit of .028.  
Three drug use estimates (27%) were found to be statistically different and 
statistically equivalent (DE) and thus classified as different but equivalent. These 
variables were “Urine Test Result for Marijuana,” “Marijuana Used within the Past 72 
Hours,” and “Ever used Marijuana.” The z-values for the traditional test were greater 
than 1.96 and thus displayed a significant difference, but the smaller z-values for the 
smaller equivalence test were also greater than 1.645 indicating that the confidence 
intervals overlap with the equivalence interval. In fact, the smaller z-values for the 
equivalence test were also greater than 1.96 indicating significance at the .025 level.  
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The remaining five variables were statistically indeterminate because they were 
not statistically different and not statistically equivalent (NDNE). The traditional z was 
not larger than 1.96 and the smaller equivalence z-value was not larger than 1.645, 
indicating that neither test was significant and as a result neither of them can be rejected. 
The confidence limits of these variables were not contained within the equivalence 
interval. Rather they were partially inside and outside the equivalence margin. The six 
drug use estimates that were indeterminate were “Urine Test for Cocaine,” “Powder 
Cocaine Used within the Past 72 Hours,” “Crack Cocaine Used within the Past 72 
Hours,” “Heroin Used within the Past 72 Hours,” and “Ever Used Heroin.”  
Figure 5.4. summarizes the results for Dallas. Overall, six variables (55%) were 
not substantially different and five variables (45%) could not be classified because they 
were statistically indeterminate. In accordance with the decisions rules outlined in the 
previous chapter, this means that no conclusions can be drawn for Dallas because more 
than one third, that is, 45%, of the variables could not be statistically assessed.  
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Figure 5.4. Distribution of Variables across the Outcome Categories in Dallas 
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Table 5.5.: Equivalence Test DUF and ADAM in Dallas, TX 
 
 
ADAM 
2000/2001 
DUF 
1997/1998 Difference Equivalence Traditional 95% CI          Equivalence 90% CI  
Variable p1 n1 p2 n2 DIF. S.E.  Criterion z P LCL UCL z pa LCL UCL 
Urine Test                
    Marijuana 0.327 802 0.434 1547 -0.107 0.021 ±.0654 -5.141 
  
000† -0.148 -0.066 -1.999   .022* -0.141 -0.073 
    Cocaine 0.271 802 0.305 1547 -0.034 0.020 ±.0542 -1.737  .041 -0.072 0.004 1.032 .159 -0.066 -0.002 
    Opiates 0.042 802 0.035 1547 0.007 0.008 ±.0084 0.825  .203 -0.010 0.024 1.815   .035* -0.007 0.021 
Self-Report Drug Use                
    Within 72 Hours                
        Marijuana 0.227 802 0.326 1547 -0.099 0.019 ±.0454 -5.212 
  
000† -0.136 -0.062 -2.822   .002* -0.130 -0.068 
        Cocaine 0.059 802 0.060 1547 -0.001 0.010 ±.0118 -0.097  .461 -0.021 0.019 1.051 .159 -0.018 0.016 
        Crack 0.121 802 0.123 1547 -0.002 0.014 ±.0242 -0.141  .444 -0.030 0.026 1.561 .059 -0.025 0.021 
        Heroin 0.020 802 0.021 1547 -0.001 0.006 ±.0040 -0.163  .435 -0.130 0.011 0.488 .316 -0.011 0.009 
    Ever Used Drug                
        Marijuana 0.685 802 0.783 1547 -0.098 0.019 ±.1370 -5.035 
 
.000† -0.136 -0.060 2.004   .023* -0.130 -0.066 
        Cocaine 0.324 802 0.330 1547 -0.006 0.020 ±.0648 -0.294  .384 -0.046 0.034 2.883   .002* -0.040 0.028 
        Crack 0.264 802 0.270 1547 -0.006 0.019 ±.0528 -0.312  .378 -0.044 0.032 2.434   .008* -0.038 0.026 
        Heroin 0.094 802 0.101 1547 -0.007 0.013 ±.0188 -0.545  .293 -0.032 0.018 0.919 .181 -0.028 0.014 
Note: Dif. = difference p1-p2; S.E. = standard error; CI = confidence interval; LCL = Lower Confidence Limit; UCL = Upper Confidence Limit; aThe highest p value of the  
two one-sided tests has been reported; bThe equivalence interval was defined as ±20% of the baseline value (ADAM); †p ≤ .025 for traditional significance test two-tailed;  
*p ≤ .05 for equivalence test, one-tailed 
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Denver  
Table 5.6. shows the findings for Denver including the 95% confidence interval 
for the traditional null hypothesis test and 90% confidence limits for the equivalence test 
and how they fall with regard to the equivalence interval. For Denver about 18% (2) of 
the variables were substantially different. These two variables were “Crack Cocaine Used 
in the Past 72 Hours,” and “Urine Test Result for Cocaine.” For these two variables, the 
z-test for the traditional test was larger than 1.96 and as a result the p-value was smaller 
than .025 indicating that the difference was statistically significant for the traditional test. 
With regard to the equivalence test, the smaller z-values with the larger p-values were not 
larger than 1.645 and as a result the equivalence test was not significant. These 
equivalence 90% confidence intervals of these two variables were not contained in the 
equivalence intervals, supporting the finding that they are not equivalent for DUF and 
ADAM.  
Four (36%) of the variables displayed equivalence, that is, the smaller 
equivalence z with the higher p-value was greater than 1.645, indicating statistical 
equivalence, and the traditional z test was not statistically significant. The four variables 
that were found to be equivalent were “Urine Test Result for Marijuana,” “Urine Test 
Result for Opiates,” Marijuana Used in the Past 72 Hours,” and “Ever Used Heroin” As 
evident in Table 5.6, the 90% equivalence confidence intervals of these variables are 
contained within the equivalence interval and include zero.  
Four (36%) variables fell into the category different but equivalent. These four 
variables were “Heroin Used in the Past 72 Hours,” “Ever Used Marijuana,” “Ever Used 
Powder Cocaine,” and “Ever Used Crack Cocaine.” The traditional z test of these 
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variables implied a statistically significant difference, but the smaller equivalence z was 
also greater than 1.645. As described previously, this finding indicates that although there 
is a statistically significant difference this difference is not believed to be substantial, and 
as a result these drug use estimates can be treated as being comparable. 
The remaining variable “Powder Cocaine Used within the Past 72 Hours” was 
classified as not different and not equivalent. The status of this drug use value with regard 
to equivalence or a substantial difference could not be statistically determined because 
neither the traditional test nor the equivalence test was statistically significant. 
The results for Denver are summarized in Figure 5.5., showing the distribution of 
the variables across the outcome categories. Overall, two variables were substantially 
different, eight variables were not substantially different, and one value could not be 
determined. The findings show that less than 20% of the drug use values were 
substantially different, which implies that the drug use estimates from DUF and ADAM 
are not substantially different for the site of Denver. 
Figure 5.5. Distribution of Variables across the Outcome Categories in Denver  
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Table 5.6.: Equivalence Test DUF and ADAM in Denver, CO 
 
ADAM 
2000/2001 DUF 1997/1998 Difference Equivalence Traditional 95% CI           Equivalence 90% CI  
Variable p1 n1 p2 n2 DIF. S.E.  Criterion z p LCL UCL z p LCL UCL 
Urine Test               
    Marijuana 0.404 1319 0.413 1908 -0.009 0.018 ±.0808 -0.511 .305 -0.043 0.025 4.081  .000* -0.038 0.020 
    Cocaine 0.334 1319 0.399 1908 -0.065 0.017 ±.0668 -3.789   .000† -0.099 -0.031 0.105   .460 -0.093 -0.037 
    Opiates 0.046 1319 0.038 1908 0.008 0.007 ±.0092 1.105 .136 -0.006 0.022 2.375  .009* -0.004 0.020 
Self-Report Drug Use               
    Within 72 Hours              
        Marijuana 0.303 1319 0.291 1908 0.012 0.016 ±.0606 0.733 .232 -0.020 0.044 4.433  .000* -0.015 0.039 
        Cocaine 0.058 1319 0.073 1908 -0.015 0.009 ±.0116 -1.711 .044 -0.032 0.002 -0.388   .352 -0.029 -0.001 
        Crack 0.125 1319 0.152 1908 -0.027 0.012 ±.0250 -2.201   .014† -0.051 -0.003 -0.163   .436 -0.047 -0.007 
        Heroin 0.026 1319 0.003 1908 0.023 0.005 ±.0052 5.047   .000† 0.014 0.032 6.188  .000* 0.016 0.030 
     Ever Used Drug               
        Marijuana 0.761 1319 0.855 1908 -0.094 0.014 ±.1522 -6.600   .000† -0.122 -0.066 4.086  .000* -0.117 -0.071 
        Cocaine 0.440 1319 0.482 1908 -0.042 0.018 ±.0880 -2.356    009† -0.077 -0.007 2.581   006* -0.071 -0.013 
        Crack 0.356 1319 0.392 1908 -0.036 0.017 ±.0712 -2.083   019† -0.070 -0.002 2.037  .023* -0.064 -0.008 
        Heroin 0.152 1319 0.156 1908 -0.004 0.007 ±.0304 -0.310 .378 -0.029 0.021 2.045  .023* -0.025 0.017 
Note: Dif. = difference p1-p2; S.E. = standard error; CI = confidence interval; LCL = Lower Confidence Limit; UCL = Upper Confidence Limit; aThe highest p value of the  
two one-sided tests has been reported; bThe equivalence interval was defined as ±20% of the baseline value (ADAM); †p ≤ .025 for traditional significance test two-tailed;  
*p ≤ .05 for equivalence test, one-tailed 
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Indianapolis 
The results for Indianapolis, as presented in Table 5.7., demonstrate that one drug 
use value (9%) was substantially different. Specifically, the value for “Marijuana Used in 
the Past 72 Hours” was statistically different and not statistically equivalent. The 
traditional z was -2.194, which equals a p-value of .014 and the equivalence z was 1.293, 
which equals a p-value of .098. Thus, the variable was significant for the traditional test 
at the .025 level and not significant for the equivalence test.   
  Further, four (36%) drug use variables demonstrated statistical equivalence. For 
the variables “Urine Test Results for Cocaine,” “Ever Used Marijuana,” “Ever Used 
Powder Cocaine,” and “Ever Used Crack Cocaine,” the smaller equivalence z was greater 
than 1.645 and a traditional z that was smaller than 1.96. The 90% confidence interval of 
these four variables was completely contained within the equivalence interval and 
included zero.  
Additionally, three variables were different but equivalent, suggesting trivial 
differences only. These variables were “Urine Test Results for Marijuana,” “Urine Test 
Results for Opiates,” and “Ever Used Heroin.” The traditional z was greater than 1.96, 
implying a significant difference, but the equivalence z of these three variables was also 
greater than 1.645, suggesting equivalence in the sense that the 90% confidence interval 
was contained within the equivalence margin. The 90% confidence interval did not 
include zero, however.  
Finally, three variables (27%) were neither statistically different nor statistically 
equivalent. The 90% confidence interval for the variables “Powder Cocaine Used in the 
Past 72 Hours,” “Crack Cocaine Used in the Past 72 Hours,” and “Marijuana Used in the 
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Past 72 Hours” fell partially inside and outside the equivalence margin. The traditional z 
was smaller than 1.96, implying that they were not statistically different, and the 
equivalence z was smaller than 1.645, suggesting that they were not statistically 
equivalent either. 
Figure 5.6. displays the overall results for Indianapolis. The chart shows that 9% 
(1) of the variables were substantially different, 64% (7) of the variables were not 
substantially different, and 27% were statistically indeterminate. These findings support a 
conclusion of no substantial difference because less than 20% of the variables were 
substantially different.  
 
Figure 5.6. Distribution of Variables across the Outcome Categories in Indianapolis 
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Table 5.7.: Equivalence Test DUF and ADAM in Indianapolis, IN 
 
 
ADAM 
2000/2001 DUF 1997/1998 Difference Equivalence Traditional 95% CI          Equivalence 90% CI  
Variable p1 n1 p2 n2 DIF. S.E.  Criterion    z p LCL UCL     z p LCL UCL 
Urine Test               
    Marijuana 0.487 1362 0.443 1545 0.044 0.019 ±.0974 2.375  .009† 0.008 0.080 7.633 .000* 0.014 0.074 
    Cocaine 0.311 1362 0.325 1545 -0.014 0.017 ±.0622 -0.809   .209 -0.048 0.020 2.786  .002* -0.042 0.014 
    Opiates 0.051 1362 0.025 1545 0.026 0.007 ±.-0132 3.630   000† 0.012 0.040 5.054  .000* 0.014 0.038 
Self-Report Drug Use               
  Within 72 Hours              
        Marijuana 0.302 1362 0.340 1545 -0.038 0.017 ±.0604 -2.194   014† -0.072 -0.004 1.293  .098 -0.066 -0.010 
        Cocaine 0.030 1362 0.032 1545 -0.002 0.006 ±.0060 -0.311   .378 -0.015 0.011 0.622  .268 -0.013 0.009 
        Crack 0.096 1362 0.117 1545 -0.021 0.011 ±.0192 -1.838   .033 -0.043 0.001 -0.158  .440 -0.040 -0.002 
        Heroin 0.013 1362 0.012 1545 0.001 0.004 ±.0026 0.242   .405 -0.007 0.009 0.871  .192 -0.006 0.008 
  Ever Used Drug               
        Marijuana 0.811 1362 0.801 1545 0.010 0.015 ±.1622 0.681   .248 -0.019 0.039 11.725  .000* -0.014 0.034 
        Cocaine 0.318 1362 0.348 1545 -0.030 0.017 ±.0636 -1.715   .043 -0.064 0.004 1.920  .027* -0.059 -0.001 
        Crack 0.291 1362 0.316 1545 -0.025 0.017 ±.0582 -1.465   .071 -0.058 0.008 1.945  .026* -0.053 0.003 
        Heroin 0.066 1362 0.112 1545 -0.046 0.010 ±.0132 -4.393  .000† -0.067 -0.025 -3.133 .001* -0.063 -0.029 
Note: Dif. = difference p1-p2; S.E. = standard error; CI = confidence interval; LCL = Lower Confidence Limit; UCL = Upper Confidence Limit; a The highest p value of the two 
one-sided tests has been reported; bThe equivalence interval was defined as ±20% of the baseline value (ADAM); †p ≤ .025 for traditional significance test two-tailed; *p ≤ .05  
or equivalence test, one-tailed 
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Miami 
Table 5.8. shows the outcome of the equivalence analysis for Miami. One value 
(9%) (“Urine Test Result for Cocaine”) was substantially different because the traditional 
z-score was -3.509, which is significant at the .025 level, and the z-score for the 
equivalence test was -0.008, which is below 1.645 and therefore not statistically 
significant. The equivalence interval was ±.0898 and the 90% equivalence confidence 
interval was -.132 for the lower limit and -.048 for the upper limit. Thus, the 90% 
equivalence interval fell partially inside and outside the equivalence interval and did not 
include zero. 
Five variables (45%) were statistically equivalent and not different and therefore 
can be considered equivalent. These equivalent variables were “Urine Test Result for 
Marijuana,” “Marijuana Used in the Past 72 Hours,” “Ever Used Marijuana,” “Ever Used 
Cocaine,” and “Ever Used Heroin.” The traditional z for the five variables was below 
1.96 and as a result not significant and the equivalence z was above 1.645, indicating 
statistical equivalence. The 90% equivalence confidence interval for these variables was 
fully contained within the equivalence margin and included zero.  
Two variables (18%) fell into the category different but equivalent. These 
variables were “Urine Test Result for Opiates,” and “Heroin Used in the Past 72 Hours.” 
Both variables had traditional z-scores above 1.96, which suggests a significant 
difference. Their equivalence z-scores were, however, also above 1.645, implying that 
they were equivalent for DUF and ADAM. Thus, the differences, although statistically 
significant, are probably small. 
Finally, three variables (27%) could not be judged either way because they were 
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neither statistically different nor statistically equivalent. The variables classified into the 
indeterminate category were “Powder Cocaine Used in the Past 72 Hours,” “Crack 
Cocaine Used in the Past 72 Hours,” and “Ever Used Crack”. As shown in figure 5.7., 
only one value (9%) was substantially different and seven variables (64%) did not show 
substantial differences. Additionally, three variables (27%) had to be classified as 
indeterminate.  
 
Figure 5.7. Distribution of Variables across the Outcome Categories in Miami 
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  Due to the finding that less than 20% of the drug use estimates were 
substantially different and less than one-third was statistically indeterminate, the overall 
conclusion for Miami is that the drug use estimates are not substantially different.  
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Table 5.8.: Equivalence Test DUF and ADAM in Miami, FL 
 
 
ADAM 
2000/2001 
DUF 
1997/1998 Difference Equivalence Traditional 95% CI Equivalence 90% CI 
Variable p1 n1 p2 n2 DIF. S.E.  Criterion    z p LCL UCL    z p LCL UCL 
Urine Test               
    Marijuana 0.353 535 0.308 1272 0.045 0.024 ±.0706 1.846 .033 -0.003 0.093 4.741 .000* 0.005 0.085 
    Cocaine 0.449 535 0.539 1272 -0.090 0.026 ±.0898 -3.509 .000† -0.140 -0.040 -0.008 .497 -0.132 -0.048 
    Opiates 0.047 535 0.022 1272 0.025 0.010 ±.0094 2.492 .006† 0.005 0.045 3.429 .000* 0.008 0.042 
Self-Report Drug Use               
 Within 72 Hours              
        Marijuana 0.221 535 0.223 1272 -0.002 0.021 ±.0442 -0.093 .463 -0.044 0.040 1.972 .024* -0.037 0.033 
        Cocaine 0.097 535 0.113 1272 -0.016 0.016 ±.0194 -1.027 .152 -0.047 0.015 0.218 .416 0.042 0.010 
        Crack 0.121 535 0.149 1272 -0.028 0.017 ±.0242 -1.621 .053 -0.062 0.006 -0.220 .413 0.056 0.000 
        Heroin 0.036 535 0.015 1272 0.021 0.009 ±.0072 2.401 .008† 0.004 0.038 3.225 .000* 0.007 0.035 
 Ever Used Drug               
        Marijuana 0.602 535 0.633 1272 -0.031 0.025 ±.1204 -1.235 .108 -0.080 0.018 3.560 .000* -0.072 0.010 
        Cocaine 0.370 535 0.384 1272 -0.014 0.025 ±.0740 -0.562 .287 -0.063 0.035 2.406 .008* -0.055 0.027 
        Crack 0.219 535 0.257 1272 -0.038 0.022 ±.0438 -1.735 .040 -0.080 0.004 0.268 .397 -0.074 -0.002 
        Heroin 0.090 535 0.076 1272 0.014 0.014 ±.0180 0.970 .166 -0.014 0.042 2.217 .014* -0.010 0.038 
Note: Dif. = difference p1-p2; S.E. = standard error; CI = confidence interval; LCL = Lower Confidence Limit; UCL = Upper Confidence Limit; aThe highest p value of  
he two one-sided tests has been reported; bThe equivalence interval was defined as ±20% of the baseline value (ADAM); †p ≤ .025 for traditional significance test two-tailed; 
*p ≤ .05 for equivalence test, one-tailed 
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New Orleans 
Table 5.9. displays the findings for New Orleans. The drug use estimates for 
“Ever Used Powder Cocaine” and “Ever Used Crack Cocaine” were categorized as 
different. The 90% equivalence confidence interval for both variables fell partially inside 
and partially outside the equivalence interval and did not include zero. Specifically, the 
equivalence interval for “Ever Used Powder Cocaine” was ±.0558. The lower limit of the 
90% equivalence confidence interval was -.090 and the upper limit was -.036. Similarly, 
the equivalence interval for “Ever Used Crack Cocaine” was ±.0512. The lower limit of 
the 90% equivalence confidence interval was -.083 and the upper limit was -.029. Also, 
the traditional z-value for “Ever Used Powder Cocaine” was -3.781 and for “Ever Used 
Crack Cocaine” was -3.449, which is associated with a significant p-value of .000 for 
both variables. The smaller equivalence z-value for the two variables was below 1.645, 
indicating that there is no equivalence. Thus, these two variables were classified as 
substantially different.  
Four variables (36%) demonstrated equivalence for DUF and ADAM, that is, the 
drug use estimates for ”Marijuana Used in the Past 72 Hours,” ”Heroin Used in the Past 
72 Hours,” “Ever Used Marijuana,“ and “Ever Used Heroin” were statistically equivalent 
and not statistically different. The 90% equivalence confidence interval of these variables 
fell within the equivalence margin and included zero. Also, the traditional z-value was 
below 1.96, suggesting that no statistically significant differences existed between the 
drug use estimates for DUF and ADAM and the equivalence z-value was greater than 
1.645, indicating that the drug use estimates were statistically equivalent. 
Additionally, five drug use variables (45%) showed trivial differences only 
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because they fell into the category different but equivalent.  These five variables were 
“Urine Test Results for Marijuana,”  “Urine Test Results for Cocaine,” “Urine Test 
Results for Opiates,” “Powder Cocaine Used in the Past 72 Hours,” and “Crack Cocaine 
Used in the Past 72 Hours.”  The traditional z-value for these variables was above 1.96, 
indicative of a statistically significant difference. At the same time, the smaller 
equivalence z was also statistically significant demonstrating that the drug use estimates 
of these five variables were equivalent for DUF and ADAM. Accordingly, the five 
variables were classified as not substantially different. 
All of the drug use variables were classified as either substantially different, 
equivalent, or equivalent but different. Figure 5.8. shows the distribution of the drug use 
estimates across the outcomes categories. About 18% of the drug use estimates were 
substantially different, and 82% were classified as not substantially different. Based on 
these results, the overall finding for New Orleans is that there is no substantial difference 
between the drug estimates for DUF and ADAM because less than 20% of the drug use 
variables demonstrated substantial differences. 
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Figure 5.8. Distribution of Variables Across the Outcome Categories in New 
Orleans 
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Table 5.9.: Equivalence Test DUF and ADAM in New Orleans, LA 
 
 
ADAM 
2000/2001 
DUF 
1997/1998 Difference Equivalence Traditional 95% CI Equivalence 90% CI 
Variable p1 n1 p2 n2 DIF. S.E.  Criterion    z p LCL UCL    z p LCL UCL 
Urine Test               
    Marijuana 0.454 1236 0.382 1959 0.072 0.018 ±.0908 4.018 .000† 0.037 0.107 9.086 .000* 0.043 0.101 
    Cocaine 0.350 1236 0.457 1959 -0.107 0.018 ±.0700 -6.070 .000† -0.142 -0.072 -2.099 .018* -0.136 -0.078 
    Opiates 0.151 1236 0.118 1959 0.033 0.013 ±.0302 2.635 .004† 0.008 0.058 5.046  .000* 0.012 0.054 
Self-Report Drug Use               
 Within 72 Hours              
        Marijuana 0.350 1236 0.331 1959 0.019 0.017 ±.0700 1.102 .136 -0.015 0.053 5.163  .000* -0.009 0.047 
        Cocaine 0.057 1236 0.085 1959 -0.028 0.009 ±.0114 -3.070 .001† -0.046 -0.010 -1.820  .034* -0.043 -0.013 
        Crack 0.121 1236 0.173 1959 -0.052 0.013 ±.0242 -4.123 .000† -0.077 -0.027 -2.204  .014* -0.073 -0.031 
        Heroin 0.112 1236 0.092 1959 0.020 0.011 ±.0224 1.803 .036 -0.002 0.042 3.821  .000* 0.002 0.038 
Ever Used Drug               
        Marijuana 0.758 1236 0.773 1959 -0.015 0.015 ±.1516 -0.972 .166 -0.045 0.015 8.855  .000* -0.040 0.010 
        Cocaine 0.279 1236 0.342 1959 -0.063 0.017 ±.0558 -3.781 .000† -0.096 -0.030 -0.432  .333 -0.090 -0.036 
        Crack 0.256 1236 0.312 1959 -0.056 0.016 ±.0512 -3.449 .000† -0.088 -0.024 -0.296  .394 -0.083 -0.029 
        Heroin 0.206 1236 0.208 1959 -0.002 0.015 ±.0412 -0.136 .444 -0.031 0.027 2.665  .004* -0.026 0.022 
Note: Dif. = difference p1-p2; S.E. = standard error; CI = confidence interval; LCL = Lower Confidence Limit; UCL = Upper Confidence Limit; aThe highest p value of  
the two one-sided tests has been reported; bThe equivalence interval was defined as ±20% of the baseline value (ADAM); †p ≤ .025 for traditional significance test two-tailed;  
*p ≤ .05 for equivalence test, one-tailed 
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Phoenix 
The results for Phoenix, as presented in Table 5.10., are somewhat different than 
the patterns of the previous five sites. The main difference is that Phoenix has the largest 
amount of drug use estimates that are substantially different. Specifically, in Phoenix four 
variables (36%) fell into the category statistically different and not statistically 
equivalent. These were “Urine Test Result for Cocaine,” and “Urine Test Result for 
Opiates,” “Cocaine Used in the Past 72 Hours,” and “Ever Used Heroin.” The traditional 
z-values for these drug estimates were greater 1.96 and as a result significant at the .025 
level. Also, the smaller equivalence z-values were not significant, suggesting that 
equivalence does not exist. The 90% equivalence confidence intervals for these four 
variables were not contained within the equivalence margin. Rather, they were partially 
inside and partially outside the margin and did not include zero.  
Three drug use variables (27%) fell into the category statistically equivalent and 
not statistically different and were classified as equivalent. These three variables were 
“Ever Used Marijuana,” “Ever Used Powder Cocaine,” and “Ever Used Crack Cocaine.” 
The 90% equivalence confidence intervals for all three variables fell completely inside 
the equivalence margin, and the equivalence z-values were statistically significant, 
indicating equivalence. Finally, the traditional z-values were not significant, suggesting 
that no statistically significant differences existed.  
Another three drug use variables—“Urine Test Result for Marijuana,” “Marijuana 
Used in the Past 72 Hours,” and “Heroin Used in the Past 72 Hours” —fell into the 
category different but equivalent. These three variables showed statistically significant 
differences but they were also statistically equivalent and thus categorized as not 
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substantially different. 
One drug use estimate (“Crack Cocaine Used in the Past 72 Hours”) was 
classified as indeterminate because the drug use variables for DUF and ADAM were not 
statistically different and not statistically equivalent. The 90% equivalence confidence 
interval for this value fell partially inside and partially outside the equivalence margin 
and did not contain zero. The equivalence margin was ±.0252. The lower limit of the 
confidence interval was -.038 and the upper limit was -.002.  
Figure 5.9. summarizes the results for Phoenix. These findings suggest that there 
is some evidence for substantial differences between the drug estimates for DUF and 
ADAM. Specifically, 36% of the drug use estimates indicated substantial differences. 
Only about 55% of the drug use estimates showed no substantial differences and one 
variable could not be assessed. In accordance with the decision rules outlined earlier the 
results for Phoenix are interpreted as substantially different because more than 20% of 
the drug use estimates were classified as different. 
Figure 5.9. Distribution of Variables across the Outcome Categories in Phoenix 
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Table 5.10.: Equivalence Test DUF and ADAM in Phoenix, AZ 
 
 
ADAM 
2000/2001 
DUF 
1997/1998 Difference Equivalence Traditional 95% CI Equivalence 90% CI 
Variable p1 n1 p2 n2 DIF. S.E.  Criterion   z p LCL UCL    z p LCL UCL 
Urine Test               
    Marijuana 0.359 2850 0.311 1611 0.048 0.015 ±.0718 3.283   .000† 0.019 0.077 8.194  .000* 0.024 0.072 
    Cocaine 0.276 2850 0.318 1611 -0.042 0.014 ±.0552 -2.935   .002† -0.070 -0.014 0.923   .179 -0.066 -0.018 
    Opiates 0.062 2850 0.079 1611 -0.017 0.008 ±.0124 -2.099   .018† -0.033 -0.001 -0.568   .285 -0.030 -0.004 
Self-Report Drug Use              
  Within 72 Hours              
        Marijuana 0.261 2850 0.220 1611 0.041 0.013 ±.0552 3.106   .000† 0.015 0.067 7.062  .000* 0.019 0.063 
        Cocaine 0.050 2850 0.066 1611 -0.016 0.007 ±.0100 -2.159   .015† -0.031 -0.001 -0.810   .209 -0.028 -0.004 
        Crack 0.126 2850 0.146 1611 -0.020 0.011 ±.0252 -1.857 .032 -0.041 0.001 0.483   .319 -0.038 -0.002 
        Heroin 0.045 2850 0.073 1611 -0.028 0.008 ±.0090 -3.706   .000† -0.043 -0.013 -2.515 .006* -0.040 -0.016 
  Ever Used Drug               
        Marijuana 0.807 2850 0.814 1611 -0.007 0.012 ±.1614 -0.574 .283 -0.031 0.017 12.665  .000* -0.027 0.013 
        Cocaine 0.508 2850 0.498 1611 0.010 0.016 ±.1016 0.642 .261 -0.021 0.041 7.161   000* -0.016 0.036 
        Crack 0.395 2850 0.416 1611 -0.021 0.015 ±.0790 -1.371 .085 -0.051 0.009 3.786  .000* -0.046 0.004 
        Heroin 0.175 2850 0.219 1611 -0.044 0.013 ±.0350 -3.514   .000† -0.069 -0.019 -0.719   .764 -0.065 -0.023 
Note: Dif. = difference p1-p2; S.E. = standard error; CI = confidence interval; LCL = Lower Confidence Limit; UCL = Upper Confidence Limit; aThe highest p value of the  
two one-sided tests has been reported; bThe equivalence interval was defined as ±20% of the baseline value (ADAM); †p ≤ .025 for traditional significance test two-tailed;  
*p ≤ .05 for equivalence test, one-tailed 
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Portland 
The results for Portland, as presented in Table 5.11., demonstrate that three (27%) 
of the drug use variables were classified as different.  These variables were “Urine Test 
Results for Opiates,” “Ever Used Powder Cocaine,” and “Ever Used Heroin.” All three 
variables had traditional z-scores above 1.96, and smaller equivalence z-values fell below 
1.645. The 90% equivalence confidence interval of these variables was not contained 
within the equivalence margin and did not include zero.  
Also, three drug use variables (27%) fell into the category equivalent; including 
“Urine Test Results for Marijuana” “Marijuana Used Within the Past 72 Hours,” and 
“Ever Used Crack Cocaine.” For these three variables, the 90% equivalence confidence 
interval fell within the equivalence margin and included zero. The traditional z was not 
statistically significant indicating that there was no significant difference, and the smaller 
equivalence z was statistically significant, suggesting that the drug use estimates for these 
variables were equivalent for DUF and ADAM.  
Additionally, five (45%) of the drug use estimates were different but equivalent. 
These estimates were “Urine Test Result for Cocaine,” “Powder Cocaine Used Within 
the Past 72 Hours,” “Crack Cocaine Used Within the Past 72 Hours,” “Heroin Used 
Within the Past 72 Hours,” and “Ever Used Marijuana.” For these variables the 
traditional z was statistically significant, indicating that there were significant differences 
for the drug estimates of DUF and ADAM. At the same time, the smaller equivalence z 
was statistically significant and the 90% equivalence confidence interval fell within the 
equivalence margin, suggesting that the differences between the drug estimates for DUF 
and ADAM were only slightly different. 
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None of the drug use variables were statistically indeterminate, that is, all 
variables were classified as either substantially different, equivalent, or equivalent but 
different. Figure 5.10. shows the findings for Portland. Overall, more than 20% of the 
drug use estimates are substantially different for DUF and ADAM and as a result the 
conclusions for Portland are that there are substantial differences.  
Figure 5.10. Distribution of Variables Across the Outcome Categories in Portland 
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Table 5.11.: Equivalence Test DUF and ADAM in Portland, OR 
 
 
ADAM 
2000/2001 
DUF 
1997/1998 Difference Equivalence Traditional 95% CI Equivalence 90% CI 
Variable p1 n1 p2 n2 DIF. S.E.  Criterion    z p LCL UCL    z p LCL UCL 
Urine Test               
    Marijuana 0.354 1295 0.375 1401 -0.021 0.019 ±.0708 -1.132  .129 -0.057 0.015 2.685 .000* -0.052 0.010 
    Cocaine 0.236 1295 0.327 1401 -0.091 0.017 ±.0472 -5.286  .000† -0.125 -0.057 -2.544 .005* -0.119 -0.063 
    Opiates 0.114 1295 0.148 1401 -0.034 0.013 ±.0228 -2.623  .004† -0.059 -0.009 -0.864 .194 -0.055 -0.013 
Self-Report Drug  
Use              
  Within 72 Hours              
        Marijuana 0.247 1295 0.248 1401 -0.001 0.017 ±.0494 -0.060  .476 -0.034 0.032 2.909 
    
.002* -0.028 0.026 
        Cocaine 0.050 1295 0.079 1401 -0.029 0.009 ±.0100 -3.081 .001† -0.047 -0.011 -2.018  .022* -0.044 -0.014 
        Crack 0.099 1295 0.140 1401 -0.041 0.012 ±.0198 -3.295 .000† -0.065 -0.017 -1.704 .044* -0.061 -0.021 
        Heroin 0.065 1295 0.110 1401 -0.045 0.011 ±.0130 -4.164 .000† -0.066 -0.024 -2.961  .002* -0.063 -0.027 
 Ever Used Drug               
        Marijuana 0.841 1295 0.874 1401 -0.033 0.013 ±.1682 -2.447 .007† -0.059 -0.007 10.025  .000* -0.055 -0.011 
        Cocaine 0.465 1295 0.541 1401 -0.076 0.019 ±.0930 -3.955 .000† -0.114 -0.038 0.885   .812 -0.108 -0.044 
        Crack 0.411 1295 0.445 1401 -0.034 0.019 ±.0822 -1.784  .037 -0.071 0.003 2.529  .006* -0.065 -0.003 
        Heroin 0.242 1295 0.310 1401 -0.068 0.017 ±.0484 -3.964 .000† -0.102 -0.034 -1.142 .127 -0.096 -0.040 
Note: Dif. = difference p1-p2; S.E. = standard error; CI = confidence interval; LCL = Lower Confidence Limit; UCL = Upper Confidence Limit; aThe highest p value of the  
two one-sided tests has been reported; bThe equivalence interval was defined as ±20% of the baseline value (ADAM); †p ≤ .025 for traditional significance test two-tailed;  
*p ≤ .05 for equivalence test, one-tailed 
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San Antonio 
The results for San Antonio are shown in Table 5.12. None of the drug use 
variables imply a substantial difference, that is, none of them were statistically different 
and not statistically equivalent. Six variables (55%) were classified as equivalent because 
the smaller equivalence z-values of these drug estimates were statistically significant, 
indicating that they were equivalent for DUF and ADAM. Contrary, the traditional z-
values were not statistically significant, providing evidence that there were no significant 
differences for these drug estimates for DUF and ADAM.  These variables were the drug 
use estimates for “Urine Test Result for Marijuana,” “Urine Test Result for Cocaine,” 
“Marijuana Used in the Past 72 Hours,” “Crack Cocaine Used in the Past 72 Hours,” 
“Ever Used Marijuana,” and “Ever Used Heroin.” The 90% equivalence confidence 
interval for these six variables was completely contained within the equivalence margin 
and included zero. 
Two variables (18%) fell into the category different but equivalent. This category 
included the variables “Ever Used Marijuana” and “Ever Used Crack Cocaine.” The 
traditional z-value for these two variables showed a statistically significant difference 
between the drug estimates but the smaller equivalence z was also statistically significant, 
indicating that the difference was not substantial. The 90% equivalence confidence 
interval for these two variables fell completely within the equivalence margin but did not 
include zero. 
Finally, three variables (27%) fell into the category not different and not 
equivalent, and as a result were classified as statistically indeterminate. These variables 
were “Urine Test Analysis for Opiates,” “Powder Cocaine Used in the Past 72 Hours,” 
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and “Heroin Used in the Past 72 Hours.”  
Figure 5.11. displays the summary results for San Antonio. These results indicate 
that 73% of the drug use estimates were not substantially different for DUF and ADAM 
and that none of drug use estimates suggested substantial differences. Three variables 
could not be judged either way. Overall, the results can be said to be not substantially 
different. 
 
Figure 5.11. Distribution of Variables Across the Outcome Categories in San 
Antonio 
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Table 5.12.: Equivalence Test DUF and ADAM in San Antonio, TX 
 
 
ADAM 
2000/2001 
DUF 
1997/1998 Difference Equivalence Traditional 95% CI Equivalence 90% CI 
Variable p1 n1 p2 n2 DIF. S.E.  Criterion z p LCL UCL z p LCL UCL 
Urine Test               
    Marijuana 0.365 1122 0.377 1840 -0.012 0.018 ±.0730 -0.656 .256 -0.048 0.024 3.337 .000* -0.042 0.018 
    Cocaine 0.253 1122 0.266 1840 -0.013 0.017 ±.0506 -0.785 .216 -0.045 0.019 2.269   .011* -0.040 0.014 
    Opiates 0.091 1122 0.099 1840 -0.008 0.011 ±.0182 -0.724 .235 -0.030 0.014 0.923   .179 -0.026 0.010 
Self-Report Drug Use              
  Within 72 Hours              
        Marijuana 0.263 1122 0.250 1840 0.013 0.017 ±.0526 0.784 .218 -0.019 0.045 3.958   .000* -0.014 0.040 
        Cocaine 0.085 1122 0.089 1840 -0.004 0.011 ±.0170 -0.376 .353 -0.025 0.017 1.221   .111 -0.022 0.014 
        Crack 0.033 1122 0.028 1840 0.005 0.007 ±.0066 0.760 .224 -0.008 0.018 1.764   .039* -0.006 0.016 
        Heroin 0.058 1122 0.051 1840 0.007 0.009 ±.0116 0.808 .212 -0.010 0.024 2.148   .016 -0.007 0.021 
  Ever Used Drug               
        Marijuana 0.700 1122 0.639 1840 0.061 0.018 ±.1400 3.450 .000† 0.026 0.096 11.370   .000* 0.032 0.090 
        Cocaine 0.356 1122 0.323 1840 0.033 0.018 ±.0712 1.836  .034 -0.002 0.068 5.796   .000* 0.003 0.063 
        Crack 0.148 1122 0.122 1840 0.026 0.013 ±.0296 1.991 
 
.023† 0.000 0.052 4.257   .000* 0.005 0.047 
        Heroin 0.135 1122 0.136 1840 -0.001 0.013 ±.0270 -0.077  .469 -0.026 0.024 2.006   .023* -0.022 0.020 
Note: Dif. = difference p1-p2; S.E. = standard error; CI = confidence interval; LCL = Lower Confidence Limit; UCL = Upper Confidence Limit; aThe highest p value of  
the two one-sided tests has been reported; bThe equivalence interval was defined as ±20% of the baseline value (ADAM); †p ≤ .025 for traditional significance test two-tailed; 
*p ≤ .05 for equivalence test, one-tailed 
  163
San Jose 
Finally, the results for San Jose are shown in Table 5.13. Only one variable (9%) 
proved to be different (“Urine Test Result for Opiates”). The traditional z-value showed a 
statistically significant difference for the drug estimates for DUF and ADAM. The 
smaller equivalence z-value fell below 1.645, indicating that equivalence did not exist. 
The equivalence margin for this variable was ±.0070, and the 90% equivalence 
confidence interval was -.030 for the lower limit and -.004 for the upper limit. That 
shows that the confidence interval falls partially inside and outside the equivalence 
margin and does not include zero.  
Three variables (27%) fell into the category equivalent, including “Urine Test 
Result for Cocaine,” “Crack Used within the Past 72 Hours,” and “Ever Used Heroin.” 
The traditional z-value did not demonstrate a statistically significant difference and the 
smaller equivalence z-value did suggest that there is equivalence between the drug 
estimates. The 90% equivalence confidence interval fell fully within the equivalence 
margin for these drug estimates and included zero.  
Additionally, five variables (45%) were categorized as statistically different and 
equivalent, suggesting the presence of only trivial differences. These five variables 
included “Urine Test Result for Marijuana,” “Marijuana Used within the Past 72 Hours,” 
“Ever Used Marijuana,” “Ever Used Powder Cocaine,” and “Ever Used Crack Cocaine.” 
These five variables showed statistically significant differences but they also showed 
statistically significant equivalence.   
Two variables (18%) could not be statistically determined. They were neither 
statistically different nor equivalent. These two variables were “Cocaine Used in the Past 
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72 Hours” and “Heroin Used in the Past 72 Hours.” The 90% confidence interval for 
these two variables fell partially inside and partially outside the equivalence margin but 
included zero. 
Figure 5.12. summarizes the results for San Jose. Overall, 71% of the variables 
demonstrated no substantial differences. Only one variable was substantially different 
and two variables could not be statistically assessed. Consistent with the decision criteria 
the site of San Jose can be said to have drug estimates for DUF and ADAM that are not 
substantially different.  
 Figure 5.12. Distribution of Variables Across the Outcome Categories in San Jose 
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Table 5.13.: Equivalence Test DUF and ADAM in San Jose, CA 
 
 
ADAM 
2000/2001 
DUF 
1997/1998 Difference Equivalence Traditional 95% CI Equivalence 90% CI 
Variable p1 n1 p2 n2 DIF. S.E.  Criterion z p LCL UCL z p LCL UCL 
Urine Test               
    Marijuana 0.351 1248 0.275 1319 0.076 0.018 ±.0702 4.160    .000† 0.040 0.112 8.003    .000* 0.046 0.106 
    Cocaine 0.120 1248 0.118 1319 0.002 0.013 ±.0240 0.156  .440 -0.023 0.027 2.033    .023* -0.019 0.023 
    Opiates 0.035 1248 0.052 1319 -0.017 0.008 ±.0070 -2.118    .017† -0.033 -0.001 -1.246 .106 -0.030 -0.004 
Self-Report Drug Use              
  Within 72 Hours              
        Marijuana 0.263 1248 0.189 1319 0.074 0.016 ±.0526 4.491    .000† 0.042 0.106 7.683   .000* 0.047 0.101 
        Cocaine 0.032 1248 0.040 1319 -0.008 0.007 ±.0064 -1.089 .138 -0.022 0.006 -0.218 .414 -0.020 0.004 
        Crack 0.042 1248 0.034 1319 0.008 0.008 ±.0084 1.058 .159 -0.007 0.023 2.170    .015* -0.004 0.020 
        Heroin 0.018 1248 0.028 1319 -0.010 0.006 ±.0036 -1.695 .045 -0.022 0.002 -1.085 .139 -0.020 0.000 
 Ever Used Drug               
        Marijuana 0.714 1248 0.670 1319 0.044 0.018 ±.1428 2.418    .008† 0.008 0.080 10.264    .000* 0.014 0.074 
        Cocaine 0.443 1248 0.379 1319 0.064 0.019 ±.0886 3.300    .000† 0.026 0.102 7.868    .000* 0.032 0.096 
        Crack 0.276 1248 0.207 1319 0.069 0.017 ±.0552 4.090    .000† 0.036 0.102 7.363    .000* 0.041 0.097 
        Heroin 0.118 1248 0.107 1319 0.011 0.012 ±.0236 0.881 .189 -0.013 0.035 2.772    .003* -0.010 0.032 
Note: Dif. = difference p1-p2; S.E. = standard error; CI = confidence interval; LCL = Lower Confidence Limit; UCL = Upper Confidence Limit; aThe highest p value of the  
two one-sided tests has been reported; bThe equivalence interval was defined as ±20% of the baseline value (ADAM); †p ≤ .025 for traditional significance test two-tailed;  
*p ≤ .05 for equivalence test, one-tailed 
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The Impact of Different Alpha Levels and the Inclusion/Exclusion of Indeterminate 
Values 
Table 5.14 shows that changes in the outcomes due to using different alpha levels 
and manipulating the inclusion and exclusion of the values found to be statistically 
indeterminate. The data shows that these manipulations can make a difference with 
regard to the findings. The analysis of all possible combinations is beyond the scope of 
this dissertation, and as a result, only four possibilities will be discussed. These four 
possibilities are shown in Table 5. Column one shows the results for the original analysis 
using a .05 alpha level for the traditional null hypothesis test and including the values that 
were statistically indeterminate in the analysis. Column two presents the findings if the 
indeterminate values would have been excluded from the calculation. The alpha level was 
kept at .05 to determine changes only due to the exclusion of certain values. Column 
three shows the results if a .01 alpha level would have been used instead of a .05 level. 
The indeterminate values were included in the analysis (as in the original analysis) to 
determine changes due solely to the more conservative alpha level. Column four 
illustrates the findings for a change in the alpha level to .01 and the exclusion of 
indeterminate values.  
With regard to the indeterminate values, it could be argued that the results of the 
analysis might be different if the values that were indeterminate would be excluded. For 
instance, assume that one site had two values that showed substantial differences, six 
values that were similar, and three values that could not be determined as either different 
or similar because neither the traditional nor the equivalence test were significant. In the 
original analyses the total number of values would be eleven. Out of these eleven values, 
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two values (18%) were substantially different, six values (55%) were similar, and three 
values (27%) were indeterminate. The conclusion would be that there are no substantial 
differences because less than 20% of the values demonstrated substantial differences.  
 This conclusion might be different if the three values that could not be statistically 
determined would be excluded; that is, the total number of values that can be evaluated is 
eight rather than eleven. For the current example this means that two out of eight values 
would be substantially different, which equals 25%; and six values are similar, which 
equals 75%. The conclusion would be that this site demonstrates substantial differences 
because more than 20% of the values demonstrated substantial differences. Thus, the 
question is whether the findings of the current study would be different if the 
indeterminate values would be excluded.  
Column two presents the results for this analysis. Column one is the reference 
category presenting the results from the original analysis. Column two suggests that 
excluding the indeterminate values would lead to differences in the results for two sites. 
In Dallas, the results would now indicate that there are no substantial differences. 
Specifically, in Dallas, none of the variables were categorized as substantially different, 
three variables were equivalent, three variables were different but equivalent, and five 
variables could not be statistically assessed. Thus, the new number of total variables 
would be six (11 – 5) and the conclusion would be that since no variable showed 
substantial differences the data for Dallas can be said to be similar and not substantially 
different. This is different from the original conclusion in that Dallas was categorized 
originally as indeterminate because more than one third of the values could not be 
statistically judged to be different or similar.  
  168
 The second site that would be categorized differently if the indeterminate values 
would be excluded is Denver. In Denver one variable was indeterminate, which results in 
a new total of variables. The new total would be 10 (11 – 1). In Denver two values were 
categorized as substantially different, which is exactly 20%. Thus, Denver could be said 
to show substantial differences across the DUF and ADAM data.  
 None of the remaining seven sites would have been categorized differently. This 
means that overall, if the indeterminate values would be excluded from the analysis, six 
sites would be said to be similar and three sites would be said to be substantially different 
(as shown in column two in Table 5).  The conclusions from the original analysis were 
that one site could not be categorized as either similar or different because too many 
values were indeterminate, two sites were substantially different, and six sites were 
similar.  
 With regard to the alpha level, it could be argued that the alpha-level used for the 
analysis should be .01 instead of .05 because the sample sizes (N) used in the current 
analysis are large. Due to the fact that N influences the outcome of the traditional 
significance test, it would be reasonable to use the smaller alpha level to reduce the Type 
I error. A Type I error leads us to reject the null hypothesis of “no difference” and 
conclude that there is a difference when in fact the null hypothesis of “no difference” is 
true. At the .05 level there is a 5% chance that the null hypothesis of “no difference” is 
correct given these data. Accordingly, at the .01 level there is a 1% chance that the null 
hypothesis of “no difference” is correct given these data. Thus, the .01 level is the more 
conservative level. The greater the sample size, the smaller or more conservative the 
alpha level should be in order to avoid a Type I Error.  
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If the alpha level is more conservative, however, the chances of making the Type 
II Error increase, that is, researchers will erroneously accept the null hypothesis of “no 
difference” when in fact there is a significant difference and the null hypothesis should be 
rejected. Researchers have to decide which alpha level is suited best for their data. For 
the current study, the sample sizes vary between 535 and 2,850 to ADAM and 1,272 to 
1,959 for DUF (as shown in Table 3.4 in Chapter Three). Thus, according to Cohen's 
Power Primer, an alpha level .01 could be used instead of the .05 level. Column Three in 
Table 5 presents the results for the analysis if an alpha level of .01 would have been used 
in the current analysis instead of .05 (as shown in Column One). Seven of the nine sites 
would have been classified into the same category at the .01 and the .05 alpha level. 
These seven sites are Dallas (“Unknown“), Denver (“Similar“), Miami (“Similar“), New 
Orleans (“Similar“), Portland (“Different“), San Antonio (“Similar“), and San Jose 
(“Similar“).  
Two sites would have been categorized differently. First, Indianapolis was 
originally classified as “Similar.” Using the .01 alpha level the results for Indianapolis 
would have changed and it would have been classified as “unknown.” Specifically, in 
Indianapolis, marijuana used within the last 72 hours was statistically different at the .05 
level but not at the .01 level. There was no statistical equivalence for this variable, and 
thus the variable was classified as indeterminate at the .01 level, increasing the number of 
indeterminate values to four, which is 36%. Thus, at the .01 alpha level, more than one 
third of the variables were statistically indeterminate and as a result Indianapolis cannot 
be said to be either different or similar. No judgment can be made for this site and it 
would be categorized as “unknown.”    
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Second, Phoenix would have been classified as “similar” at the .01 level whereas 
it was “different” at the .05 level. This change occurred because at the .05 level four 
variables were statistically different and not equivalent, and as a result more than 20% of 
the variables were different leading to a classification of substantially different. At the .01 
level, only two variables were statistically different and not equivalent, which is 18%, 
and as a result Indianapolis would have been categorized as “similar.”  
Finally, the question is what would happen if the variables that are statistically 
indeterminate would be excluded from the calculation and an alpha level .01 would be 
used instead of .05. Column four shows the findings for this analysis. Again, the 
reference category is Column one (original analysis). Comparing Column four and 
Column one shows that eight of the nine sides would have been categorized into the same 
category. Only one side (Dallas) would have been judged differently, that is Dallas would 
have been classified as “similar” instead of “unknown”.     
The results presented in Table 5 suggest that the classification for five sides 
(Miami, New Orleans, Portland, San Antonio, and San Jose) did not change regardless of 
the intervention. Stated differently, the findings for these five sides were the same in the 
original analysis, at the .01 level, and excluding the values that were indeterminate. This 
suggests that the results for these sites are very stable and the conclusions can be drawn 
with confidence.  
For four siTes, however, some changes took place when using a different alpha 
level and excluding the values that were indeterminate from the analysis. Dallas showed 
the most changes. In the original analysis (Column One) and at the .01 alpha level 
(Column Three) Dallas was categorized as “unknown.” This classification would have 
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changed if the indeterminate values would have been excluded (Column Two) and if the 
analysis would have employed a .01 alpha level and excluded the indeterminate values 
(Column Four). In this case Dallas would have been judged to be “similar.”  
The findings for Indianapolis would have changed from being “similar” to 
“unknown” if the .01 level would have been used with everything else being the same 
(Column Three). At all other conditions, Indianapolis was classified as “similar.” The site 
Phoenix would be classified as “different” under all conditions except when using the .01 
alpha level instead of .05 (Column Three). Denver was classified as “similar” in all 
circumstances except when the indeterminate variables were excluded from the analysis 
(Column Two), in which situation Denver would have been classified as “different.” 
Overall, it appears that the results of the current analysis are very consistent for 
some sites, but also show some differences across different conditions. The consistency 
of the findings is especially obvious in column four as compared to column one, where 
only one site (Dallas) would have been classified differently, as “similar” rather than 
“unknown,” if both changes (using a .01 alpha level and excluding indeterminate values) 
would have been made. This would strengthen the conclusion that the drug estimates 
contained in the DUF and ADAM data are similar. Further, the data suggests that the 
drug use estimates contained in the DUF and ADAM data show no differences for five 
sites regardless of the intervention. These sites are Miami, New Orleans, Portland, San 
Jose, and San Antonio. There are, however, also some differences. Classification would 
have changed for four sites: Dallas, Denver, Indianapolis, and Phoenix. There is no 
consistency with regard to the direction of change. The classification of Dallas and 
Indianapolis varied between “similar” and “unknown,” Denver and Phoenix varied 
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between “similar” and “different.” The implications of these changes will be discussed in 
the final chapter. 
Certainly, the changes of the alpha level and the inclusion and exclusion criteria 
of indeterminate values can be expected to lead to some changes in the findings, which is 
also true for the current study. Using a more conservative alpha level decreases the 
number of values that are statistically different in the traditional null hypothesis test, and 
as a result reducing the number of variables and sides categorized as substantially 
different. Excluding values that are statistically indeterminate lead to only one change, 
namely that Denver was classified as “different” rather than similar. A comprehensive 
analysis of all possible conditions and changes is beyond the scope of this study. These 
changes due to different conditions are, however, very important as they can lead to 
substantial differences in the results of empirical studies. Thus, future research should 
address how different alpha levels, inclusion and exclusion criteria and equivalence 
intervals influence study outcomes and inferences and possible policy implications made 
from these studies.  
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Table: 5.14 Differences in Outcomes by Using different Alpha Levels and Changes in the Inclusion and Exclusion Criteria 
 
 
 
 Original Indeterminate Excluded Alpha-Level .01 
Alpha-Level .01 & Indeterminate 
Excluded 
Site 
 
Different Similar Unknown 
 
Different Similar Unknown 
 
Different Similar Unknown  Different Similar Unknown  
Dallas   x  x    x  x   
Denver  x  x    x   x   
Indianapolis  x   x    x  x   
Miami  x   x   x   x   
New Orleans  x   x   x   x   
Phoenix x   x    x  x    
Portland x   x   x   x    
San Antonio  x   x   x   x   
San Jose  x   x   x   x   
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CHAPTER SIX 
DISCUSSION AND CONCLUSION 
 
 This Chapter provides a review of the study purpose, the results that emerged 
from the statistical analysis, and the inferences that can be drawn. This is followed by a 
discussion of the implications and limitations of the current study.  This Chapter 
concludes by conferring the contributions and possible extensions of this work and 
opportunities for future research in this area.  
Major Goal and Possible Outcomes of the Study 
The major goal of the current study is to assess whether the drug estimates for 
selected drugs are similar or different between DUF and ADAM. It was hypothesized that 
the drug use information in the two samples might not be substantially different for two 
main reasons: (1) both the probability sample of ADAM and the non-probability sample 
of DUF rely on volunteers; and (2) both DUF and ADAM were only able to sample 
arrestees who were held in the facility long enough, resulting in a sample of more serious 
offenders and offenders who did not have the financial means to post bail.  
The analysis included the following nine sites: Dallas, Denver, Indianapolis, 
Miami, New Orleans, Phoenix, Portland, San Antonio, and San Jose. These nine sites 
were chosen because they have the same catchment area for DUF and ADAM and 
sufficient data for each time period to allow for a meaningful comparison. The variables 
included in the analysis are the same for all sites. These variables are urine analysis 
results (positive/negative) for marijuana, cocaine, and opiates; self-reported drug use 
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within the last 72 hours for marijuana, powder cocaine, crack cocaine, heroin; and self-
reported drug use for the question whether the arrestee had ever used marijuana, powder 
cocaine, crack cocaine, or heroin.  
For the purpose of examining the research question, the current study employed 
equivalence analysis. Using equivalence analysis, it was determined that there existed 
four possible outcomes for the current study. These four possible outcomes were:  
1) DUF and ADAM can be said to be equivalent (Eq) 
2) DUF and ADAM are different (D) 
3) DUF and ADAM are different and equivalent (D&Eq) 
4) DUF and ADAM are not different and not equivalent (indeterminate) 
(ND&NEq) 
The interpretation of the results for each site and for the selected drugs was 
completed in accordance with the three decision criteria laid out in Chapter Four. These 
three decision criteria were: 
1) The findings of Equivalent (Eq) and Different but Equivalent (D&Eq) will be 
interpreted as not substantially different or similar. 
2) Sites will be classified as “unable to be assessed” if more than one third of the 
drug use values fall into the category “Not Statistically Different and Not 
Statistically Equivalent” (ND&NEq). 
3) Third, sites will be classified as substantially different if 20% or more of the 
drug use values show substantial differences (D). 
Analytical Strategy of the Current Study 
The current study uses a research strategy that is commonly used in medical 
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research: equivalence testing. Equivalence testing has also become more popular in other 
fields, however, because it is useful to assess the comparability of scales, groups, and 
other outcomes. The underlying idea is to test whether two outcomes can be said to be 
equivalent or whether they are substantially different. To reiterate, substantially different 
does not simply mean that there is a statistically significant difference using the 
traditional null hypothesis test but that the difference is of practical importance. For this 
type of analysis, two simultaneous tests are carried out: the traditional null hypothesis test 
and the equivalence test. A substantial difference can only be established if the traditional 
test is statistically significant and the equivalence test is not statistically significant. The 
results can be said to be equivalent if the equivalence test is statistically significant and 
the traditional test is not. A result of different but equivalent is typically interpreted as a 
lack of substantial differences and an indication that the two outcomes are comparable (as 
discussed in Chapter 4). Finally, it is possible that the result of the analysis show that 
neither the traditional test nor the equivalence test is statistically significant. In this case it 
cannot be statistically determined whether the results are different or equivalent. No 
conclusion can be drawn either way (Tryon, 2001). 
Equivalence testing is typically applied to test the comparability of the effect of 
different drugs or treatments (i.e., established drug versus alternative drug). The current 
study is different from clinical studies in that superiority of a certain treatment cannot be 
established. That, however, was not the goal of this study. Instead, the main purpose was 
to determine whether the percentage outcomes for 11 drug use variables are substantially 
different or whether they are similar.  
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Main Findings 
Overall Findings for All Sites  
Out of a total of 99 drug use values, 14 (14%) were found to be substantially 
different, 67 (68%) were classified as not substantially different or similar, and 18 (18%) 
values were deemed indeterminate because they were neither statistically different nor 
statistically equivalent. Thus, the overall analysis of all drug use values suggests that 
there are no substantial differences because less than 20% of the values were categorized 
as different.  
The site with the greatest number of values classified as equivalent and different 
but equivalent was New Orleans with nine values (82%), followed by Denver, Portland, 
San Antonio, and San Jose with eight values (73%). Seven values (64%) were classified 
as equivalent and different but equivalent in Indianapolis and Miami. Finally, in Phoenix 
and Dallas, six values fell into either of these categories. None of the sites had less than 
six values classified as equivalent and different but equivalent.   
Further, the analysis shows that each site has a certain pattern with regard to the 
distribution of the drug use estimates across the outcome categories. In Dallas and San 
Antonio, neither of the drug use values was substantially different. In Indianapolis, 
Miami, and San Jose, one of the 11 drug use values was substantially different, but it was 
not the same for the three sites. Rather, at each site a different value was categorized as 
substantially different. In Denver and New Orleans, two of the drug use values were 
classified as substantially different. Again, both sites had different drug use values that 
were classified as substantially different.  Portland had three drug use values that were 
substantially different, and Phoenix had four values that were classified as substantially 
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different. None of the sites had more than four values that fell into this category.  
With regard to the outcome category not different and not equivalent, the analysis 
demonstrates that only one site that had more than one-third of the drug use values 
categorized as indeterminate, which was Dallas with five values (45%). In Indianapolis, 
Miami, and San Antonio, three values (27%) could not be statistically assessed. In San 
Jose, two values (18%) fell into this category, and in Denver and Phoenix one value (9%) 
was classified as indeterminate. The remaining sites, New Orleans and Portland, had no 
values that were indeterminate. Following the examination of the distribution of drug use 
values overall, the next analysis step was to take a closer look at the specific drugs to 
determine whether there are patterns for each drug with regard to their outcomes.  
Overall Findings by Drug 
The overall results for each drug (marijuana, cocaine, and opiates) are that none 
was substantially different between DUF and ADAM. Specifically, all but one of the 
drug estimates for marijuana fell into the categories equivalent or different and 
equivalent. Thus, 26 of the 27 drug use estimates for marijuana use, including urine test 
results for marijuana, self-reported marijuana use within the past 72 hours, and self-
reported marijuana use over the lifetime were classified into the category no substantial 
difference. In accordance with the decision criteria, the drug use estimates more 
marijuana can be said to show no substantial differences between DUF and ADAM 
because less than 20% of the drug use estimates were significantly different and not 
equivalent.  
The drug use estimates for cocaine consisted of urine test results for cocaine, self-
reported powder cocaine use within the past 72 hours, self-reported crack cocaine use 
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within the past 72 hours, self-reported powder cocaine use over the lifetime, and self-
reported crack cocaine use over the lifetime. Altogether, the analysis included 45 drug 
use estimates for cocaine. Of those 45 values for cocaine, eight values (18%) fell into the 
category “Statistically Different and Not Statistically Equivalent;” 25 values (56%) were 
classified as either “Statistically Equivalent and Not Statistically Different” or 
“Statistically Different but Statistically Equivalent;” and 12 values (27%) were neither 
statistically different nor statistically equivalent. Less than 20% of the drug estimates 
demonstrated substantial differences, and as a result the drug use estimates for cocaine 
can also be said to show no substantial differences between DUF and ADAM. The results 
for cocaine were, however, not as clear cut as for marijuana. Specifically, the drug use 
estimates for cocaine demonstrate some differences, that is, one or more of the drug use 
values for cocaine were classified as substantial different in Denver, Miami, New 
Orleans, Phoenix, and Portland.  
With regard to opiates, the analysis included the following variables: urine test 
results for opiates, self-reported heroin use within the past 72 hours, and self-reported 
heroin use over the lifetime resulting in a total of 27 drug use values. Of these 27 values, 
five values (19%) showed substantial differences. Sixteen values (59%) were not 
substantially different; and six values (22%) could not be statistically determined. 
Overall, the conclusion is that the drug use estimates for opiates are not substantially 
different because less than 20% of the values demonstrated substantial differences. It is 
also apparent, however, that there are a few differences. Specifically, one or more of the 
opiate values was categorized as substantially different in Phoenix, Portland, and San 
Jose. 
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The question why there are differences for some sites and for cocaine and opiates 
but not for marijuana cannot be answered with the data currently available. This question 
is very problematic to assess given the nature of the issues that are being looked at in this 
study.  It is, however, an important question that should be explored in future research. 
There are some alternative techniques that could be used, such as Monte Carlo simulation 
and perhaps a Bayesian approach to this analytic problem.  
Simulation studies would permit some exploration of different scenario outcomes 
under alternative models of distribution of drug use patterns – for example, comparing an 
aggregate theoretical site derived from the current empirical data for both DUF and 
ADAM as a comparator. A Bayesian paradigm might also fit here. If one thinks of 
Bayesian approaches as being a technique for the assessment of informational utility it 
might be that coupling Bayesian analysis, perhaps with a proportional-reduction-of-error 
objective, would be a useful avenue. These types of alternative analysis methods will be 
discussed in more detail later in the discussion. After having assessed the overall findings 
for each drug, the next step in the analysis was to explore the specific findings for each 
site. 
Site Specific Findings 
Dallas was the only site that could not be judged either way because more than 
one third of the drug use values were not different and not equivalent and as a result were 
classified as indeterminate. The remaining eight sites had 27% or less of the variables 
that fell into this category. Of these eight sites, two demonstrated substantial differences, 
that is, in Phoenix and Portland more than 20% of the drug use values were statistically 
different and not equivalent. Specifically, in Phoenix four values (36%) demonstrated 
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substantial differences and in Portland three values (27%) were substantially different. At 
the sites of Denver, Indianapolis, Miami, New Orleans, San Antonio, and San Jose, less 
than 20% of the drug use values were classified as substantially different. The analysis 
suggests that the outcome is site specific, that is, each site has a specific pattern of how 
the specific drug use values are distributed over the outcome categories. In sum, Dallas 
could not be assessed; Phoenix and Portland were categorized as substantially different; 
and Denver, Indianapolis, Miami, New Orleans, San Antonio, and San Jose were 
categorized as not substantially different or similar.   
Discussion of the Findings 
The results of this study suggest that the overall results for all sites combined are 
not substantially different and that the outcomes for three drug categories are not 
substantially different. The site-specific analysis implies that two sites are substantially 
different, five sites are similar, and one site could not be judged either way. The majority 
of findings demonstrate that the drug use estimates in the DUF and ADAM data for the 
three major drugs are similar. There are, however, some differences, which will be 
discussed in more detail now. 
As described above, there are some variables that do show substantial differences. 
The variables that fell into the category different most often were “urine test results for 
cocaine,” “urine test results for opiates,” “ever used powder cocaine,” and “ever used 
heroin.” The variable “urine test results for cocaine” was substantially different for three 
sites: Miami, Phoenix, and Denver. For all three sites there was a substantial increase in 
the number of arrestees who tested positive.  Additionally, “ever used powder cocaine” 
was substantially different in New Orleans and Portland. The results are consistent in that 
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the data shows an increase in cocaine use from 1997/98 to 2000/01. The same is true for 
“ever used crack cocaine,” which demonstrated a substantial increase in New Orleans. 
These findings suggest that cocaine might have increased within that five-year period. 
Another variable that showed substantial differences at some sites was “urine test results 
for opiates.” Opiate use significantly increased between the DUF and ADAM data in 
Phoenix, Portland, and San Jose. Also, the variable “ever used heroin” substantially 
increased in Phoenix and Portland. The question of why there are differences for those 
three sites cannot be determined with the current data. There is also no other data 
currently available to researchers to explore this question. Future research should further 
explore data collection and analytic strategies that might allow for a better analysis of this 
question. This might be very difficult, however, because the DUF and ADAM data is 
historic data and cannot be altered at this point.  
Consistency of Findings 
Despite the differences apparent in the data the overall findings suggest that the 
drug estimates of DUF and ADAM are not substantially different. It is noteworthy that 
this finding supports what a study by NIJ found, that is, that although the charge 
distribution for arrestees of the DUF sample differed from the charge distribution of 
arrestees from the UCR, the drug use estimates derived from the DUF data were almost 
identical to the estimates for the UCR data (NIJ, 1990). The current findings are also 
consistent with the study from Anchorage, which suggested that the sample of females 
was representative of the female arrestee population despite the fact that the sample of 
females was a convenience sample (Myrstol and Langworthy, 2005).   
 
  183
Explaining the Results 
 One explanation for the results of this study, namely that DUF and ADAM are not 
substantially different, might be that both studies used volunteers and suffered from non-
response bias. This is not a problem for drug research alone but for research in general. 
As stated earlier, in the case of ADAM, the interview refusal rate for all sites combined 
was 17.5%. Additionally, of the individuals that did choose to participate in the interview 
(82.5%), 15.6% refused to provide a urine sample (NIJ, 2000). The DUF data shows that 
approximately 10% of the selected arrestees refused to interview. Of the arrestees that 
agreed to participate in the survey, about 20% refused to provide a urine sample (NIJ, 
1995). Non-respondents constitute a problem for a study if they are different from 
respondents in ways that bias the study outcome. Research suggests that non-respondents 
share certain characteristics (Sharp and Feldt, 1959; Hill, 1997). Similarly, volunteers 
also appear to share certain characteristics.  
Although researchers recognize non-response bias, it is rarely quantified. A 
number of studies that do attempt to quantify non-response bias suggest that non-
respondents differ from respondents in various ways. A number of researchers have 
found differential survey responses, meaning that some population types of the sample 
have significantly higher response rates than other population subgroups. For instance, 
Sharp and Feldt (1959) found that younger persons are significantly more likely to 
respond than older persons. Response rates decline with increasing age. Additionally, 
response rates varied considerably depending on the marital status. Widowed persons 
were the least likely to grant an interview (74%), followed by adults who had never been 
married (82%). Married adults with children had the highest response rate (93%).  
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The Oslo Health Study also assessed non-response patterns and found that a 
number of population sub-groups were significantly underrepresented. The 
underrepresented population subgroups were males, young persons, single/never married 
and divorced/separated persons, persons not born in Norway, persons with lower or 
unknown education level, persons with a low socio-economic status, and persons 
receiving disability benefits (Sogaard, et al., 2004). Additionally, Vivienne (2002) 
assessed differences between respondents and non-respondents in a survey about alcohol 
consumption and found that abstainers were overrepresented among the non-respondents, 
biasing the sample towards individuals who drink alcohol.   
Hill, et al. (1997) examined non-response bias in a lifestyle survey and found that 
respondents and non-respondents varied significantly with regard to current smoking, 
hazardous alcohol consumption, and lack of moderate or vigorous exercise. More 
specifically, non-respondents were significantly more likely to be current smokers. This 
finding was also confirmed by Bostram, et al. (1993), who studied smoking behavior in 
Sweden, and Smith and Nutbeam (1990). Contrary, respondents showed significantly 
higher hazardous alcohol consumption. This finding should caution researchers against 
believing that non-respondents are always engaging in more risky behavior and unhealthy 
lifestyles than respondents.      
Non-response is of concern especially if it is associated with the variable of 
interest (Oberski, 2008). For example, if the variable of interest is the prevalence of illicit 
drug abuse among school children and the majority of children who are using illicit drugs 
are either absent from school or refuse to participate in the interview, the researcher 
might draw the conclusion that illicit drug abuse among school children is very rare. If 
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the children who were absent and who refused would have truthfully reported their drug 
abuse, the researcher might have come to a different conclusion.   
With regard to DUF and ADAM, it is possible that the similar results of drug use 
estimates can be attributed to the fact that probability samples suffer from some of the 
same shortcomings as do non-probability samples, that is, the sample consists of 
volunteers. Arrestees who did not volunteer to participate in the DUF study might also 
have refused to complete the interview in the ADAM program. To date, there is very 
little research that assesses this question. To this author's knowledge, there is only one 
study from Anchorage that looked at demographic differences between respondents and 
non-respondents in the ADAM program. They found no differences for the male 
probability sample and the female convenience sample. Specifically, the female 
convenience sample was just as representative of the population of female arrestees as the 
male probability sample was of the population of male arrestees (Myrstol and 
Langworthy, 2005). This supports the results of the current study, which showed that 
both DUF and ADAM produced drug use estimates that were not substantially different 
despite the differences in the sampling design. Even though the current study only 
examined the drug use information it is likely that other information contained in DUF 
and ADAM is also not substantially different. This question should be explored in future 
studies. 
Implications of the Current Study 
The main implication of the current study and the two studies by NIJ and Myrstol 
and Langworthy (2005) is that the general assumption of researchers that a non-
probability sample produces estimates that are substantially different from a probability 
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sample is not necessarily correct. These three studies assessed only one program, DUF 
and ADAM, but the findings are remarkably similar and imply that researchers can use 
the drug use data from both studies and explore research questions that have not been 
assessed yet because the DUF data was said to be unreliable. This implication is 
strengthened by the fact that these three studies used different analytical strategies and 
sites and still arrived at similar conclusions. 
With regard to policy makers this would imply that the DUF and ADAM data 
would lead to similar conclusions about drug use prevalence and patterns a. Thus, if the 
main concern is the implementation of programs aiming to reduce drug use, the non-
probability sample DUF data would very likely be sufficient. Specifically, the DUF data 
as well as the ADAM data showed that some drugs are more popular than others across 
sites and that these differences were apparent in DUF and ADAM. It is likely that policy 
makers would have implemented the same programs regardless of whether they used 
DUF or ADAM. This is a crucial finding because budget restraints currently inhibit the 
collection of data from arrestees nationwide. Due to this lack of data and knowledge, 
necessary programs are not implemented and drug trends go undetected until they show 
up in the general population or until the problem has become epidemic.   
Limitations of the Current Study 
 First, one of the major limitations stems from the data itself, specifically, only 
nine sites could be examined because the majority of sites did not either have the same 
catchment area or had too few cases for the ADAM sample. The implication of this 
limitation is that the current study cannot make inferences about the similarity or 
dissimilarity of the DUF and ADAM data for all sites. This means that the results and 
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conclusions of this study are limited to the available sites. It is possible that the analyzed 
sites are dissimilar from the sites excluded from this analysis. It is also possible that the 
analyzed sites are not different than the sites not included. At this point this question 
cannot be answered.  
Second, for both DUF and ADAM, it is unknown whether the arrestees who 
volunteered to participate and who were in the facility long enough to be interviewed are 
representative of the arrestee population overall with regard to their drug use prevalence 
and patterns. This question is important and should be assessed in future research to 
determine whether arrestees who are available and volunteer to participate differ in their 
drug use habits from arrestees who are either not available or refuse participation. As 
described earlier, programs are implemented on the basis of what is known about drug 
use and these programs are only effective if the information they are based upon is 
accurate. Thus, future research should attempt to collect data from non-respondents and 
compare it to the individuals who participated in the study.  
Third, equivalence analysis has certain limitations in itself. First, researchers have 
to determine the equivalence margin. At this time there are no standard rules that are 
applied by all researchers using equivalence testing. Rather, it is a discretionary decision 
and as a result it is possible to manipulate the results of the study. For example, setting a 
higher equivalence margin with improve the chances of finding equivalent result. The 
opposite is true also; researchers looking for substantial differences might choose a very 
small equivalence margin (Gotzsche, 2006). Thus, researchers suggest that the 
equivalence margin should be determined based on scientific grounds, past research 
results, and clinical standards (LeHenann, 2006). These recommendations are fairly 
  188
vague and leave much room for discretion.  
For social scientists it is even more difficult to find an appropriate equivalence 
margin than for biomedical researchers. Equivalence is more difficult to assess when 
factors are not completely constant. Even though clinical research often assumes that a 
certain drug produces a constant outcome this might not necessarily be true (Gotzsche, 
2006). This is also true for the current study. The constancy of drug use over time cannot 
be assumed. As described above, some changes are to be expected due to the natural 
fluctuations in drug use prevalence and patterns. This has implications for the 
equivalence margin. For the current study, the equivalence margin was based on previous 
drug use research and what has been established as a substantial difference with regard to 
changes in drug use among arrestees. For researchers who are using this type of analysis 
it is important to find an equivalence margin that is appropriate for the research topic.  
Fourth, the current study found no substantial differences for the majority of 
variables for DUF and ADAM. Also, all of the findings appear to be in congruence with 
data from other drug survey. Still, it is possible that the differences found are due to the 
sampling method. Due to the limitations of probability samples, this possibility cannot 
definitely be excluded. Unfortunately, there is no dataset that could be examined against 
the DUF and ADAM data to determine the reason for these differences. The question 
about why some sites and drug use values are substantially different relates to another 
question. How can we determine the error associated with using the DUF and ADAM 
data combined and separately? The current study used a 20% margin, that is, if less than 
20% of the drug use values were substantially different then the data for this site was said 
to be similar enough to be considered equivalent. Using this margin, two sites (Phoenix 
  189
and Portland) were categorized as substantially different. Further, depending on the alpha 
level and the inclusion or exclusion of the indeterminate values the findings changed. 
These changes were discussed in detail earlier.  
These findings suggest that researchers can use the DUF data for their analysis. 
There is, however, a certain risk or error associated with doing so. The current analysis 
has shown that overall 14% of the drug use estimates were substantially different. Thus, 
if researchers would draw one of the tests at random assuming that they are using 
equivalent data, there would be a .14 probability that the data is not equivalent. This 
probability of using data that is believed to be equivalent when it is not differs depending 
on the drug and site. For marijuana, the probability would be 0 because none of the 
estimates were substantially different. For cocaine, the probability would be .18, and for 
opiates it would be .19. With regard to the ten sites, the probability would be .36 for 
Phoenix, .27 for Portland, .18 for Denver and New Orleans, .9 for Indianapolis, San Jose, 
and Miami, and .0 for Dallas and San Antonio.  
Final Remarks 
In spite of these limitations, however, the findings demonstrate that the drug use 
information collected via a non-probability sampling procedure in DUF are not 
substantially different than the drug use information collected via a probability sampling 
procedure in ADAM. As a result, this dissertation presents a contribution to researchers, 
especially drug use researchers using the DUF and ADAM data and researchers 
examining hard-to-access populations, policy makers, and law enforcement.  
The termination of the DUF and ADAM study and the reinstatement in 2006 by 
the ONDCP in only ten counties across the United States (now called ADAM II) has 
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robbed researchers of the ability to track drug using behaviors among arrestees and 
inform police agencies and policy makers of changes in drugs used by arrestees and 
prevalence of drug use across different geographic areas at the local level. The current 
study hopes to lay the groundwork for the implementation of a national study that 
systematically tracks drug use patterns among arrestees – similar to the NSDUH and the 
MTF. Considering the budget crisis, it is understood that this national study must be cost 
effective, yet provide valid data. One solution might be to supplement a probability 
sample with a convenience sample. 
In fact, some researchers have suggested that it might be possible to use a 
convenience sample to supplement a probability sample as a means of saving research 
money and to produce a sample with a smaller mean squared error than would be 
possible with the probability sample given cost and time restraints The bias in the 
convenience sample can be reduced, for example, by using the known population 
variables to calibrate the convenience sample (Kalton and Kasprzyk, 1986). This 
approach allows researchers to compute inferential statistics from the probability sample, 
including the calculation of confidence intervals, standard errors, and the 
representativeness of data with regard to the population of interest and draw a large 
enough sample that allows researchers to assess a variety of research questions.   
Considering the fact that the federal government spends $50 million to study drug 
abuse among the general population who use drugs rarely, it is reasonable to expect that 
the government also examines drug abuse among arrestees, who use drugs at much higher 
rates than the general population and school children. 
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Appendix A - Demographic Profile by Site 
 
 
Table A.1.: Dallas, TX 
 
                  DUF 97/98          ADAM 00/01   
Variable                N   %            N          %  
Race  
 Black              903     58.4           394     49.1 
 White   450     41.4           280     34.9 
 Hispanic   152       9.8           119     14.8 
 Other     14       0.9               9       1.1 
 Not obtained         28       1.8   
Employment       
 Full time              892     57.7           473     59.0 
 Part time   269     17.4             81     10.1 
 Unemployed    71       4.6           189     23.6 
 Other   305     19.7             58       7.2 
 Not obtained  197     12.7    1       0.1 
Highschool Graduate 
Yes              904     58.4           576     71.8 
Offense Category 
Violent Offense  448     29.0           156     19.5 
Property Offense  675     43.6           160     20.0 
Drug Offense  468     16.0           201     25.3 
Other Offense  234     15.1           283     35.2  
Age in years (mean)        30          30   
N       1,547      802 
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Table A.2.: Denver, CO 
 
                  DUF 97/98          ADAM 00/01   
Variable                N   %            N          %  
Race  
 Black              662     34.7           350     26.5 
 White   545     28.6           364     27.6 
 Hispanic              645     33.8           547     41.5 
 Other     42       2.2             57       4.3 
 Not obtained         14  0.7    1       0.1 
Employment        
 Full time              979     51.3           667     50.6 
 Part time   392     20.5           181     13.7 
 Unemployed  141       7.4           355     26.9 
 Other   382     20.0           116       8.8 
      Not obtained         14  0.7     
Highschool Graduate 
Yes           1,028     53.9           858     65.0 
Offense Category 
Violent Offense  524     27.5           313     23.7 
Property Offense  361     18.9           247     18.7 
Drug Offense  565     23.9           274     20.8 
Not obtained           2  0.1           485     36.8 
Age in years (mean)        32        32   
N        1,908     1,319 
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Table A.3.: Indianapolis, IN 
 
                  DUF 97/98          ADAM 00/01   
Variable                N   %            N          %  
Race  
 Black              884     57.2           771     56.6   
 White              586     37.9           577     42.4   
 Hispanic     64       4.1             11       0.8   
 Other       9       0.6               3       0.2   
 Not obtained           2       0.1                     
Employment 
 Full time              846     54.8           771     56.6   
 Part time   280     18.1           182     13.4    
 Unemployed  116       7.5           281     20.6   
 Other   277     17.9           120       8.8   
 Not obtained         26       1.7                    
Highschool Graduate 
Yes              824     53.3           848     62.3   
Offense Category 
Violent Offense  404     26.1           359     26.4   
Property Offense  372     24.1           291     21.4   
Drug Offense  326     21.1           339     24.9 
Other   443     28.7  17       1.2   
Age (mean)          31        31   
N        1,545    1,362 
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Table A.4.: Miami, FL 
 
                  DUF 97/98          ADAM 00/01   
Variable                N   %            N          %  
Race  
 Black              588     46.2           283     52.9   
 White   200     15.7           231     43.2 
 Hispanic   480     37.7             21       3.9 
 Other                           
 Not obtained           4       0.3     
Employment 
 Full time              627     49.3           296     55.3 
 Part time   257     20.2             65     12.1 
 Unemployed  118       9.3           134     25.0 
 Other   263     20.7             40       7.5 
 Not obtained                7        0.6 
Highschool Graduate 
Yes              512     40.3           359     67.1 
Offense Category 
Violent Offense  446     35.1           119     22.2 
Property Offense  296     23.3           129     24.1 
Drug Offense  404     31.8           123     23.0 
 Other   126       9.9           164     30.7 
Age in years (mean)         33        33   
N        1,272      535
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Table A.5.: New Orleans, LA 
 
                  DUF 97/98          ADAM 00/01   
Variable                N   %            N          %  
Race  
 Black           1,747     87.0        1,070     86.6   
 White   216     11.0           158     12.9   
 Hispanic     15       0.8               2       0.2   
 Other     12       0.6               4       0.3   
 Not obtained         12       0.6    2       0.2    
Employment 
 Full time              905     46.2           556     45.0   
 Part time   454     23.2           204     16.5   
 Unemployed      73       3.7           321     26.0   
 Other   503     25.7           155     12.5 
 Not obtained         24       1.2    
Highschool Graduate 
Yes              847     43.2           670     54.2   
Offense Category 
Violent Offense  628     32.1           176     14.2   
Property Offense  728     37.2           214     17.3   
Drug Offense  187       9.5                256     20.7   
Age in years (mean)         30                   30    
N        1,959    1,236 
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Table A.6.: Phoenix, AZ 
 
                  DUF 97/98          ADAM 00/01   
Variable                N   %            N          %  
Race  
 Black   221     13.7           340     11.9   
 White              790     49.0        1,585     55.6   
 Hispanic              520     32.3           730     25.6   
 Other     77       4.8           188       6.6   
 Not obtained      3       0.2               7       0.2 
Employment 
 Full time              953     59.2        1,597     56.0   
 Part time   210     13.0           313     11.0   
 Unemployed  106       6.6           674     23.6   
 Other   339     21.0           264       9.3   
 Not obtained      3       0.2               2       0.1 
Highschool Graduate 
Yes              956     59.3        1,914     67.2   
Offense Category 
Violent Offense  271     16.8           607     21.3   
Property Offense  414     25.7           625     21.9   
Drug Offense  317     19.7           703     24.7 
Other   609     37.8           914     32.1 
Age in years (mean)        31        31   
N       1,611    2,850 
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Table A.7.: Portland, OR 
 
                  DUF 97/98          ADAM 00/01   
Variable                N   %            N          %  
Race  
 Black   421     30.0          318     24.6   
 White              865     61.7          837     64.6   
 Hispanic     78       5.6            95       7.3   
 Other     35       2.5            41       3.2   
 Not obtained           2  0.1              4       0.3     
Employment 
 Full time   478     34.1          480     37.1   
 Part time   312     22.3          152     11.7   
 Unemployed    80       5.7          479     37.0   
 Other   527     37.6          184     14.2 
 Not obtained           4  0.3                
Highschool Graduate 
Yes              828     59.1          963     74.4   
Offense Category 
Violent Offense  217     15.5          269     20.8   
Property Offense  225     16.1          219     16.9   
Drug Offense  407     29.1          448     34.6 
Other                11       0.8 
Age in years (mean)        33       33    
N        1,401    1,295
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Table A.8.: San Antonio 
 
                  DUF 97/98          ADAM 00/01   
Variable                N   %            N          %  
Race  
 Black   203     11.3           142     12.7 
 White              606     32.9           396     35.3 
 Hispanic              995     54.1           577     51.4 
 Other       6       0.3               4       0.4 
 Not obtained         25       1.4    3       0.3 
Employment       
 Full time           1,043     56.7           691     61.6 
 Part time   306     16.6           119     10.6 
 Unemployed  216     11.7           207     18.4 
 Other   272     14.8           103       9.2 
 Not obtained      3       0.2    2       0.2 
Highschool Graduate 
Yes              874     47.5           685     61.1 
Offense Category 
Violent Offense  449     24.4           145     12.9 
Property Offense  453     24.6           150     13.4 
Drug Offense  281     15.3           198     17.6 
Other   657     35.7           627     55.9 
Not obtained       2       0.2 
Age in years (mean)        29        29   
N       1,840    1,122 
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Table A.9.: San Jose 
 
                  DUF 97/98          ADAM 00/01   
Variable                N   %            N          %  
Race  
 Black   147     11.1           149     11.9 
 White   424     32.1           379     30.4 
 Hispanic              568     43.1           574     46.0 
 Other   170     12.9           148     11.4 
 Not obtained         10       0.8           144     11.5 
Employment       
 Full time              739     56.0           743     59.5 
 Part time   206     15.6           121       9.7 
 Unemployed  158     12.0           317     24.5 
 Other   214     16.2           111       8.9 
 Not obtained      2       0.2 
Highschool Graduate 
Yes              657     49.8           969     77.6 
Offense Category 
Violent Offense  551     41.8           383     30.7 
Property Offense  338     25.6           197     15.8 
Drug Offense  168     12.7           427     34.2 
Other   338     25.6           239     19.2 
Not obtained      8       0.6    2       0.2  
Age in years (mean)         31        32   
N        1,319    1,248  
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Appendix B – Drug Use Frequencies by Year and Site 
 
 
Table B.1.: Dallas, TX 
 DUF ADAM  
 1997 1998 2000 2001  
Variable N % N % N % N %  
Urine Test          
    Marijuana 429 43.8 243 42.9 177 33.8 85 30.6  
    Cocaine 311 31.7 161 28.4 149 28.4 68 24.5  
    Opiates 42 4.3 12 2.1 21 4.0 13 4.7  
Self-Report Drug 
Use          
    Within 72 Hours          
        Marijuana 321 32.8 184 32.5 121 23.1 61 21.9  
        Cocaine 62 6.3 31 5.5 34 6.5 13 4.7  
        Crack 133 13.6 58 10.2 60 11.5 37 13.3  
        Heroin 24 2.4 9 1.6 12 2.3 4 1.4  
        PCP 8 0.8 5 0.9 5 1.0 0 0.0  
        Amphetamines 24 2.4 13 2.3 1 0.2 1 0.4  
        Barbiturates 6 0.6 3 0.5 1 0.2 0 0.0  
Ever Used Drug          
        Marijuana 794 81.0 418 73.7 369 70.4 180 64.7  
        Cocaine 334 34.1 176 31.0 172 32.8 88 31.7  
        Crack 271 27.7 146 25.7 144 27.5 68 24.5  
        Heroin 97 9.9 59 10.4 45 8.6 30 10.8  
        N 980 567 524 278  
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Table B.2.: Denver, CO 
 
 DUF ADAM  
 1997 1998 2000 2001  
Variable N % N % N % N %  
Urine Test          
    Marijuana 394 41.4 394 41.2 254 41.1 279 39.8  
    Cocaine 383 40.2 379 39.6 210 34.0 230 32.8  
    Opiates 34 3.6 38 4.0 23 3.7 38 5.4  
Self-Report Drug 
Use          
    Within 72 Hours          
        Marijuana 259 27.2 296 31.0 175 28.3 225 32.1  
        Cocaine 62 6.5 78 8.2 32 5.2 44 6.3  
        Crack 161 16.9 129 13.5 73 11.8 92 13.1  
        Heroin 26 2.7 32 3.3 14 2.3 20 2.9  
        PCP 0 0.0 0 0.0 0 0.0 0 0.0  
        Amphetamines 12 1.3 12 1.3 5 0.8 6 0.9  
        Barbiturates 4 0.4 4 0.4 5 0.8 1 0.1  
Ever Used Drug          
        Marijuana 814 85.5 818 85.6 478 77.3 526 75.0  
        Cocaine 465 48.8 454 47.5 258 41.7 323 46.1  
        Crack 382 40.1 366 38.3 218 35.3 252 35.9  
        Heroin 151 15.9 147 15.4 95 15.4 105 15.0  
        N 952 956 618 701  
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Table B.3.: Indianapolis 
 
 DUF ADAM  
 1997 1998 2000 2001  
Variable N % N % N % N %  
Urine Test          
    Marijuana 411 43.9 273 44.9 302 47.9 361 49.3  
    Cocaine 295 31.5 207 34.0 187 29.7 236 32.2  
    Opiates 28 3.0 11 1.8 23 3.7 46 6.3  
Self-Report Drug 
Use          
    Within 72 Hours          
        Marijuana 329 35.1 197 32.4 175 27.8 236 32.2  
        Cocaine 29 3.1 21 3.5 17 2.7 24 3.3  
        Crack 111 11.8 69 11.3 54 8.6 77 10.5  
        Heroin 16 1.7 3 0.5 4 0.6 14 1.9  
        PCP 1 0.1 1 0.2 1 0.2 1 0.1  
        Amphetamines 13 1.4 4 0.7 2 0.3 1 0.1  
        Barbiturates 16 1.7 15 2.5 2 0.3 1 0.1  
Ever Used Drug          
        Marijuana 747 79.7 491 80.8 507 80.5 597 81.6  
        Cocaine 325 34.7 212 34.9 198 31.4 235 32.1  
        Crack 299 31.9 189 31.1 162 25.7 234 32.0  
        Heroin 119 12.7 54 8.9 39 6.2 51 7.0  
        N 937 608 630 732  
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Table B.4..: Miami 
 
 DUF  ADAM   
 1997 1998 2000   
Variable N % N % N %   
Urine Test         
    Marijuana 270 31.6 122 29.2 189 35.3   
    Cocaine 388 45.4 198 47.4 240 44.9   
    Opiates 18 2.1 10 2.4 25 4.7   
Self-Report Drug 
Use         
    Within 72 Hours         
        Marijuana 192 22.5 92 22.0 118 22.1   
        Cocaine 100 11.7 44 10.5 52 9.7   
        Crack 124 14.5 65 15.6 65 12.1   
        Heroin 14 1.6 5 1.2 19 3.6   
        PCP 1 0.1 0 0.0 1 0.2   
        Amphetamines 0 0.0 0 0.0 1 0.2   
        Barbiturates 5 0.6 3 0.7 0 0.0   
Ever Used Drug         
        Marijuana 538 63.0 267 63.9 322 60.2   
        Cocaine 329 38.5 159 38.0 198 37.0   
        Crack 219 25.6 108 25.8 117 21.9   
        Heroin 70 8.2 27 6.5 48 9.0   
        N 854 418 535   
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Table B.5.: New Orleans 
 
 DUF ADAM   
 1997 1998 2000 2001   
Variable N % N % N % N %  
Urine Test           
    Marijuana 381 38.3 368 38.1 280 46.4 281 44.5   
    Cocaine 456 45.9 440 45.6 205 33.9 227 35.9  
    Opiates 106 10.7 126 13.1 92 15.2 95 15.0   
Self-Report Drug 
Use          
    Within 72 Hours          
        Marijuana 318 32.0 331 34.3 194 32.1 238 37.7  
        Cocaine 98 9.9 68 7.0 26 4.3 45 7.1  
        Crack 165 16.6 174 18.0 66 10.9 84 13.3  
        Heroin 84 8.5 97 10.1 67 11.1 71 11.2  
        PCP 1 0.1 3 0.3 0 0.0 0 0.0   
        Amphetamines 3 0.3 3 0.3 1 0.2 1 0.2  
        Barbiturates 7 0.7 10 1.0 1 0.2 1 0.2  
Ever Used Drug          
        Marijuana 762 76.7 752 77.9 475 78.6 462 73.1  
        Cocaine 332 33.4 337 34.9 167 27.6 178 28.2  
        Crack 310 31.2 302 31.3 154 25.5 162 25.6  
        Heroin 190 19.1 217 22.5 132 21.9 122 19.3  
         N 994 965 604 632   
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Table B.6.: Phoenix 
 
 DUF ADAM  
 1997 1998 2000 2001  
Variable N % N % N % N %  
Urine Test          
    Marijuana 299 30.4 202 32.2 423 33.4 601 37.9  
    Cocaine 318 32.3 195 31.1 378 29.9 408 25.8  
    Opiates 92 9.4 36 5.7 76 6.0 101 6.4  
Self-Report Drug 
Use          
    Within 72 Hours          
        Marijuana 211 21.5 143 22.8 276 21.8 468 29.5  
        Cocaine 65 6.6 41 6.5 62 4.9 80 5.1  
        Crack 150 15.3 86 13.7 175 13.8 184 11.6  
        Heroin 80 8.1 38 6.1 62 4.9 67 4.2  
        PCP 3 0.3 1 0.2 7 0.6 2 0.1  
        Amphetamines 17 1.7 18 2.9 22 1.7 19 1.2  
        Barbiturates 12 1.2 5 0.8 6 0.5 4 0.3  
Ever Used Drug          
        Marijuana 813 82.7 498 79.3 979 77.3 1320 83.3  
        Cocaine 494 50.3 309 49.2 619 48.9 830 52.4  
        Crack 428 43.5 242 38.5 504 39.8 622 39.3  
        Heroin 231 23.5 122 19.4 229 18.1 269 17.0  
        N 983 628 1266 1584  
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Table B.7.: Portland 
 
 DUF ADAM   
 1997 1998 2000 2001   
Variable N % N % N % N %  
Urine Test           
    Marijuana 246 38.1 280 37.0 212 35.3 246 35.4  
    Cocaine 238 36.9 220 29.1 130 21.6 176 25.4  
    Opiates 89 13.8 118 15.6 80 13.3 67 9.7  
Self-Report Drug 
Use          
    Within 72 Hours          
        Marijuana 169 26.2 178 23.5 118 19.6 202 29.1  
        Cocaine 59 9.1 52 6.9 24 4.0 41 5.9  
        Crack 104 16.1 92 12.2 39 6.5 89 12.8  
        Heroin 73 11.3 81 10.7 41 6.8 43 6.2  
        PCP 0 0.0 2 0.3 1 0.2 0 0.0  
        Amphetamines 28 4.3 10 1.3 7 1.2 7 1.0  
        Barbiturates 5 0.8 5 0.7 1 0.2 1 0.1  
Ever Used Drug          
        Marijuana 562 87.1 663 87.7 514 85.5 575 82.9  
        Cocaine 348 54.0 410 54.2 278 46.3 324 46.7  
        Crack 301 46.7 323 42.7 235 39.1 297 42.8  
        Heroin 184 28.5 251 33.2 150 25.0 164 23.6  
        N 645 756 601 694   
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Table B.8.: San Antonio 
 
 DUF ADAM  
 1997 1998 2000 2001  
Variable N % N % N % N %  
Urine Test          
    Marijuana 319 34.3 374 41.1 177 34.0 232 38.5  
    Cocaine 244 26.2 245 27.0 124 23.8 160 26.6  
    Opiates 96 10.3 87 9.6 47 9.0 55 9.1  
Self-Report Drug 
Use          
    Within 72 Hours          
        Marijuana 225 24.2 235 25.9 118 22.7 177 29.4  
        Cocaine 83 8.9 80 8.8 39 7.5 56 9.3  
        Crack 30 3.2 22 2.4 15 2.9 22 3.7  
        Heroin 52 5.6 42 4.6 30 5.8 35 5.8  
        PCP 1 0.1 0 0.0 1 0.2 1 0.2  
        Amphetamines 10 1.1 11 1.2 1 0.2 4 0.7  
        Barbiturates 8 0.9 7 0.8 2 0.4 1 0.2  
Ever Used Drug          
        Marijuana 588 63.2 587 64.6 336 64.6 449 74.6  
        Cocaine 316 33.9 279 30.7 158 30.4 241 40.0  
        Crack 120 12.9 105 11.6 68 13.1 98 16.3  
        Heroin 128 13.7 122 13.4 64 12.3 87 14.5  
        N 931 909 520 602  
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Table B.9.: San Jose 
 
 DUF ADAM   
 1997 1998 2000 2001   
Variable N % N % N % N %  
Urine Test           
    Marijuana 256 28.9 107 24.7 167 31.7 271 37.5   
    Cocaine 120 13.6 35 8.1 71 13.5 79 10.9   
    Opiates 49 5.5 19 4.4 24 4.6 20 2.8   
Self-Report Drug 
Use          
    Within 72 Hours          
        Marijuana 171 19.3 78 18.0 118 22.4 210 29.1   
        Cocaine 39 4.4 14 3.2 12 2.3 28 3.9  
        Crack 40 4.5 5 1.2 23 4.4 29 4.0   
        Heroin 29 3.3 8 1.2 10 1.9 12 1.7   
        PCP 5 0.6 4 0.9 4 0.8 16 2.2  
        Amphetamines 36 4.1 9 2.1 5 1.0 13 1.8  
        Barbiturates 4 0.5 1 0.2 0 0.0 4 0.6   
Ever Used Drug          
        Marijuana 599 67.7 285 65.7 354 67.3 537 74.4  
        Cocaine 332 37.5 168 38.7 208 39.5 345 47.8  
        Crack 198 22.4 75 17.3 131 24.9 213 29.5   
        Heroin 96 10.8 45 10.3 55 10.5 92 12.7  
        N 885 434 526 722   
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